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Abstract 
In the last two decades, lots of progresses have been made in the application of nanomaterials in 
biology, giving rise to a new revolutionary field of the biomedical research that is called 
nanomedicine. Carbon nanotubes (CNTs) and graphene are among the most attractive candidates 
under investigation in this context. Such carbon-based nanomaterials possess outstanding chemico-
physical properties and their high surface area provides multiple attachment sites for almost all the 
molecules of biological interest. In fact, chemical strategies allow for their conjugation with DNA, 
proteins, peptides and small drugs. The so-functionalized materials have shown great promises in 
several biomedical contexts, from diagnosis to tissue regeneration. In addition, the ability of CNTs 
and graphene to enter and accumulate inside the cells makes them good candidates as nanovectors 
for drugs. In vitro and in vivo studies showed how these nanomaterials could enhance the drug 
accumulation inside the cells and its bioavailability. CNTs and graphene are also able to passively 
target tumor tissues exploiting the so-called enhanced permeability and retention effect, and 
actively, following the conjugation with targeting moieties.  
On the other hand, the use of these materials in nanomedicine will be approved only after the 
demonstration of their safety in terms of tissue damage, carcinogenicity and proinflammatory 
response. Different approaches have been used to make these materials biocompatible and recently, 
it has been demonstrated that functionalized CNTs and graphene oxide can be degraded by 
oxidative enzymes. However, the results obtained on CNT and graphene toxicity are often 
conflicting; thus, further investigations are needed.  
In the first introductive chapter of this thesis, an overview of the general features of nanomaterials 
is given. The focus goes then on CNTs and graphene. First, we will see how their biocompatibility, 
biodegradability and in vivo fate strictly depend on several factors. The mechanisms by which the 
two nanomaterials are able to enter the cells are also illustrated. In the second part of the 
introduction, the potential of CNTs and graphene in targeted drug delivery is described, focusing on 
anticancer therapy. 
The three following chapters illustrate the results obtained by three related studies carried out 
during my PhD internship.  
Results described in the second chapter shed more light on the impact of CNTs on living cells. 
CNTs having single walls (SWCNTs) were dispersed with the biocompatible protein bovine serum 
albumin (BSA). BSA protein showed to be a good dispersant agent for the CNTs and was able to 
enhance their biocompatibility. The impact of the protein-coated materials on cell vital parameters, 
such as viability, activation and interaction/internalization mechanisms, is described. In addition the 
effect of nanotubes on the plasma membrane dielectric characteristics and ion flux, very poorly 
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investigated up to date, is presented.  
In the following chapter, a cisplatin prodrug was encapsulated within the inner cavity of two types 
of multi-walled CNTs (MWCNTs) having different diameters, in order to allow a controlled release 
inside the cells. The efficacy of the complexes was investigated on human cervix cancer cells and 
compared to murine macrophages. The latter were also used to evaluate the possibility of a 
proinflammatory effect.  Results on cell viability, cell activation and cell uptake show that CNTs 
are promising nanocarriers to improve the accumulation of a chemotherapeutic drug inside the cells, 
without inducing a high proinflammatory response. In addition, by tuning CNT diameter it is 
possible to control the time of release of the drug prolonging its anticancer efficacy.  
The fourth chapter gives more insights about the impact of different types of graphene on cells, 
focusing on macrophages. Results evidenced a specific cytotoxic effect of graphene oxide (GO) 
towards this cell population among the other murine immune cells. The mechanisms by which 
macrophages internalize GO are also elucidated. In addition, GO was conjugated with lysozyme 
protein and was tested for its ability to selectively target a B cell model overexpressing a lysozyme-
specific B cell receptor. Results showed that graphene is able to target B cells in a selective manner, 
thus suggesting its possible application in therapies where the specific elimination of B 
lymphocytes is required.    
Finally, a conclusive chapter summarizes the main findings obtained during my doctoral work, 
focusing, in particular, on future perspectives.  
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CHAPTER I 
Introduction 
 
I.1 A world at the nanoscale level 
The term nano originates etymologically from the greek meaning “dwarf” and it indicates physical 
dimensions that are in the range of one-billionth of a meter: the nanoscale. By comparison, we are 
speaking about objects five orders of magnitude smaller than the diameter of a human hair. 
Several organizations gave a definition for nanomaterials over the last two decades. In particular, in 
October 2010 the European Commission invited the member States, the Euopean Agencies and 
industries to define such materials as objects which meet at least one of the following criteria:  
- Consist of particles, with one or more external dimensions in the size range of 1 nm to 100 
nm for more that 1 % of their number size distribution; 
- Have internal or surface structures in one or more dimensions in the size range of 1 nm to 
100 nm; 
- Have a specific surface area by volume greater than 60 m2/cm3, excluding materials 
consisting of particles with a size lower than 1 nm.  
Nanoparticles (NPs) can originate either unintentionally from environmental processes, such as 
volcanic activities or spontaneous combustions, or can be the result of human actions. The latter are 
the so-called anthropic NPs, derived, for example, from industrial processes or car pollution. 
However, in the context of this thesis, we are referring to another type of NPs, which are 
intentionally synthesized and engineered to be exploited for specific applications. These nano-
objects can be composed of various materials. They can be metals (for example gold, zinc or 
copper), ceramics, polymeric materials (such as polystyrene) and carbon (such as carbon nanotubes 
and graphene). They can also display various shape, such as tubular, spheres and rods. The interest 
toward these materials arises from their outstanding physicochemical properties, related to 
conductivity or reactivity (for example), which differ from the same material in bulk. Such 
properties are attributable to NP small size, high surface area to volume ratio, chemical 
composition, surface reactivity, solubility, shape and agglomeration status (Nel et al. 2006; Bakand 
et al. 2012).  
By taking advantage of those special characteristics of NPs, a new field that is called 
nanotechnology has emerged and represents nowadays an area of scientific research and industrial 
applications in full expansion. Despite this technology has emerged as matter of enormous interest 
quite recently, the concept was raised over 40 years ago by the physicist Richard Feynman who 
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delivered its famous talk in 1959 entitled “There's Plenty of Room at the Bottom” (Feymann 1960). 
From that pioneering talk, there have been many revolutionary developments in physics, chemistry 
and biology which have demonstrated Feynman’s idea of manipulating matter at an extremely small 
scale. Although the idea had been already introduced, the term nanotechnology was fashioned by 
Nori Taniguchi in 1974 at the Tokyo International Conference on Production Engineering, where he 
described how materials could be processed to nanoscale precision (Taniguchi 1974). The world of 
nanotechnology is highly interdisciplinary and it requires knowledge from a variety of scientific and 
engineering areas which collaborate to create materials with fundamentally new properties and 
functions. In fact, the researches in this context involve efforts coming from physics, chemistry, 
engineering and biology, whose work together into an integrated field. Nanomaterials are already an 
economic reality and they have demonstrated to benefit society in several contexts. In fact, 
engineered nanomaterials have been exploited in energy technologies, including economic solar 
cells (Law et al. 2005) and high-performance batteries (Chan et al. 2008); in electronics, with 
ultrahigh density data storage (Vettiger et al. 2002) and single-atom transistors (De Franceschi et 
al. 2002); but also in food and agriculture technologies, offering smart delivery of nutrients and 
increased screening for contaminants (Sozer et al. 2009).   
On the other hand, the size of nanomaterials falls within the same range of biological 
macromolecules and, therefore, it is compatible with the size of the fundamental components of life 
that are the cells (Figure 1). In fact, one of the most interesting and promising issues, is the 
possibility to apply these materials in biology, in a new field named nanomedicine. Nanotechnology 
has been exploited to improve both diagnosis and therapy of diseases. Relating to the first purpose, 
their small size enable nanostructures to measure and detect biological entities at the level of single 
molecules and single cells. This ability is often lost in traditional bulk assays, which usually afford 
average information about heterogeneous populations pooled from large numbers. One example of 
this is the use of nanoscale pores that can discriminate between molecules on the basis of size and 
biochemical characteristics. Taken together, these observations make nanostructures promising 
candidates for imaging and diagnosis purposes. On the other hand, nanotechnology has been 
employed in the treatment of diseases. The researches in this field are related to implantable 
materials, tissue regeneration, and multifunctional drug delivery platforms. Concerning the latter 
application, nanomaterials can be designed as carriers for the delivery of therapeutic molecules to 
targeted locations thus enhancing the bioavailability and pharmacokinetics of the drug. This avoids, 
for example, the complications associated with conventional drug delivery strategies, which are 
often associated with poor and inconsistent uptake. (Etheridge et al. 2013; Wong et al. 2013). The 
latest observations provide essential implications in diseases, in which the specific depletion of 
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diseased cells without affecting normal cells is demanded (e.g. cancer or autoimmune diseases). 
Some examples of nanostructures currently under investigation for biomedical applications are 
liposomes, micelles, surfactant vescicles, dendrimers, hydrogels, gold NPs, quantum dots, 
polymeric NPs and carbon nanostructures (Figure 1). In the latter category are included 
nanodiamonds, fullerene, carbon nanotubes and graphene (Wong et al. 2013).  
 
 
Figure 1. Size of nano-objects. The image underlines nanomaterials similitude to large biological molecules. 
 
On the other hand, in view of the enormous development of nanomaterial-based technologies in the 
last few decades, a careful assessment of their impact on health and environment is demanded. This 
applies, first, to professional exposure, since nanomaterials can be inhaled and enter more deeply 
into the lungs, compared to the same materials of conventional size. Second, the investigation of 
their cytotoxicity is of fundamental importance in the context of their application in medicine. In 
fact, secondary side effects of therapies have to be avoided (Nel et al. 2006; Bakand et al. 2012).  
 
I.1.1 Carbon nanomaterials 
Among all carbon-based nanomaterials, carbon nanotubes (CNTs) and graphene are of particular 
interest in biological applications as they have shown enormous promises in many important areas 
of biomedical research (Cha et al. 2013).  
The unique electronic structure of carbon allows for sp, sp
2
 and sp
3
 hybridization leading to a large 
number of stable allotropes. Natural and most common allotropic forms of carbon include 
amorphous carbon, graphite, which consist of sp
2
 hybridized carbon atomic layers stacked together 
by weak van der Waals forces, and diamond, which display a tridimensional form, with carbons 
0.1         1          10        100    1000      104           105 106          107          108
H2O
Glucose
molecule
Virus
Eucariotic
cell
Pencil tip
Tennis
ball
Fullerenes
Carbon 
nanotubes 
Graphene 
Gold
NPs 
Bacterium
Nanometers
Dendrimers
Liposomes
Antibodies
6  Chapter I: Introduction 
 
hybridized sp
3
. Graphite is present in nature as an abundant natural mineral and, together with 
diamond, is well known since antiquity (Spyrou and Rudolf 2014). In 1985, a new form of carbon 
was discovered by the groups of Richard Smalley (Kroto et al. 1985). This was the case of fullerene 
(C60), in which carbon atoms are hybridized sp
2
 and organized to form pentagonal and hexagonal 
structures arranged in a spherical shape, similar to the soccer ball. Afterwards, a large family of 
other carbon-based nanomaterials has been discovered (Figure 2). In particular, CNTs have been 
described for the first time at the atomic level in 1991 by Iijima (Iijima 1991). CNTs were identified 
casually during the process of synthesis of fullerene. On the other hand, graphene history is more 
recent. In fact, the research group guided by Geim and Novoselov, reported for the first time a 
method for the isolation of single layer graphene from graphite only in 2004 (Novoselov et al. 
2004).  
 
 
 
Figure 2.  Molecular structure of six forms of carbon: A) amorphous carbon, B) diamond, C) graphite, D) 
fullerene, E) single-walled carbon nanotube, and F) graphene.  
 
I.2 An introduction to carbon nanotubes and graphene 
 
I.2.1 General features of carbon nanotubes 
Carbon nanotubes share graphene and fullerene characteristics. In fact, they can be considered as 
graphene sheets rolled up to form a cylindrical structure. They can be either single-walled 
(SWCNTs) or multi-walled (MWCNTs), the latter being formed by two or more cylinder wrapped 
one inside each other (Figure 3A). SWCNTs have a diameter going from 0.7 to 2.5 nm, while 
A B C
D E F
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MWCNTs diameter can be up to 100 nm. Both CNT types have a length ranging from 0.2 to few 
µm and even mm. According to the way how the graphene sheet is twisted, CNTs can display a 
chiral, a zig zag, or an armchair form (Figure 3B), which confers to the materials different 
electronic properties being conductors, semiconductors and metallic, respectively.  
 
 
Figure 3. Carbon nanotubes forms (A) and chirality (B).  
 
CNT structure allows the materials to have outstanding physical, chemical and mechanical 
properties, thermal conductivity and large aspect ratio. Thanks to these properties, CNTs were 
exploited in several industrial fields. In fact, upon the first industrial synthesis of what are now 
known as MWCNTs in 1980, a widespread interest in CNT research has begun. During the past 
decade, worldwide production of CNTs has considerably increased, and the annual number of CNT-
related publications and patents continues to grow (De Volder et al. 2013). The development of 
large-scale methods of CNT production, have substantially decreased CNT price. However, the so-
produced CNTs are not free of contaminants (e. g. metals), which can influence CNT properties (De 
Volder et al. 2013) and also their bio-compatibility (see below). 
Thanks to their particular mechanical properties such as high resistance and elasticity, CNTs have 
been employed in composite materials, in order to enhance material stiffness; they were used as 
coating materials and films with antibacterial properties; their outstanding electronic properties 
allow for their use in microelectronics such as transistors and condenser or in energy storage and as 
components of lithium ion batteries for notebook computers and mobile phones (De Volder et al. 
2013). On the other hand, one of the most interesting applications of CNTs, which could bring 
enormous benefits to society, concerns their possible use in the biomedical field (see below). 
 
 
 
2-100 nm
SWCNT MWCNT
A B
Armchair       Zig-Zag        Chiral 
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I.2.2 General features of graphene 
Despite being the basic structural element of other allotropes, including carbon nanotubes and 
fullerenes, graphene history is quite recent (Novoselov et al. 2004). Graphene can be described as a 
one-atom thick single layer of graphite. As well as CNTs, graphene can display different forms 
which are conventionally put together in the so called graphene family nanomaterials (GFNs). 
GNFs comprise few-layer graphene (FLG), graphene oxide (GO), reduced graphene oxide (rGO), 
graphene nanosheets, ultrafine graphite, graphene ribbons and graphene dots. The most common 
graphene forms are illustrated in Figure 4. FLG is constituted by 2-10 graphene layers, while GO 
and rGO are normally composed of a single-layer. In particular, GO is the oxidized form of 
graphene and therefore, it presents numerous oxygenated groups such as carboxyl, hydroxyl and 
epoxil, on its surface. GO can be reduced upon thermal and chemical treatment becoming rGO 
(Bianco 2013).  
 
 
Figure 4. Representative chemical structures of some of the members of the graphene family. (adapted from 
Bianco 2013). 
 
As well as CNTs, and according to its particular shape, graphene displays exceptional properties 
such as electronic, optical, thermal and mechanical (Huang et al. 2011 A). Since its first isolation, 
graphene has emerged as a new carbon allotrope with great potential for several applications, 
similar to CNTs. In fact, graphene was firstly exploited in material sciences (Huang et al. 2011 B) 
and very recently it has been proposed to be a good candidate for the development of graphene-
based electronics, photonics, composite materials, energy generation, energy storage and sensors. 
Together with CNTs, graphene is also gaining a lot of interest in the biomedical field (see below). 
Graphene is commonly isolated from graphite flakes by repeated mechanical exfoliation which 
provides large amounts of graphene with a high degree of purity, making it suitable for biomedical 
applications (Spinato et al. 2014).  
 
 
 
Few-layer Graphene
(FLG)
Reduced Graphene Oxide
(rGO)
Graphene Graphene Oxide
(GO)
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I.3 Carbon nanotube and graphene biocompatibility 
As mentioned, CNT and graphene-based nanomaterials have attracted a strong interest toward their 
application in the biomedical field. Among all, one of the main properties which make the materials 
good candidate for a large variety of bio-applications is their high surface area which allows for the 
conjugation with almost all the biological macromolecules such as DNA, proteins, peptides or small 
drug molecules. In fact, both materials can be conjugated with special moieties which make 
graphene and nanotubes both dispersible and suitable for their use as biosensors, as scaffold for cell 
growth and for drug delivery applications. Such applications are strictly dependent on CNT and 
graphene biocompatibility.  
First of all, the material dispersibility is a conditio sine qua non the development of nanomaterial-
based therapeutic strategies would not be possible. In fact, it has to be noticed that both materials, as 
well as they are produced, are completely insoluble in most aqueous media. This is related to the 
strong van der Waals forces that take place among the tubes or graphene sheets leading to their 
aggregation in large bundles (Bianco et al. 2011; Spinato et al. 2014). Moreover, at the beginning, 
bundled non-purified CNTs have been associated with negative cellular effects (Kolosnjaj et al. 
2007; Holt et al. 2010). However, several progresses have been made in order to significantly 
enhance both CNT and graphene dispersibility and biocompatibility. For this purpose, two main 
strategies are possible. The first one is the non-covalent adsorption of biocompatible molecules on 
CNT or graphene surfaces, while the second strategy involves the covalent functionalization of their 
surface by chemical methods.  
 
I.3.1 Non-covalent and covalent functionalization  
Non-covalent functionalization of CNTs (f-CNTs) is a simple method to disperse the material 
without perturbing the nanotube structure. These interactions normally occur via π-π stacking 
and/or van der Waals interactions. Several biocompatible agents are able to disperse CNTs in 
aqueous media. Some examples are DNA (Zheng et al. 2003; Tardani and Sennato 2014), proteins 
(Matsuura et al. 2006; Nepal and Geckeler 2006), polysaccharides (Piovesan et al. 2010) polymers 
(Rice et al. 2006) and others. Among them, protein dispersions are of particular interest in the 
context of CNT bio-applications (Figure 5A). First, proteins have a high affinity with CNTs. This is 
due to the hydrophobic interactions that occur between the CNT sidewall and the hydrophobic 
regions of the proteins. Moreover, it has been shown that the interaction of some proteins with 
CNTs, such as lysozyme or bovine serum albumin, can enhance their biocompatibility with respect 
to pristine CNTs (Shim et al. 2002; Ge et al. 2011). Despite, it is not related to their solubility, 
another interesting CNT feature is the possibility to fill their inner cavity with diverse molecules (e. 
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g. drugs) by a chemical method called endohedral functionalization (Figure 5A). This approach 
permits also to increase the degree of functionalization and the easy release of adsorbed molecules, 
without perturbing CNT structure, thus having important implications in drug delivery (Li et al. 
2012).   
 
 
Figure  5. Representative examples of non-covalent (A) and covalent (B) functionalization of CNTs. 
 
On the other hand, CNTs can be covalently functionalized with organic moieties through different 
reactions, occurring at the sidewall or on the tips of CNTs (Figure 5B). Briefly, CNTs can be firstly 
oxidized and then, exploiting oxidized defect sites, coupling reactions can be performed such as 
amidation or esterification. In addition to a remarkable increase in solubility, the so-functionalized 
CNTs are suitable for further chemical modifications allowing the conjugation with special 
bioactive molecules for biomedical application purposes (Bianco et al. 2004; Prato et al. 2007).  
Thanks to the experience gained with CNTs, similar approaches have been developed in the last few 
years to modify graphene or GO surfaces. In fact, similar strategies have been used to improve 
graphene and GO solubility and to allow for the conjugation with various molecules. Differently to 
CNTs, having two free surfaces, the moieties of interest can be stacked onto both graphene faces 
thus allowing a high density of functionalization. As it was described above for CNTs, both a non-
covalent and covalent functionalization is possible. Graphene and graphene oxide can be wrapped 
with polymers and can be dispersed with surfactants or with biomolecules such as DNA, proteins 
and peptides, which adsorb on their surfaces.  On the other hand, several reactions exist, permitting 
to covalently functionalize their surfaces with different groups, similarly to CNTs. In particular, the 
various reactive GO functional groups make this graphene form the most suitable for biological 
applications in comparison to pristine graphene. Therefore, upon specific chemical reactions, 
bioactive molecules, such as nucleic acids, peptides antibodies and small drug molecules can be 
Adsorption of proteins      
Endohedral functionalization
A B
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covalently conjugated to both sides of the graphene sheet (Spinato et al. 2014). Noteworthy is the 
fact that both materials can carry different molecules at the same time. In fact, their surface can also 
be multifunctionalized. Such possibility has many implications in the context of drug delivery, as it 
will be described later. Taken together, these characteristic make CNTs and graphene revolutionary 
materials like no others which could change completely the field of biomedicine. 
 
I.3.2 Toxicity 
The cytotoxicity of carbon nanotubes and graphene in vitro and in vivo is an important issue to be 
investigated, especially in view of their possible application in the biomedical field. In fact, if these 
materials have to be used for therapeutic applications, they absolutely do not have to provoke tissue 
damage or a proinflammatory response. A large variety of studies can be found in literature 
reporting the cytotoxicity findings on the two material types. Despite this, in most cases the 
described results are incompatible with each other. Such conflictuality has to be ascribed to 
variability in the doses, properties, purification level and type and degree of functionalization of the 
two materials used in the different cytotoxicity studies. The use of diverse cellular models may also 
be responsible of paradoxical findings. Moreover, in the case of CNTs, common cytotoxicity test 
such as the Mosmann colorimetric assay may give false results as CNTs are able to bind to the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) die (Belyanskaya et al. 2007).  
Thus, further explorations in this context are certainly needed and a major standardization is 
required. Despite the variability in the results, an overview can be given on the main characteristics 
affecting CNT and graphene toxicity. 
Concerning CNTs, their cytotoxicity can be first correlated to the effect of the impurities derived 
from their production process. In fact, metal catalysts are the main source of adverse effects as 
evidenced by early studies in which poorly purified CNTs were used. For instance, such behavior 
was evidenced in human HEK 293 cells. Results showed that SWCNTs could inhibit the cell 
proliferation and decrease HEK 293 cell ability to adhere in a dose- and time-dependent manner 
(Cui et al. 2005). The role of metal catalysts on CNT toxicity was also evidenced by Kagan et al. 
who investigated the impact of iron-purified or iron-rich SWCNTs in RAW 264.7 murine 
macrophages in terms of oxidative stress induction (Kagan et al. 2006). As SWCNTs are more 
prone to aggregate into bundles due to their stronger van der Waals forces compared to MWCNTs, 
the latter seems to be less toxic as the aggregation of CNTs is known to be harmful to the living 
cells, organs and tissues (Colvin 2003). As it was previously described in this thesis, the surface 
functionalization of CNTs allowed the materials to have an improved biocompatibility. In fact, 
some publications have demonstrated a significant reduction in the CNT cytotoxicity due to their 
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high degree of functionalization. For instance, a cytotoxicity study performed on human dermal 
fibroblasts showed how, as the degree of sidewall functionalization increases, the SWCNT samples 
become less cytotoxic compared to the underivatized SWCNTs stabilized in 1% Pluronic F108 
(Sayes et al. 2006). Another study carried out by our laboratories studied the behavior of two types 
of f-CNTs, oxidized and or amidated, on primary immune cells. Both types of f-CNTs were uptaken 
by B and T lymphocytes as well as macrophages in vitro, without affecting cell viability. Although 
amidated f-CNTs provoked the secretion of proinflammatory cytokines by macrophages, any 
impairment of immune cell functional activity was observed (Dumortier et al. 2006). CNT 
dimensions are also important in determining their cytotoxicity. For instance, the effect of CNT 
length was assessed by Poland et al. Inflammation was chosen as cytotoxicity readout as it is a key 
factor in tissue remodeling and carcinogenesis. In a first study, the peritoneal mesothelium was 
exposed to CNTs in order to determine whether there was asbestos-like, length-dependent 
cytotoxicity. The authors demonstrated how long fibrous CNTs were able to induce inflammation 
and fibrosis in the peritoneal cavity, similarly to asbestos fibers. On the other hand, short CNTs 
caused any significant inflammation (Poland et al. 2008). These findings were confirmed by the 
same group, in another study. In this case, CNTs having different lengths were instilled into the 
pleural cavity of mice (Murphy et al. 2011). Such behavior could be explained first by the fact that 
long CNTs failed to surpass the diaphragmatic or pleural stomata thus being consequently retained 
at the vicinity of the diaphragm or the pleural cavity, in contrast to smaller particles. Second, as it 
was subsequently demonstrated, macrophages could not fully engulf the long CNTs. Such 
phenomenon is named frustrated phagocytosis (Figure 6A) and promotes the recruitment of 
inflammatory cells and mesothelial cell damage leading to chronic inflammation and granuloma 
formation (Murphy et al. 2012).  The latter studies, give also an example of the CNT toxicity in 
vivo. Few studies also investigated the CNT toxicokinetics upon systemic exposure (Ali-Boucetta 
and Kostarelos 2013). Also in this case, CNT aggregation and impurity seems to be the most 
responsible factors for toxicity. Again, CNT chemical functionalization dramatically reduces their 
in vivo cytotoxicity (Figure 6B). This could be also due to the fact, that certain types of f-CNT can 
be degraded thus allowing for their better elimination trough the renal system (see session I.3.4).  
On the other hand, graphene researches towards their application in nanomedicine started more 
recently. For this reason, a limited amount of data there are in literature on the impact of graphene 
on health and the environment (Bianco 2013). As well as CNTs, graphene exists in different forms 
having different chemical-physical characteristics. For this reason its toxicological profile is little 
understood and more studies are required. Despite this, it is possible also in this case to give an 
overview of the major findings in this subject. Similarly to CNTs it seems that the nature of the 
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graphene type used is strictly linked to its behavior in biological environment and that the chemical 
modification of graphene modulates the toxicity impact. The explanations for such observations 
could be derived, as in the case of CNTs, from a reduction in their aggregation and from the 
possibility of modified graphene to be degraded in vivo. This issue will be described later in this 
thesis. The biological response varies also depending on graphene number of layers, lateral size, 
rigidity, hydrophobocity, dose administered and purity of the material (Bianco 2013). As GO and 
rGO are better soluble in water and consequently more prone to be used in biology, the toxicity of 
these two graphene types is the most investigated. 
 
 
Figure 6. Factors influencing the safety of CNTs in vivo. (a) The effect of CNT structure on phagocytosis by 
macrophages and clearing from tissues. Whereas macrophages can engulf MWNTs with a low aspect ratio 
(ratio of length to width) before their clearance by draining lymph vessels, MWNTs with a high aspect ratio 
cannot be cleared and accumulate in tissues. (b) In addition to their dimensions, other considerations relevant 
to the safety of CNTs include increasing their solubility and preventing their aggregation, to facilitate urinary 
excretion and thereby prevent tissue accumulation (from Kostarelos 2008).  
 
 
To give some examples, in an initial study, pristine graphene was tested on rat neuronal PC12 cells 
and it was compared with CNTs. Graphene induced oxidative stress and caspase-3 activation, which 
was indicative of an apoptotic process, in a larger extent compared to CNTs thus indicating the 
importance of the material shape (Zhang et al. 2010). In another study, GO and carboxylated GO 
were tested on monkey renal cells. While the first accumulated in the cell membrane and caused 
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oxidative stress, F-actin destabilization and cell death, carboxylated GO penetrated into the cells 
and did not induce any cytotoxic effect up to a concentration of 300 µg/ml (Sasidharan et al. 2011).  
Such study suggests that graphene functionalization may reduce the material toxicity. Other studies 
evidenced that GO cytotoxicity can be also strongly dependent on the type of cell tested and on the 
purity of the material (Bianco 2013). GO behavior towards immune system cells is also of great 
interest. In an interesting study, different GO layers having different lateral sizes were tested on 6 
different cell models among which two were phagocytic (J774A.1 macrophages and primary 
peritoneal macrophages). While the GO samples were not uptaken by the non-phagocytic cell lines, 
macrophages were able to internalize the materials. Interestingly, the bigger GO flakes (about 2 
µm), triggered a much stronger inflammatory response with high release of key cytokines, 
contrarily to the nano-sized GO (Yue et al. 2012). Another work performed by Russier et al. was 
again focused on the effect of GO sheet lateral dimension on human primary monocyte-derived 
macrophages and murine intraperitoneal macrophages (mIPM). Contrarily to the previous findings, 
the authors have shown that, the more the lateral dimensions of GO were reduced, the higher was 
the impact on both cellular activation and TNFα production in mIPM (Russier et al. 2013).  
As well as CNTs, graphene in vivo toxicity was evaluated. For instance, significant pathological 
changes including inflammatory cell infiltration, pulmonary aedema and formation of granulomas 
were found after intravenous administration of GO into mice and rats (Wang et al. 2011; Zhang et 
al. 2011). It seems that GO is responsible of pulmonary toxicity as compared to pristine graphene 
dispersed in pluronic surfactant after injection in mice, suggesting that a stable dispersion can 
improve graphene biocompatibility in the lung (Duch et al. 2011). Not surprisingly, pristine 
graphene having few layers and a big lateral size (about 25 µm) induced an acute pulmonary 
inflammatory response in mice after inhalation.  As well as in the case of CNTs, the accumulation 
of large graphene sheets and induction of frustrated phagocytosis by macrophages was responsible 
for the observed toxicity (Schinwald et al. 2012). As for CNTs, chemical functionalization can 
reduce graphene in vivo toxicity. It is likely that, tuning the graphene sheet lateral size and its 
surface functionalization, it will be possible to create a material that can be easily cleared from the 
body also trough degradation.  
 
I.3.3 Biodistribution  
Strictly related to their toxicity it is also the CNT and graphene biodistribution in vivo. In fact, 
having particular properties, they can exhibit new and unexpected metabolism kinetics. As 
mentioned, such objects can enter the human body both unintentionally and this concerns the 
occupational exposure, but can they be also voluntary administrated in the case of therapeutic 
Chapter I: Introduction  15 
 
applications. According to the context, nanomaterials can enter the blood stream upon inhalation, 
ingestion, injection or dermal exposure (Wang et al. 2013; Ali-Boucetta et al. 2013 A).  
In the context of biomedical applications, a good therapeutic molecule has to display a correct 
balance between its retention into the blood, its biodistribution and ability to reach its target tissue 
(bioavailability) and finally its clearance from the tissues and its excretion. A special field of 
pharmacology named pharmacokinetics is interested in such investigations (Ruiz-Garcia et al. 
2008). Once in the blood system, nanomaterials are distributed in various tissues. In particular, they 
have the tendency to accumulate in the reticuloendothelial system (RES) organs (Wang et al. 2013). 
RES is the common name given to phagocytic cells as monocytes and macrophages which are 
located throughout the body in various organs and tissues. They are present, for istance, in the 
connective tissues, having the name of histiocytes, in the lungs (alveolar macrophages), in the 
lymphonodes, in the in liver (Kupffer cells), in the spleen and in the central nervous system where 
they are component of microglia. Being an important part of the immune system their function is to 
filter out dead and toxic particles and to identify foreign substances, thus maintaining the body 
homeostasis (Wynn et al. 2013).  
The rapid blood clearance followed by an overaccumulation of nanomaterials in non target organs 
such as liver and spleen is considered one of the main causes of their in vivo side effects and, in the 
context of therapeutic applications, a major challenge in the delivery of nanomaterials to the organs 
of interest (Wang et al. 2013). On the other hand, the tissue accumulation and clearance of 
nanomaterials is highly dependent to the tissue-specific properties of endothelial cells (Figure 7).  
 
 
Figure  7. The tissue-specific extravasation of nanomaterials (adapted from Wang et al. 2013).  
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Liver capillaries, named sinusoids, possess endothelial cells with fenestrations sized 100-200 nm 
which facilitate the extravasation of nanomaterials. Thus, it is assumed that small nanomaterials 
(10-20 nm) can be cleared from the blood via rapid hepatocyte uptake or via the lymphatic 
circulation. On the contrary, larger ones (> 200 nm), as in the case of CNTs and graphene, are 
cleared by Kuppfer cells upon phagocytosis being too big to cross the sinusoidal endothelium. In 
the case of spleen, blood flows through the discontinuous capillary into the splenic venous system. 
The dimension of spleen cellular fenestrations, could allow nanomaterials bigger than 100 nm to be 
cleared from the blood by splenic filtration via the lymphatic circulation or they could be uptaken 
by the RES cells resident in the organ. Concerning renal clearance, glomeruli are the filtration units 
of the kidney. Their endotheliums, which interact with a basal membrane, have fenestrations of 80-
100 nm. In contact to the basal membrane, glomeruli possess a layer of special cells named 
podocytes which form a structure called slit diaphragm having pores of 4-5 nm. Glomeruli structure 
makes the glomerular barrier highly selective. CNTs and graphene have a much bigger size 
compared to glomeruli pores. Despite this, renal elimination of functionalized CNTs has been 
reported (Ali-Boucetta and Kostarelos 2013). This could be due to metabolic modifications of 
CNTs by phagocytic cells (see next session) or to a special perpendicular orientation of the material 
toward endothelial fenestrations (Ruggero et al. 2010). Finally a special issue concerns the lungs. In 
fact, these organs are the first point of entry of inhaled nanomaterials into the body. Moreover, 
CNT- and graphene-induced pulmonary toxicity has been reported (see previous session). The lung 
endothelium is characterized by a continuous morphology that allows only small particles (having a 
size below 3 nm) to cross the interendothelial fenestrations. For these reasons, once graphene or 
CNTs arrive in the lung, they are likely to be cleared by alveolar macrophages which can be 
recruited to the site upon nanomaterial exposure. Upon being phagocytosized, the materials could 
be eliminated by mucociliary movement or could be exocytated in the interstices. Afterwards, some 
particles could be further transported into the blood circulation (Wang et al. 2010). On the other 
hand, the interstitial biopersistence of the the nanomaterials in the lungs could enhance or be the 
cause of pulmonary inflammation (see previous session).  
CNT and graphene biodistribution profiles have been investigated by different groups exploiting 
diverse methods. The most used strategy is to radiolabel the materials with radioactive isotopes in 
order to follow their fate in the body. This method allows for both CNT quantification through 
gamma scintigraphy and CNT imaging in vivo by tomography techniques such as SPECT (single 
photon emission computed tomography) or PET (positron emission tomography). CNT signatures 
in tissues can be also identified by Raman spectroscopy techniques.  
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It is now clear that CNT biodistribution is dependent to several parameters as CNT surface 
modifications, surface density of functional groups, CNT aggregation and length (Ali-Boucetta and 
Kostarelos 2013). It has been found that non-covalently functionalized CNTs accumulate mainly in 
RES organs such as liver and spleen. Despite this, the type of CNT coating could influence in some 
extent their accumulation in such organs and enhance their blood circulation (Ali-Boucetta and 
Kostarelos 2013). To this regard, one of the first studies was carried out by Yang et al. who 
investigated pristine CNT biodistribution in mice using 
13
C-enriched SWNTs coated with Tween 80 
as dispersant. The materials could be followed in the body by mass spectrometry. CNTs were 
administered to the mice via a single tail vein injection. The materials were cleared from the blood 
stream quickly and distributed throughout most of the organs within 24 h where they accumulated 
mostly in the lungs, liver, and spleen. Noteworthy was the fact that the materials persisted in such 
organs over 28 days. Moreover, pristine CNTs could hardly be detected in urine and feces, 
suggesting other excretion ways, for example from the lung (Yang et al. 2007). In another study 
SWCNTs were coated with branched polyethylene glycol (PEG) and injected intravenously in mice. 
As detected by Raman spectroscopy, the materials could be retained in the blood circulation for 
longer time (up to 15 h). Moreover, CNT accumulation in the RES organs, especially the liver, was 
highly reduced and the materials could be cleared from the main organs in 2 months. It was 
suggested that the coating with the polymer, could avoid non-specific binding of blood proteins 
with the CNTs which could be, consequently, less recognized by the RES cells. Moreover, in this 
case, the excretion and clearance of SWCNTs from mice occurred via the bile and renal pathways 
(Liu et al. 2008 A). On the other hand, several evidences showed that covalently functionalized 
CNTs generally display a reduced uptake by RES organs and an increased excretion by the renal 
system. Despite this, as in the case of CNTs non-covalently coated, the type and degree of 
functionalization affect their in vivo fate (Ali-Boucetta and Kostarelos 2013). The first study toward 
this observation was performed by Wang et al. 
125
I-labeled hydroxylated SWCNTs were 
intraperitoneally injected in mice. The materials were rapidly distributed in most organs having the 
highest affinity for the stomach, kidney and bone. Interestingly was the fact that the materials were 
almost completely excreted with the urines (Wang et al. 2004). Another example of covalently-
functionalized CNT biodistribution, is given by the interesting work of Al-Jamal et al. MWCNTs 
were conjugated with DTPA (diethylene triamine pentaacetic acid), a molecule which allowed the 
complexation with radioisotopes. The resulting CNTs were radiolabeled with 
111
I and followed 
throughout the body by SPECT/CT after injection into mice via the tail vein. All the complexes 
where rapidly cleared from the blood and distributed in the organs. Interestingly, the more the 
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CNTs were functionalized, the less their accumulation in the liver or spleen and the more urinary 
excretion were observed as highlighted in Figure 8 (Al-Jamal et al. 2012).   
 
 
Figure 8. Nano-SPECT/CT fused images of the whole mouse. Images were taken at 0.5, 3.5 and 24 h post-
injection for three types of MWNT having increasing degree of functionalization (from 6 to 8) (from Al-
Jamal et al. 2012).  
 
Several other works has been performed in order to enhance the circulation half life of CNTs, 
characteristic that is demanded for a molecule to efficiently reach its target tissues. For example, 
CNTs were covalently PEGylated. On the other hand, other parameters such as the size, diameter 
and dispersibility, could affect with some extent CNT biodistribution. These issues were 
investigated by several groups (Al-Jamal et al. 2012; Wang et al. 2014). Despite the abundant CNT 
pharmacokinetic studies published, a comparison between them is rather difficult for the large 
amount of parameters taken into account. However, the main findings toward CNT fate into the 
body can be evidenced in Figure 9. Generally, pristine/non-covalently functionalized CNTs are 
mainly retained in the RES organs, making their excretion difficult. Their biopersistence could then 
be associated with toxicity. On the other hand, covalently functionalized CNTs show a significant 
reduced accumulation in the RES organs and can be easily excreted trough the renal system, being 
more suitable for future biomedical applications (Ali-Boucetta and Kostarelos 2013).  
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Figure 9. CNTs biodistribution based on the nature of functionalization (from Ali-Boucetta and Kostarelos 
2013).  
 
Similar studies have been recently published concerning the in vivo biodistribution of graphene. 
Such works were mostly performed with GO. One of the first works was carried out by Yang et al. 
where PEGylated nanographene sheets (NGS), derived from GO having a size range of about 10-30 
nm, where intravenously injected in mice and followed inside the body after radiolabelling. The half 
life of the material in the blood circulation was about 7 hours. On the other hand, the material 
accumulated mainly in the RES organs (liver and spleen) over time. NGS complete clearance from 
these organs was achieved after about 2 months and they could be excreted via the biliary pathway 
into feces or via the renal system upon degradation as it will be described in the next session (Yang 
et al. 2011). More recently, the same group did a similar investigation using different PEG-GO 
derivatives and control GO. This time the routes of administration into mice were different since the 
materials were administered orally or were intraperitoneally injected. In the first case, the materials 
displayed a major accumulation in the stomach and intestine and no biodistribution in other organs, 
indicating their limited intestinal adsorption. In the other case, GO derivatives again accumulated 
mainly in the RES organs in which they were retained for up to 30 days. Interestingly, control GO 
could not be found in the liver or spleen, but it was observed agglomerated in the mouse abdominal 
cavity. They suggested that GO aggregated after injection to form big agglomerates that could not 
be taken up by the mouse organs (Yang et al. 2013).  
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I.3.4 Biodegradation 
One important issue related to the pharmacokinetic studies concerns how therapeutic nanoparticles 
can be eventually decomposed in simple molecules allowing for their easier excretion from the 
body. Despite several progresses have been made toward the design of non-toxic carbon-based 
nanomaterials for biomedical applications, clinical use of such materials will be facilitated by the 
demonstration of their degradation in vivo (Bianco et al. 2011, Li et al. 2014). Nanomaterial special 
properties such as elasticity and rigidity make CNTs and graphene generally resistant to chemical 
treatments. For this reason, their biopersistence into organs and tissues was hypothesized with the 
fear of severe long-term side effects. Although further explorations in this context are certainly 
needed, there are already some encouraging evidences that both CNTs and graphene can be 
degraded by oxidative enzymes which are normally present in some cells of our body. Moreover, 
the ability of both materials to be degraded by the cells was also evidenced in vitro and in vivo.  
Among all, peroxidases are one example of oxidative enzymes which are present in the phagocytic 
cell matrix. Physiologically, these enzymes are activated in order to oxidize molecules thus leading 
to the formation of compounds toxic for external pathogens. These types of enzymes require 
hydrogen peroxide for their functions that is generated during the respiratory burst. One example is 
given by the myeloperoxidase (MPO), produced mainly by neutrophil granulocytes but also by 
macrophages (Hampton et al. 1998; Sugiyama et al. 2001). The enzyme is stored in the lysosomes, 
and it contains a heme group as cofactor. MPO, when activated, produces hypohalous acids, mainly 
hypochlorous acid, from hydrogen peroxide and chloride anion. MPO can also oxidize tyrosines to 
tyrosyl radical. The resulting molecules are cytotoxic for bacteria and other pathogens allowing the 
cells to exert their immune function. Another important hemo-containing human peroxidase is the 
eosinophil peroxidase (EPO). This enzyme is mainly present in eosinophil granulocytes and, 
physiologically, it exerts anti-parasites functions.  Being similar to MPO, EPO catalyzes the 
oxidation of molecules, specifically halides (such as bromide, chloride and iodide) and 
pseudohalides (such as thiocyanate) producing the corresponding hypohalous acids (Hogan  et al. 
2008). Moreover, this peroxidase is the major oxidating enzyme expressed in the human lung  
during inflammatory states (Kinnula 2005).  
Starting for the observations described above, CNT and graphene degradation assays were 
performed, at the beginning, in cell-free environments; the materials were put in contact with 
horseradish peroxidase (HRP), a commonly used model of peroxidase derived from the horseradish 
plant (Azevedo et al. 2003). The enzyme was able to degrade oxidized SWCNTs in the presence of 
low concentrations of H2O2. Noteworthy was the fact that after ten days of HRP exposure, all the 
CNTs were degraded as it is shown in Figure 10A (Allen et al. 2009). More recently, the same 
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group carried out a study in which, in similar conditions, HRP catalyzed the oxidation of graphene 
oxide, which resulted in the formation of holes on its basal plane after ten days of exposure (Figure 
10B). Moreover, in the same conditions, rGO structure was not affected by the enzyme (Kotchey et 
al. 2011). GO extracellular degradation was also shown by Li et al. who designed a non-toxic GO 
through its functionalization with biocompatible molecules PEG or BSA. However, PEG and BSA-
coated GO were rather resistant to HRP degradation compared to free GO. Interestingly, they 
developed a method to conjugate the material with PEG or BSA via a cleavable bond obtaining a 
conjugated able to be degraded (Li et al. 2014). On the other hand, oxidized SWCNTs but not 
pristine, were also degraded by fluids which mimic the acidic phagolysosome environment such as 
the phagolysosomal simulating fluid (PSF) (Liu et al. 2010). Being formed by more concentric 
tubes, oxidized MWCNTs were more resistant to degradation but were also partially biodegraded 
by HRP or in PSF after two months of incubation (Russier et al. 2011).  
 
 
Figure  10. (A) TEM observations of carboxylated SWCNTs exposed for 10 days to HRP (adapted from 
Allen et al. 2009). (B) TEM observations of GO after 10 days of exposure to HRP (adapted from Kotchey et 
al. 2011).  
 
More interestingly, CNT degradation was demonstrated in test tube studies in which they were put 
in contact with MPO and EPO, the two physiological peroxidases expressed mainly by neutrophils 
and eosinophils, respectively. Moreover, a strong role of the generated hypohalous acids HClO and 
HBrO was demonstrated (Kagan et al. 2010; Vlasova et al. 2011). Since these molecules are the 
product of physiological oxidation processes, these encouraging results allowed further in vitro 
exploration in cells. In fact, it has been evidenced that neutrophils, macrophages and eosinophils 
A
B
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were able to degrade oxidized SWCNTs ex vivo upon activation. In particular, primary human 
neutrophils were treated in order to trigger MPO production and then, were exposed to CNTs. In 
half a day, all the CNTs were degraded inside the cells as evidenced by Raman microscopy. Despite 
less evident, CNT degradation was observed also in macrophages, which produce MPO but to a 
minor extent. Moreover, the resulting products of CNT degradation did not elicit an inflammatory 
response when aspirated into the lung of mice (Kagan et al. 2010). Similarly, CNTs could be 
degraded by primary murine eosinophils. Contrarily to neutrophils, in this case the degradation 
occurred extracellularly since EPO is exocytosed upon cellular activation (Andon et al. 2013).  
Finally, the last and most important evidence concerns CNT degradation in vivo. This phenomenon 
was suggested firstly by Elgrabli et al. Oxidized MWCNTs were intratracheally instilled into the rat 
lungs. As a consequence, alveolar macrophages where recruited in the organ in a dose-dependent 
manner, suggesting a proinflammatory response. Despite this, interestingly was the fact that, 15 
days after instillation, MWCNTs underwent important modifications such as a decrease in their 
length. The authors proposed that macrophages, upon phagocytosis of the materials, were able to 
degrade the CNTs facilitating afterwards their elimination from the lung (Elgrabli et al. 2008). The 
in vivo degradation CNTs was later confirmed. In an interesting study, oxidized SWCNTs were 
instilled into the lung of both MPO knock-out and wild type mice. In the first case, phagocytized 
CNTs remained persistent in the neutrophils recruited in the organ thus inducing a strong fibrogenic 
response. On the contrary, the material was significantly decreased in the lung of wild type mice as 
evidenced through quantitative imaging. Moreover, 28 days after the instillation, CNT underwent 
degradation as their length was strongly reduced. This phenomenon was higher in wild type mice 
compared to MPO knock-out mice, reinforcing the evidence of MPO fundamental importance in the 
process. Since a certain rate of CNT degradation was also observed in MPO knock-out mice, other 
peroxidases such as EPO were probably involved in the process (Shvedova et al. 2012). CNT 
biodegradation was also demonstrated in the mouse brain. In this case, amino-functionalized 
MWCNTs were stereotactically injected into the motor cortex of the murine brain. CNTs were 
uptaken by diverse cellular types (see session I.4.1) including neurons and the phagocytic cells of 
the microglia. Noteworthy, already 2 days after administration, MWCNTs underwent structural 
deformation as observed by transmission electron microscopy (TEM) and further confirmed by 
Raman spectra (Nunes et al. 2012).   
As it was described in this session, several studies concerning CNT biodegradation were carried 
out; but can graphene also be degraded in vivo? The answer came from Girish and co-workers who 
for first reported the phenomenon. After systemic administration, graphene oxide was localized in 
different organs of the mouse, such as lung, kidney and spleen. Structural defects in the graphene 
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structure were identified over a period of 3 months in the various organs. The biodegradation was 
predominant in graphene phagocytized by tissue-bound macrophages, result consistent with what 
obtained previously with CNTs. Macrophage-mediated graphene biodegradation was then 
confirmed in vitro in the same study (Girish et al. 2013).   
Taken together, the results described in this session demonstrate the possibility of CNT and 
graphene oxide degradation upon administration in the body. Such evidences have important 
implications for the long-term toxicological profiles of these materials, particularly related to any 
potential clinical application. Further studies will be certainly needed to address the possible 
toxicity of CNT and graphene degradation products (Bianco et al. 2011).  
 
I.4 CNT and graphene interaction with cells  
 
I.4.1 Energy-dependent mechanisms of cellular internalization 
Energy-dependent internalization processes, are normally used by the cells to engulf molecules that 
cannot pass through the hydrophobic cell membrane. On the other hand, in the case of immune 
phagocytic cells, these processes are involved, for example, in the digestion and immune responses 
toward pathogens or external materials. ATP-consuming internalization pathways are represented 
by four main processes that are the clathrin-mediated endocytosis, also called receptor-mediated 
endocytosis (RME), caveolae-mediated endocytosis (CME), macropinocytosis and phagocytosis, 
the latter being a feature of specific cells. In the first pathway external molecules bind to specific 
plasma membrane receptors. This event leads to membrane coating with clathrin protein and to the 
formation of a membrane invagination. As a consequence, the receptor and its ligand are 
internalized in clathrin-coated vesicles. Upon internalization of the complexes, the clathrin-coated 
vesicle uncoats and individual vesicles fuse to form the early endosomes. Two of the most known 
physiological functions of RME concern the internalization of low density lipoproteins (LDL) and 
transferrin (McMahon and Boucrot 2011). On the other hand, RME is also implicated in signal 
transduction from the cell periphery to the nucleus, as in the case of the epidermal growth factor 
(EGF) signaling pathway (Vieira et al. 1996). The second endocytic process is clathrin-independent 
and is mediated by small proteins named caveolins which are associated to the cell membrane lipid 
rafts. Caveolins oligomerize allowing the formation of caveolin-rich microdomains leading to 
plasma membrane invagination. This phenomenon is also helped by the increased levels of 
cholesterol at the invagination place. Caveolar vesicle can also fuse with the early endosomes. 
Physiologically, the uptake of albumin by endothelial cells and the internalization of the insulin 
receptor in primary adipocytes are mediated by this process (Lajoie and Nabi 2010). 
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Macropinocytosis is another clathrin-independ ATP-consuming internalization mechanism which 
consists in the invagination of the cell membrane to form a large vesicle and it is driven by actin 
filaments. This is a non-specific process where large volumes of extracellular fluid and molecules 
within it can be engulfed. The vesicle then travels into the cytosol and fuses with other vesicles such 
as endosomes and lysosomes. Macropinocytosis is important in several physiological processes. For 
example, it is highly used by macrophages and dendritic cells where it is a major pathway for the 
internalization of antigens but it is also relevant to cell migration and tumour metastasis (Lim and 
Gleeson 2011). Finally, phagocytosis occurs in specialized cells such as macrophages through an 
actin-based mechanism involving the interaction with various specialized cell surface receptors. 
This process is important in the internalization of solid agents such as bacteria and it is a major 
mechanisms used by immune system phagocytic cells to activate an immune response against 
external pathogens or to digest apoptotic cells. The latter are internalized upon the formation of 
large endocytic vesicles called phagosomes. The phagosome then fuses with the lysosomal 
compartment leading to the formation of phagolysosomes, where the foreign particles are 
enzymatically degraded (Wynn 2013).  
Remarkable is the fact that the lysosome is often the last compartment of the different 
internalization pathways. The vesicle is characterized by an acidic lumen and by the presence of 
several hydrolytic enzymes. Extracellular materials such as microorganisms taken up by 
phagocytosis or macromolecules by endocytosis, reach this compartment in which they are digested 
and eventually recycled within the cells (Grant
 
and Donaldson
 
2011).   
 
I.4.2 Carbon nanotube and graphene internalization by cells 
The interaction of CNTs and graphene with cells and their consequent ability to cross the plasma 
membrane is a critical issue which agrees with their possible use for drug delivery purposes.  
Cellular CNT internalization has been widely investigated in parallel to the development of CNT-
based therapeutic strategies in the last decade. Few studies have been already carried-out showing 
also the graphene cell uptake. CNT and graphene internalization can be followed with diverse 
techniques. First, the conjugation with fluorescent probes allows for their detection by flow 
cytometry or their direct visualization within the cells by fluorescence microscopy. The materials 
can be followed inside the cells also by TEM or by other techniques such as Raman spectroscopy.  
Despite some parameters and physicochemical properties can affect their cellular uptake pathways, 
it is now clear that CNTs are able to enter the cells by both passive diffusion and energy-dependent 
mechanisms. The passive CNT insertion and diffusion through the lipid bilayer of the plasma 
membrane have been suggested for the first time in 2004 by Pantarotto et al. The phenomenon was 
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visualized thanks to the CNT conjugation with a fluorescent peptide. The internalization was due to 
an energy-independent pathway since it was not affected by the temperature or by the presence of 
endocytosis inhibitors. Moreover, when the cells were exposed to the free peptide, the latter was not 
detected intracellularly. The result encouraged the CNT use to enhance the intracellular 
accumulation of therapeutic peptides (Pantarotto et al. 2004 A). In the same year the same group 
published a study in which f-CNTs were conjugated with a plasmid DNA. By TEM observations 
they showed how single CNTs were able to pierce the plasma membrane of HeLa cells by the so 
called nanoneedle penetration mechanism (Figure 11A). Furthermore, the plasmid DNA was 
successfully expressed inside the cells encouraging CNT exploitation for gene delivery (Pantarotto 
et al. 2004 B). More recently, models for CNT passive penetrations have been also elucidated by 
molecular dynamics methods which are based on the use of artificial membrane and informatics 
tools. Results obtained by these methods evidenced how the passive internalization process was 
often composed by three consecutive steps: landing and floating of the CNT on the membrane 
surface, penetration of the lipid headgroup area and finally sliding into the membrane core. 
Moreover, the study revealed that the degree of CNT functionalization influenced the two first steps 
and seems to specifically determine the CNT membrane penetration angle. Two representative 
models are shown in Figure 11B where the penetration features of low and highly functionalized 
CNT (model 1 and model 2, respectively) are evidenced (Kraszewski et al. 2012).  
 
 
 
Figure 11. TEM image of a multi-walled carbon nanotube crossing the cell membrane of HeLa cells (A) 
(from Pantarotto D et al. 2004). Two proposed molecular dynamic models for CNT passive diffusion trough 
the plasma membrane (B) (adapted from Kraszewski et al. 2012).  
 
On the other hand, several evidences showed how CNTs are also able to penetrate the cells by ATP-
consuming cellular mechanisms as endocytosis or phagocytosis. First studies toward the hypothesis 
of an energy-dependent CNT internalization pathway were performed by Kam et al. In an early 
work, CNTs conjugated to fluorescent proteins were uptaken by the cells in which they localized 
Model 1
Model 2
A B
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into endosomes, as assessed by confocal microscopy. Reinforcing this observation was the fact that 
protein-CNT complexes did not penetrate at 4 °C, condition in which the energy-dependent 
mechanisms are inhibited. Since the free protein did not penetrate inside the cells, this was another 
evidence of an enhanced accumulation of therapeutic molecules like proteins, inside the cells (Kam 
et al. 2004). The same group confirmed CNT ability to enter the cells trough endocytosis in another 
study. Moreover, CNT-protein conjugates were able to escape from the endosomes by endosomal 
rupture allowing the protein to express its biological functions as demonstrated by the induction of 
apoptosis (Kam and Hongjie 2005). Another early work demonstrated how CNTs were able to be 
actively ingested by phagocytic cells (Cherukuri et al. 2004). From these pioneering studies, CNT 
internalization by the two type of pathways were further confirmed by other groups and the 
mechanisms were further underlined (Kostarelos et al. 2007; Raffa et al. 2010; Yaron et al. 2011; 
Al-Jamal et al. 2011). On the other hand, specific endocytic pathways for CNT internalization were 
also investigated. Using specific inhibitors, it has been shown that clatrin-mediated endocytosis, 
caveolin-mediated endocytosis and macropinocytosis were all involved with some extent in CNT 
internalization by non-phagocytic epithelial cells (Lacerda et al. 2012).   
Having a more recent history, graphene cellular uptake mechanisms are less investigated. Despite 
this, thanks to the strategies developed for CNTs, similar mechanisms were fast discovered. In fact, 
different groups have suggested both a passive diffusion and endocytic pathways for graphene 
internalization. It has been shown that protein-coated and fluorescent GO nanosheet internalization 
by murine myoblasts was mainly due to an energy-dependent process since it was inhibited of more 
than 80 % at 4 °C, as demonstrated by flow cytometry. Moreover, a size dependent GO 
internalization was demonstrated. In particular, smaller GO sheets displayed an increased 
internalization after 14 hours of cellular exposure compared to larger ones. Thanks to the use of 
specific inhibitors, it was also suggested that larger nanosheets entered the cells predominantly by 
phagocytosis, while smaller ones were internalized mostly by clathrin-mediated endocytosis. On the 
other hand, GO sheets were frequently observed adhering face to face onto the cell surface, but not 
bind perpendicularly, as shown by TEM (Mu et al. 2012). The involvement of a clathrin-mediated 
pathway of GO internalization was also confirmed by Huang et al., as investigated by surface-
enhanced Raman spectroscopy upon conjugation of GO with gold NPs (Huang et al. 2012). In the 
study performed by Russier et al., TEM observations were carried out on primary macrophages 
exposed to GO samples having different sizes. First, smaller GO sheets were more internalized than 
largest ones, result consistent with the work of Mu et al. In addition, GO was found inside vesicles, 
suggesting again an endocytic/phagocytic internalization pathway, but also free in the cytoplasm. 
The latter observation could be correlated to a passive translocation of single sheets through the 
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plasma membrane. Single GO sheets were also found stacked parallel onto the cell membrane 
surface. The observed and so called “mask effect” could isolate cells from their environment and 
consequently be responsible for the GO impact on cellular parameters, but could also represent the 
first step in GO diffusion through the membrane (Russier et al. 2013). Finally, exploiting molecular 
dynamic membrane models, it has been suggested that microsized graphene can enter cells through 
passive diffusion through the cell membrane and that this process is initiated at GO corners or 
asperities. The proposed model is illustrated in Figure 12 (Li et al. 2013).  
 
 
Figure 12. Molecular dynamic model of graphene passive diffusion trough the plasma membrane. The 
temporal steps of internalization are marked with letters from A to D (from Ly et al. 2013).  
 
It has been proposed that, after internalization via one or more of the endocytic pathways, carbon 
nanomaterials are transported along the endolysosomal network inside vesicles with the help of 
motor proteins and cytoskeletal structures (Figure 13). Vesicles can transport their contents into 
sorting endosomes, or excrete/recycle them back to the cell surface by fusing with the plasma 
membrane. On the other hand endosomes can mature in lysosomes and this phenomenon is 
characterized by luminal acidification and recruitment of degradative enzymes, which target the 
vesicle contents for degradation (Chou et al. 2011). However, for drug delivery purposes, 
nanomaterials must be able to escape from the endolysosomal compartments in order to access 
cytoplasmic or nuclear targets. On the other hand, CNTs and graphene can be engineered in order to 
create a conjugate with a therapeutic molecule sensitive to pH. As an example, in a work performed 
by Sobhani et al, CNTs were functionalized on their surface with the chemotherapeutic drug 
Paclitaxel via a specific chemical bond which could be cleaved in acidic conditions, allowing a 
controlled release of the drug in the acidic tumoral environment or inside the lysosomes (Sobhani et 
al. 2011).  
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Figure 13. Endocytic uptake mechanisms of nanomaterials and their intracellular transport (adapted from 
Chou et al. 2011).   
 
I.5 Carbon nanotubes and graphene for drug delivery: focus on 
anticancer therapy 
 
I.5.1 Generalities  
The administration of free drugs is often associated with several drawbacks. First, the poor 
solubility of the drug and its aggregation in biological fluids together with its possible premature 
inactivation and poor biodistribution could reduce the molecule bioavailability. On the other hand, 
the lack of selectivity of the drug for the diseased tissues may be the cause of severe side effects, 
associated with healthy tissue damage (Bianco et al. 2004). These are just some of the 
disadvantages of conventional therapies, particularly relevant in cancer, the latter being one of the 
main socially relevant disorder, together with autoimmune diseases. In fact, despite several 
progresses have been made toward the design of more powerful and specific anticancer therapies, 
the development of new strategies to achieve a better control of the disease is still demanded.  
Drug delivery systems have been developed in order to improve the therapeutic profile of a drug. 
Among all, liposomes are one of the best known drug delivery systems. Such objects are made of a 
lipid bilayer and display a reduced cytotoxicity due to their similarity to the cell membrane. As their 
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inner cavity can be filled with one or more drug molecules, they have been developed, for instance, 
to replace conventional chemotherapy for the treatment of metastatic ovarian cancer (Gabizon et al. 
1994). Despite this, liposomes are rather instable in solution for their amphiphilic nature. Another 
example of drug delivery systems under investigation is dendrimers, branched multi-shaped 
polymers having a diameter of few nanometers (Gillies and Fréchet 2005). Despite their favorable 
size and promising abilities to delivery molecules or nucleic acids, some dendrimers have shown 
significant cytotoxicity.  
The special properties of CNTs and graphene, such as their high surface area, together with the 
development of chemical strategies to functionalize their external surface, opened the doors for their 
use as nano-platforms for the delivery of therapeutic molecules enhancing also the material 
biocompatibility (Bianco et al. 2011). In fact, as it was already described, any biological 
macromolecule can be conjugated to the surface of both materials or even encapsulated in the inner 
cavity of CNT. For example, CNTs and graphene can be conjugated with nucleic acids for plasmid 
DNA or siRNA delivery, having implications in gene therapy; with peptides, having implications 
on vaccine delivery; with proteins or antibodies, which can be useful for specific cellular targeting; 
with small therapeutic drugs, being promising tools for anticancer drug delivery (Prato et al. 2008; 
Goenka et al. 2014).  
 
I.5.2 Eluding multi-drug resistance with nanomaterials 
One of the major phenomena associated to the failure of conventional therapeutic strategies occurs 
at the cellular level. In fact, cancer cells can elude chemotherapy becoming resistant to a drug. Drug 
resistance affects patients with different types of cancer, from blood to solid tumors, including 
breast, ovarian, lung and gastro-intestinal cancers. This phenomenon could derive from a primary or 
intrinsic resistance or can be induced secondarily by a drug treatment. In both cases mutations in the 
genome of cancer cells and/or epigenetic changes are the factors responsible for the therapeutic 
failure (Figure 14), (Rebucci and Michiels 2013). For instance, gain of function mutations can occur 
in genes which are typically related to cell proliferation and survival (oncogenes). One example is 
the PI3K/Akt/mTOR signaling pathway which is activated upon the binding of a growth factor 
(such as epidermal growth factor, EGF) to its receptor. The pathway is critical in regulating the cell 
cycle entry but it is also involved in the regulation of apoptotic proteins. Several activating 
mutations of proteins which are part of this signaling pathway have been reported in human tumors 
(Hafsi et al. 2011). The Ras/Raf/MAPK or the NF-kB pro-survival signaling pathways are also 
impaired in tumors (Dhillon et al. 2007, Dolcet et al. 2005). On the other hand, loss of function 
genetic mutations were observed in tumor suppressor genes. One example is PTEN protein, which 
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is also involved in the PI3K signaling pathway, acting towards the mitotic signal derived from 
growth factors. The inactivation of the protein, by mutations in its gene or by methylation of the 
gene promoter, results in a strong pro-survival signal leading to cancer cell apoptotic-drug 
resistance (Hollander et al. 2011). Another example of tumor suppressor genes encodes for p53 
protein which is one of the main relevant transcription factors, involved in the cell cycle arrest upon 
DNA damage. When the damage is so severe to not be repaired, cells undergo apoptosis and this 
response is mediated by p53. The gene is mutated in more than half human tumors. Due to its 
fundamental function in induce apoptosis, tumor cells harboring mutated p53 are more resistant to 
chemotherapeutic drugs as demonstrated in in vitro studies but also in patients (Muller and Vousden 
2014). Several other mechanisms are then involved in drug resistance such as defective DNA 
damage response, which allow the cancer cells to survive despite the severe drug-induced DNA 
damage, or mutation in pro-apoptotic or anti-apoptotic proteins involved in the mitochondrial 
apoptosis pathway (Rebucci and Michielis 2013).  
 
 
Figure 14. Overview of the cellular mechanisms involved in cancer cell resistance to common 
chemotherapeutic drugs. The mechanisms which could be eluded by the use of CNTs and graphene as drug 
carriers are highlighted in pink.  
 
However, another interesting observation has been made in the past and consisted in the fact that 
cancer cells could be resistant to different related chemotherapeutic drugs, a phenomenon called 
multidrug resistance (MDR), (Persidis 1999). MDR is associated with a decrease in the cellular 
drug accumulation (Figure 14) by an ATP-consuming mechanism which is attributed to the 
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overexpression of particular members of the ATP-binding cassette (ABC) transporter proteins. ABC 
transporters are one of the largest and oldest families of transmembrane proteins which are highly 
conserved from prokaryotes to humans. Besides having a transmembrane domain, they are also 
composed of nucleotide binding domains necessary for ATP recognition and of a third domain 
named ABC signature motif, probably involved in the hydrolysis of ATP. In humans, 48 ABC 
genes that are organized into seven subfamilies (A–G) have been described. ABC proteins are 
responsible for the active transport of a large variety of molecules across the plasma-membrane, 
including phospholipids, ions, peptides, steroids, polysaccharides, amino acids, organic anions, bile 
acids, drugs, and other xenobiotics (Leslie et al. 2005). The first member of ABC proteins which 
was correlated to drug resistance is P-glycoprotein, encoded by the gene MDR1 (multidrug 
resistance 1) or ABCB1. Later, other members were discovered and found to be overexpressed in 
cancer cell lines which were resistant to chemotherapeutic drugs: the multidrug resistance protein 1 
(MRP1, gene symbol ABCC1), MRP2 (gene symbol ABCC2), the breast cancer resistance protein 
(BCRP, gene symbol ABCG2) and others (Persidis 1999; Leslie et al. 2005). According to the 
particular overexpressed efflux transporter, cancer cells showed resistance to several 
chemotherapeutic molecules such as DNA crosslinking agents (e.g. platinum-based drugs), anti-
microtubule drugs (e.g. taxols and vinca alkaloids) and topoisomerase inhibitors (e.g. doxorubicin 
and etoposside), all involved in blocking the cell replication. On the other hand, the drug 
accumulation inside cancer cells could be also reduced by a decrease in its active intracellular 
transport (Figure 14). For instance, cisplatin uptake has been correlated to the transporter Ctr1, 
physiologically involved in the intracellular uptake of copper. In vitro mutation or deletion of the 
Ctr1 gene results in increased cisplatin cell resistance and reduced intracellular accumulation of the 
drug (Ishida et al. 2002). Very recently, a study was performed in non-small cell lung cancer 
patients treated with platinum-based drugs. The study showed how patients having an undetectable 
Ctr1 expression in their tumors had reduced platinum concentration in the tissues and, 
consequently, a reduced tumor response compared to those with any level of Ctr1 expression (Kim 
et al. 2014).  
As we have seen, the cellular mechanisms of drug resistance are various and can act also in a 
cumulative way resulting in therapeutic failure. Despite this, for some particular agents as platinum-
based drugs, the reduction in the intracellular drug accumulation is the principal mechanism of 
resistance, accounting for 70–90% of total resistance (Siddik 2003). On the other hand, enhanced 
active transport of the drug outside the cell, but also the decrease in its uptake, requires the 
administration of higher doses. However, the non specific tissue accumulation of the therapeutic 
molecule upon administration could cause severe side effects limiting the amount of the drug that 
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can be dispensed. It is in this context that the use of CNTs and graphene as drug carriers could be 
very advantageous. In fact, as it was described previously in this thesis, CNTs and graphene have 
the ability to be efficiently internalized by endocytosis or passive diffusion by any cellular types 
and independently from the functional groups grafted on their surface (Kostarelos et al. 2007). As a 
consequence they could enhance the drug accumulation and retention inside the cells compared to 
the free drug, thus reducing the amount of compound administered. This behavior represents just 
one of multiple advantages which can be achieved using such materials as drug delivery platforms. 
In fact, they could also enhance the drug solubility and limiting aggregation phenomena. Moreover, 
in some cases, they could protect the molecule conjugated to their surface or inner cavity from 
premature inactivation, which could occur before the drug reach its target (Siddik 2003). In 
addition, the conjugation of the active molecule with both CNTs and graphene could be designed in 
order to achieve a controlled drug release. For instance, as mentioned, a drug could be linked to the 
materials through a pH sensitive cleavable bond. The molecule could be then released only once 
internalized by the cells in the acidic lysosomal lumen or in the acidic tumor environment, thus 
allowing a controlled release. Some successful works in which these and other strategies were 
exploited against cancer cells will be described in session I.5.5.  
 
I.5.3 Passive tumor targeting by the enhanced permeability and retention effect 
Another major problem related to the use of free drugs is the onset of severe secondary side effects 
due to the molecule accumulation in non-specific organs. In fact, chemotherapeutic agents generally 
act blocking at different levels the replication of fast-dividing cells, typical feature of cancer cells. 
However, they also affect cells that divide rapidly under normal circumstances such as cells in the 
bone marrow, digestive tract, and hair follicles thus inducing common side effect such as 
myelosuppression, inflammation of the digestive tract and hair loss. One example is given by 
cisplatin and its derivatives, which are used for the treatment of many types of cancer (including 
ovarian, cervical, head and neck, non-small cell lung, and lymphoma). This type of drugs are known 
to induce frequently nephrotoxicity and peripheral neurotoxicity, which derive from the non-
specific drug uptake by the proximal tubule cells of the nephron and from its accumulation on the 
dorsal root ganglion, respectively (Rabik et al. 2007).  
Besides helping in fighting drug resistance, another remarkable advantage in the use of CNTs and 
graphene as drug nanocarriers, is their ability to passively target tumor cells by the so called 
enhanced permeability and retention (EPR) effect (Iyer et al. 2006). The EPR effect is based on the 
observation made more than 30 years ago, that certain macromolecules accumulate preferentially to 
tumors (Matsumura and Maeda 1986). The phenomenon is based on the fact that most solid tumors 
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possess unique pathophysiological characteristics that are not present in normal tissues and organs. 
In fact, when a solid tumor reaches a size of 2-3 mm, cancer cells start to suffer of oxygen 
deficiency. Such stress induces the cells to secrete growth factors such as the vascular permeability 
growth factor (VEGF), which trigger angiogenesis from the adjacent capillaries. The process 
promotes the rapid development of irregular new blood vessels which differs widely from that of 
normal tissues. In fact, tumor blood vessels show an irregular shape and can be dilated and leaky, as 
endothelial cells are poorly aligned or disorganized. This results in large fenestrations in the 
capillaries that can reach sizes ranging from 200 to 2000 nm, depending on the tumor type, its 
environment and its localization. Moreover, the perivascular cells, the basal membrane and the 
smooth-muscle layer can be absent or defective. Such abnormalities promote an easy and enhanced 
extravasation of blood components to the tumor interstitium across the fenestrations of the 
discontinuous vascular bed. On the other hand, in normal tissues, the extracellular fluid is 
constantly drained to the lymphatic vessels allowing for the continuous renewal of interstitial fluid 
and the recycling of extravasated molecules back to the circulation. In tumors, the lymphatic system 
is impaired. Despite this, molecules having low molecular weight (e. g. free chemotherapeutic 
drugs) can diffuse back to the blood circulation being cleared through the renal system. However, 
bigger complexes like macromolecules and nanoparticles, are not cleared efficiently and accumulate 
in the tumor intersititium while the extravasation of such molecules to the tumor continues (Figure 
15), (Iyer et al. 2006; Bertrand et al. 2014). For example, some studies in patients have shown the 
advantage of PEGylated liposomes conjugated with the chemotherapeutic agent doxorubicin (DOX) 
compared to the free drug. In these studies, the distribution of liposomes and their loaded agent in 
patient tumors was assessed. In particular, the drug concentration in malignant exudates and tumor 
biopsies was measured. The studies usually reported an increase tumor deposition of the liposomes 
compared to the free DOX. This behavior was correlated to the preferential accumulation of 
liposomes in the tumor via the EPR effect (Bertrand et al. 2014).  
According to these observations, the advantage in the conjugation of therapeutic molecules with 
CNTs or graphene compared to the fee drug can be also hypothesized.  In fact, among all the other 
advantages described above, they have the correct size to exploit the EPR effect. Moreover, the 
ability of SWCNTs to accumulate in tumors in vivo has been already observed. In particular, in a 
work carried out by Liu et al., SWCNTs were subjected to different degree of PEGylation. The 
samples were intravenously injected in murine cancer bearing mice and the blood circulation and 
the biodistribution of the materials were assessed after two days. The materials accumulated 
preferentially into the tumors by the EPR effect, despite a certain rate of skin accumulation was also 
noticed. Interesting was the fact that the tumor accumulation increased in correlation with the 
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increase in the degree of PEGylation. This behavior was correlated with the fact that, increasing 
PEG chain densities and lengths, a significant prolonged SWCNT blood circulation was achieved 
(Liu et al. 2011).  
 
 
Figure 15. Schematic representation of the mechanism by which nanomaterials can deliver drugs to tumors 
by the EPR effect. Polymeric NPs are shown in this image as representative nanocarriers (adapted from Peer 
et al. 2007).  
 
I.5.4 Carbon nanotubes and graphene for selective cell targeting  
Although passive targeting approaches have demonstrated to be advantageous to enhance the drug 
accumulation in tumor tissues, such strategies suffer from some limitations. For example, certain 
tumors do not exhibit the EPR effect, and the permeability of vessels may not be the same 
throughout a single tumor. One way to overcome these limitations is to modify the nanocarriers in 
order to permit their active binding to specific cells after extravasation (Peer et al. 2007). Before 
describing how CNTs and graphene can be good candidates to achieve this ambitious goal, a brief 
overview of targeted therapeutic strategies will be given.  
Nowadays, the rational design of drugs able to target particular molecules which are specifically 
expressed or over-expressed by cancer cells but not by normal ones is the main focus of anticancer 
drug development and the basis of the so-called personalized medicine. The first step toward this 
objective is the identification of good biomarkers. These molecules have to be important for the 
cancer cell survival but less critical for normal tissues (Bailey 2014). Targeted therapies can be 
based on small molecules, typically developed for targeting intracellular biomarkers, or by 
monoclonal antibodies, commonly used for targets that are expressed on the cell surface. One good 
example of molecular target is represented by the ERBB receptor family (Hynes and Lane 2005).  
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ERBB are receptor tyrosine kinase (RTK) commonly known as epidermal growth factor receptors 
(EGFR). Other members of the family in humans are HER2, HER3 and HER4. Physiologically, 
ERBB receptors are expressed on the cell surface of various tissues such as epithelial, mesenchymal 
and neuronal. Upon activation by several ligands such as EGF, tumor necrosis factor α (TNF α), 
heparin-binding EGF and others, the homo- and hetero-dimerization of the receptor is induced. This 
leads to the phosphorylation on specifc tyrosine residues within the cytoplasmic tail of the receptor. 
The recruitment of a range of proteins on these phosphorylated residues leads to the activation of 
intracellular signaling pathways fundamentals for the cell proliferation and differentiation such as 
the PI3K/Akt/mTOR previously mentioned (see session I.5.2). ERBB receptors also show various 
types of alterations in human tumors. Among them, EGFR overexpression is often found in human 
cancers together with an enhanced production of EGF by the tumor cells themselves. These 
phenomena lead to a constitutive activation of the receptors promoting cancer cells survival, thus 
making ERBB receptors excellent candidates for selective anticancer therapies. In fact, several 
antibodies directed against the extracellular domain of such receptors or to their kinase domain are 
in clinical use. One example is Cetuximab, which is a potent inhibitor of cancer cells which display 
high EGFR activation. Cetuximab treatment was approved in 2003 for the treatment of advanced 
colorectal cancer. Another example is Trastuzumab, which is effective against HER2-
overexpressing breast cancer cells. Despite the mechanisms of many targeting antibody have to be 
still clarified, generally, they are able to block the ERBB-induced intracellular signaling pathways 
thus leading to cancer cell depletion. Together with ERBB receptors several other tumor biomarkers 
and related targeted therapies have been approved by the FDA (Bailey et al. 2014).  
On the other hand, targeted therapies showed advantages not only in cancer treatment, but also in 
autoimmune diseases (Townsend et al. 2010). Most of the approaches in this context are directed 
toward a specific cell population that is represented by B lymphocytes. In fact, B cells have a role in 
several autoimmune diseases such as Systemic Lupus Erythematosus (SLE) or Rheumatoid 
Arthritis (RA) in which autoreactive B lymphocytes, the direct precursors of autoantibody-secreting 
cells, are involved in the exacerbation of the disease (Yanaba et al. 2008). To give an example, 
important progresses have been made with the use of the chimeric antibody Rituximab, which 
specifically targets the CD20 molecule (Gürcan et al. 2009). CD20 is mainly expressed at the 
surface of B lymphocytes, and its function is to enable an optimal B cell immune response. B cells 
can be depleted upon recognition by anti-CD20 antibodies (Anolik et al. 2004).   
Although significant progresses have been made in the field of targeted therapies they are not free 
from disadvantages. In fact, not all patients respond in the same way to the targeted anticancer 
treatments; secondary side effects and acquired resistance to targeted therapies were also evidenced 
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(Hynes and Lane 2005; Widakowich et al. 2007). On the other hand, despite Rituximab therapy has 
been reported to be successful for systemic autoimmune diseases such as RA (Keystone et al. 2008), 
trials with the same antibody gave variable results in other autoimmune diseases such as SLE 
(Albert et al. 2008). Secondary side effects upon Rituximab administration were observed also in 
this context (Carson et al. 2009). The latter observations evidence the fact that other strategies are 
demanded for a better specific depletion of cells involved in the disease pathogenesis.  
We have seen how chemical reactions have been developed for CNT and graphene multiple 
functionalization (Prato et al. 2007; Spinato et al. 2014) allowing them to carry several molecules 
at once. The latter characteristic makes the materials advantageous, compared to other nanocarriers, 
in the treatment of cancer, but also of other diseases in which the specific depletion of a cell 
population is demanded. In fact, both materials can be conjugated with the targeting antibodies 
described above but also with a large variety of other groups, able to recognize molecules 
specifically expressed on the surface of a particular cell population. This, together with the ability to 
carry a suitable therapeutic molecule, which can also be encapsulated in the inner cavity of CNTs 
makes the materials powerful tools for a combined and more effective therapeutic strategy (Figure 
16).  
 
 
Figure 16. Targeted drug delivery using CNTs and graphene. Some examples of targeting and therapeutic 
moieties which can be conjugated with the materials are also shown.  
 
In order to better understand the potentiality of CNTs and graphene towards anticancer therapy, all 
the advantages can be summarized with an example. CNTs could be filled with a chemotherapeutic 
Targeting
moiety
Drug
Drug
Target cell
 EGF
 Folic acid
 anti -P-glycoprotein
 Cisplatin
Doxorubicin
 Paclitaxel
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drug, which could be also designed in order to achieve a controlled drug release (e. g. only after 
cellular internalization), while their external surface could be functionalized with a specific 
targeting molecule such as the monoclonal antibodies Cetuximab or Transtuzumab. Once injected 
into patients, having cancer overexpressing EGFR or HER2, the conjugates could specifically target 
the tumor tissues by both the EPR effect and active targeting. Moreover, in this case, the antibodies 
could exert both a targeting function but also therapeutic as they are able to block ERBB-induced 
intracellular survival signaling pathways leading to cancer cells depletion. CNTs could be also 
internalized by the cancer cells (e. g. by receptor-mediated endocytosis) allowing the cytotoxic 
drug, encapsulated within their inner cavity, to be release and exert its cytotoxic effect. Such 
example show how, by the use of CNTs as multiple drug delivery platform, we could specifically 
reach cancer tissues combining two different mechanisms of tumor targeting, avoiding the 
unwanted drug accumulation in non-specific tissues and consequently the onset of secondary size 
effects. In addition, cancer cells could be killed via a powerful strategy which combines two 
different mechanisms: the first derived by the targeting antibody and the second exploiting the 
cytotoxicity of the encapsulated drug.  
 
I.5.5 Delivery of anti-tumor agents using carbon nanotubes and graphene  
In this session, some examples of successful in vitro and in vivo studies in which the mechanisms 
described above were exploited using CNTs and graphene as anti-cancer drug carriers will be 
described. 
In a work carried out by Liu et al. in 2007, the chemotherapeutic drug DOX was non-covalently 
conjugated to the surface of PEGylated SWCNTs. The complexation between DOX and the 
materials was pH dependent, allowing the drug to be released in acidic conditions (as in tumor 
environment or inside the cells in the lysosome lumen). The DOX-SWCNTs were then tested for 
their anticancer activity on human glioblastoma cancer cells. In this case, the complexes showed the 
same cytotoxicity as the free drug in the in vitro test. However, in the same study, DOX-SWCNT 
complexes were further conjugated with the RGD peptide (arginylglycylaspartic acid). The latter 
acts recognizing the integrin αvβ3 which is a receptor over-expressed in a wide range of solid tumors 
where it is implicated in tumor angiogenesis. The conjugate was tested towards the glioblastoma 
cancer cell line which was αvβ3-positive and showed enhanced drug delivery ability compared to the 
CNTs without RGD. Moreover, the IC50 value (half maximal inhibitory concentration), was smaller 
compared to both the free drug and the derivative without the targeting peptide, thus making RGD-
DOX-SWCNTs more cytotoxic then DOX-SWCNTs (Liu et al. 2007). In another study, the same 
drug was non-covalently conjugated on the surface of SWCNTs which were also functionalized 
with an antibody directed towards P-glycoprotein (P-gp) the latter being one of the major player in 
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the phenomenon of MDR (see session I.5.2). The construct was then used to treat human leukemia 
cells, over-expressing P-gp and consequently resistant to DOX. Upon near-infrared cell irradiation, 
the drug could be released from the carrier. After 24 hours, DOX was localized inside the cells in 
much higher quantities compared to cells exposed to the drug alone or together with the anti P-gp 
antibodies but without CNTs. Moreover, the free drug could only partially inhibit cell growth, while 
the construct was more efficient in killing the DOX-resistant cancer cells and in a time-dependent 
manner (Li et al. 2010). Several other drug types have been conjugated with carbon nanotubes. An 
example is the anti-microtubules agent Paclitaxel (PTX) which has been attached on the surface of 
PEGylated SWCNTs through an ester bond, allowing a controlled drug release in acidic conditions 
or upon enzymatic hydrolysis of the ester. The construct was then tested both in vitro in a murine 
breast cancer cell model (4T1) and then in vivo in 4T1 murine breast cancer mice model. While in 
the in vitro experiment the conjugate displayed the same toxicity as the free drug, the in vivo 
experiment gave promising results as the SWCNT-PTX complex was able to inhibit the tumor 
growth two times more compared to the free drug Taxol
®
. Despite a higher PTX amount was found 
in the RES organs, biodistribution studies showed that PTX levels in the tumors were 10 times 
higher for the SWCNT-PTX derivative compared to the free drug 2 hours post-injection. The 
accumulation in normal organs was also reduced, thus evidencing a better selectivity of the CNT-
delivered drug for the tumor due to the EPR effect (Liu et al. 2008 B). The last example in the use 
of CNTs for tumor targeted drug delivery involves the platinum-based chemotherapeutic drug 
cisplatin. In the study performed by Bhirde et al, SWCNTs were covalently conjugated with 
cisplatin. At the same time the materials carried EGF as targeting moiety, in order to selectively act 
on EGFR over-expressing cancer cells. The conjugate was first tested for its in vitro ability to 
specifically target human head and neck squamous cancer cells (HNSCC), using also the non 
targeting control SWCNT-cisplatin without EGF. The bioconjugates were rapidly uptaken by the 
cancer cells. Limited uptake occurred for control cells without EGF, and uptake was blocked by 
siRNA knockdown of EGFR in cancer cells, revealing the importance of EGF-EGFR binding. 
Moreover, when the conjugates were injected into mice bearing HNSCC tumor, the EGF-CNTs 
showed a much higher accumulation in the tumor compared to the control CNTs without the 
targeting group. In addition, the tumor growth in the case of the targeting complex was inhibited in 
a larger extent compared to the control CNT-cisplatin alone, demonstrating the efficient and 
selective deliver of the drug towards EGFR over-expressing tumors (Bhirde et al. 2009).  
Inspired by the encouraging studies towards the use of CNTs in drug delivery, promising results 
have been obtained also with graphene, in particular in the form of graphene oxide. Liu et al. 
investigated for first the possibility to deliver water insoluble anticancer drugs into cells using GO 
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as nanocarrier. After GO covalent PEGylation, an analogue of the chemotherapeutic drug 
camptothecin (CPT) was non-covalently conjugated with GO and tested on a cell line of human 
colorectal carcinoma (HCT-166). Interestingly, PEGylated CPT-GO was 1000 times more cytotoxic 
compared to the drug alone, thus evidencing the potential of graphene in drug delivery (Liu et al. 
2008 C). The same group demonstrated the possibility to use graphene also for cell targeting 
conjugating PEG-GO with the antibody Rituximab directed towards the molecule CD20, expressed 
on the surface of B lymphocytes. GO was also non-covalently conjugated with DOX whose binding 
was pH dependent thus allowing a controlled release of the drug. The complex efficiently targeted a 
B cell lymphoma cell line CD20 positive, but not a control cell line not expressing the target 
molecule. Moreover, in vitro cytotoxicity experiments showed a significant increased efficacy 
toward Raji cells of the GO-PEG-Ab/DOX conjugate compared to both free DOX and the GO 
conjugate without the targeting antibody (Sun et al. 2008). Finally, the ability of GO to target tumor 
neovasculature was demonstrated in vivo in a proof of concept study. For this purpose, GO was 
covalently conjugated with an antibody (TRC105) directed against CD105, an endoglin almost 
exclusively expressed on proliferating endothelial cells, thus being an ideal marker for tumor 
angiogenesis. After observing the specific targeting ability toward CD105 positive cells in vitro, the 
complexes were injected in mice bearing 4T1 breast tumors (which express high levels of CD105 
on their vasculature). The biodistribution of the conjugates could be then followed by PET because 
GO was radiolabeled. Results showed a significantly higher uptake in the tumors in the case of 
TRC105-GO compared to the non targeted GO (Hong et al. 2012).  
 
I.5.6 Delivery of other therapeutic molecules  
Besides the small anti-cancer drugs described in the previous session, other molecules of biological 
interest/therapeutic can be conjugated with both CNTs and graphene exploiting diverse chemical 
strategies. For instance, the materials can be conjugated with nucleic acids having important 
implication in gene therapy, the latter being another promising research area which has the purpose 
to treat genetic disorders and cancer by replacing/silencing the diseased gene responsible for the 
impaired phenotype. Successful gene therapy requires efficient and safe gene vectors that protect 
DNA or RNA from nuclease degradation as well as facilitate their uptake with high transfection 
efficiency. CNTs and graphene have been explored for their ability to efficiently protect and deliver 
plasmid DNA to diverse cellular models enhancing the transfection efficiency in comparison to 
other standard transfection systems. Similarly, the materials successfully delivered small interfering 
RNA (siRNA) to cells showing silencing activity towards specific genes (Vashist et al. 2011; 
Goenka et al. 2014). The majority of such studies were performed in vitro thus requiring further 
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exploration to validate the in vivo use of this methodology. However, in a recent work, a siRNA 
specific for the proto-oncogene Braf, was delivered topically to a mouse melanoma model resulting 
in the successful attenuation of tumor growth (Siu et al. 2014).  
Another class of CNT-based therapeutic candidates consists in complexes between the material and 
synthetic peptide for immune system activation (Pantarotto et al. 2003).  A B cell epitope from a 
coat protein of foot and mouth-disease virus (FMDV) was conjugated to CNTs. The antigenic and 
immunogenic properties of the materials were then measured in mice. The conjugates were able to 
elicit a higher antibody response in comparison to the non-conjugated peptide. Furthermore, the 
generated antibodies neutralized the virus, thus demonstrating the potential of carbon nanotubes as 
components for synthetic vaccine development.  
Finally, CNTs could be useful for the delivery of radioactivity to tumors as the materials can be 
filled in their inner cavity with particular radioisotopes and then sealed to avoid non-specific 
leakage of the carried agent (Zhang et al. 2010). In fact, once again, the CNT-isotope conjugate 
could passively target solid tumors by the EPR effect or actively, after conjugation with targeting 
groups thus allowing for a targeted anti-cancer radiotherapy.  
 
I.6 Other biomedical applications of carbon nanotubes and graphene  
I.6.1 Hyperthermia therapy 
In the medical field, hyperthermia consists in a rise in temperature of body tissues, globally or 
locally. Concerning cancer therapy, this elevation in temperature can be modulated intentionally to 
induce cancer cell death. If very high temperatures are used, cancer cells can die immediately, 
largely through necrosis. This is often called local hyperthermia or thermal ablation. On the other 
hand, the temperature of a part of the body (or even the whole body) can be raised a few degrees 
higher than normal helping other cancer treatments such as radiation, immunotherapy, or 
chemotherapy to work better. This is called regional hyperthermia or whole-body hyperthermia 
(www.cancer.org).  Carbon nanotubes and graphene offer a great combination of characteristics for 
the development of a new generation of the so-called photothermal agents. In fact, following 
exposure to near infrared radiation (NIR), CNTs and graphene enter an excited state and release 
vibrational energy that is transformed into heat (Singh and Torti 2013). Several in vitro and in vivo 
preclinical studies were performed in cancer models exploiting carbon nanotubes as hyperthermia 
agents (Singh and Torti 2013). For instance, a study carried out by Burke and co-authors evidenced 
how CNTs can be superior to other heat delivery modalities in ablating cancer stem cells. Triple-
negative breast cancer stem cells (BCSCs) were markedly resistant to traditional hyperthermia and 
become enriched in the surviving cell population following treatment. However, BCSCs were found 
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to be sensitive to the nanotube-mediated thermal therapy and lost their long-term proliferative 
capacity after the treatment. Moreover, the use of this strategy in vivo promoted complete tumor 
regression and long-term survival of mice bearing cancer stem cell-driven breast tumors (Burke et 
al. 2012). The thermal ablation of tumors has been performed also with graphene. A study showed 
how PEGylated nano-graphene sheets were able to accumulate into tumors in mice, in different 
xenograft tumor models. Highly efficient tumor destruction was then achieved by intravenous NGS 
injection followed by low power NIR laser irradiation (Yank et al. 2010). 
 
I.6.2 Tissue regeneration  
CNTs and graphene are protagonists of another fundamental biomedical field that is tissue 
engineering, being particularly relevant in the context of neurodegenerative diseases or traumatic 
injuries. In fact the damage to the central nervous system (CNS) is particular devastating because of 
its limited regenerative capacity. The strategies to repair the CNS address the regrowth of injured 
axons, the plastic remodeling of neuronal circuitry and the generation of new neurons or other CNS 
cell types by stem-cell transplantation. These objectives require governing several processes. For 
instance, axon regrowth necessitates of proper axonal spatial organization, target recognition and 
the reconstruction of functional synapses. On the other hand, stem cell transplantation requires cell 
survival and appropriate differentiation toward the specific cells of interest. To reach these goals, 
the design of new neuroregeneration-supporting scaffolds is demanded. Such scaffolds must be 
biocompatible and should promote the cellular reorganization toward a functional neuronal 
assembly. Proof-of-concept studies showed how CNTs could be promising candidates to develop 
synthetic material-based implants (Fabbro et al. 2013). In fact, CNTs, but also graphene, possess 
the ability to highly improve neural cell adhesion and growth, improve cell viability and mimic the 
extracellular matrix environment due to their nanoscale organization and rugosity. For instance, 
CNT scaffolds showed to promote neuronal cell growth and neurite elongation, but also to increase 
the spontaneous synaptic activity of nerve cells. Moreover, it has been suggested that the same 
material could promote neural stem cell (NSC) differentiation toward the neuronal lineage (Fabbro 
et al. 2013). Concerning graphene, an interesting paper evidenced how graphene-polycaprolactone 
hybrid scaffolds could promote NCS differentiation into olygodendrocytes, simply mimicking their 
in vivo microenvironment (Figure 17). Such observation is promising has the differentiation of 
NSCs into this cell type is particularly challenging and could have great implications in 
demyelinating diseases such as multiple sclerosis (Shah et al. 2014).    
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Figure 17. Field emission-scanning electron microscope (FE-SEM) images of PCL nanofibers coated with 
GO (a). FE-SEM of differentiated NSCs cultured on graphene-nanofiber hybrid scaffolds after six days of 
culture (b). The cells are pseudo-colored blue for contrast and display the typical morphological 
characteristics of oligodendrocytes (adapted from Shah et al. 2014).  
 
I.6.3 Biosensing 
A biosensor is a device able to detect a certain biologically relevant molecule quantity and 
transduce it into a signal. The development of new material-based biosensors is of fundamental 
importance in healthcare, where new diagnostic tools, are needed to improve clinical treatment. 
Carbon nanotubes and graphene have shown great promises also in this field as they can be used as 
building blocks for the fabrication of highly sensitive and selective biosensors. In fact, their 
nanoscale size allows improving the sensor performance as the sensing elements have the same 
dimensions (i.e. nm) of the biological entities that have to be detected. To do this, they have to be 
composed of a recognition unit that provides a selective interaction with the analyte and of a 
transduction unit that converts the recognition event into an observable signal. Concerning the first 
unit, CNTs and graphene can be conjugated with any biological entity of interest, as a molecule 
complementary to the one which has to be detected (e.g. single stranded-DNA). Upon analyte 
recognition, the signal can be transduced in several ways according also to the type of material. For 
example, the binding with the molecule of interest can change the charge of the carrier or can 
change its fluorescent spectrum (in the case of auto-fluorescent semi-conducting CNTs) (Kruss et 
al. 2013). Complementary molecules can be also conjugated with a fluorophore and the binding 
with the analyte is detected exploiting the phenomenon of fluorescence resonance energy transfer 
(FRET). The use of graphene for FRET-based biosensors is of particular interest (Wang et al. 
2011). Examples of biological entities that were successfully detected by these types of biosensors 
are shown in Figure 18. For instance, the ability to detect changes in DNA sequence and structure 
may be useful for applications in personalized medicine, while the detection of proteins and 
2 µM
10 µM2 µM
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Chapter I: Introduction  43 
 
biomarkers, either circulating in body fluids, or displayed in the cell surface, is indicative of 
relevant diseased states such as cancer. Other interesting molecules involved in important cellular 
processes were detected by CNT-based biosensors: ATP, reactive oxygen/nitrogen species (ROS), 
H2O2, nitric oxide (NO) and glucose (Kruss et al. 2013).  
 
 
Figure 18. Principles of graphene-based FRET biosensors. ssDNA, aptamers and MBs (molecular beacons 
can be adsorbed onto the surfaces of graphene. Fluorophore labels on the ends of probes are quenched 
rapidly when adsorbed onto the graphene surface. When analytes (e.g. complementary DNA, thrombin and a 
designed complementary ssDNA are introduced into the systems and bind their probes (ssDNA, aptamer and 
MB, respectively), the probe fluorescence is recovered, thus allowing detection. Conversely, double stranded 
DNA remains fluorescent before an enzyme (e.g. helicase) is introduced; ssDNA is then released, and 
fluorophore on the ssDNA is quenched by graphene-based nanomaterials (from Wang et al. 2011).  
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Aims of the thesis 
The work presented in this thesis has been carried out both at Sapienza Università di Roma under 
the supervision of Dr. Gianfranco Scarsella and Dr. Gianfranco Risuleo and at the Institut de 
Biologie Moléulaire et Cellulaire in Strasbourg. In the latter, I could develop my research in the 
team of Dr. Alberto Bianco as a guest for fourteen months of my PhD. During the three years of my 
PhD internship, I was involved in three different projects, all based on the investigation of the 
effects of carbon nanomaterials in a biological environment. Furthermore, I investigated the 
possibility to use these materials for biomedical applications.  
In detail, the project started by our group in Roma as a new project that involved the use of carbon 
nanotubes. This was possible thanks to the experience obtained by precedent works on the 
application of other types of nanomaterials such as cat-anionic vesicle systems as transfection 
vectors. The project was carried out in collaboration with the chemistry and physics department at 
the same university. As mentioned in the first chapter, a careful assessment of carbon nanomaterial 
toxicity is still an issue under intense investigation; the aim is the further exploitation of such 
materials in nanomedicine. For this reason, the project started with the assessment of the 
cytotoxicity of pristine single-walled carbon nanotubes using different cell lines and exploiting 
various techniques. In particular, the idea was to disperse CNTs using biocompatible molecules 
that, after adsorption on their surface, could increase their solubility in aqueous media and could 
protect the materials from their intrinsic toxicity. To this end, CNTs were dispersed with Bovine 
Serum Albumin (BSA) and several cell vital parameters such as cell viability, cell activation and 
cellular interaction mechanisms, were investigated.  
Hereafter, my research has focused more on the bio-applications of carbon nanomaterials. 
Therefore, the second project, in which I was involved in the group of Alberto Bianco, concerned 
the use of carbon nanotubes for drug delivery, aimed particularly to anticancer therapy. For this 
purpose, a hydrophobic Pt(IV) prodrug of cisplatin was encapsulated within the internal cavity of 
two types of functionalized multi-walled carbon nanotubes with different diameter in order to allow 
a controlled release inside the cell. Subsequently, the anticancer efficacy, the possible induction of a 
pro-inflammatory response and the cellular uptake were investigated on different cell types. The 
intracellular platinum accumulation after exposure to the different complexes was also explored. In 
addition, the effect of the diameter of multi-walled carbon nantubes on the release and activity of 
the Pt(IV) prodrug was examined for the first time.  
Finally, following the experience gained with carbon nanotubes, the theme of my research moved 
on graphene. Like carbon nanotubes, the first important step in view of a possible biological 
application of graphene is the investigation of its toxicity. For this reason, initially, different types 
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of graphene were tested for their cytotoxicity, cell activation and internalization mechanisms on 
different cell lines and primary macrophages. Afterwards, the final part of my research was focused 
on one of the most interesting bioapplication of carbon nanomaterials: the specific cell targeting. 
For this purpose, graphene oxide was conjugated by non-covalent interaction with Hen Egg 
Lysozyme (HEL). The complexes were then tested for their ability to target a model of B cells 
genetically modified to overexpress a B cell receptor specific for lysozyme.  
The results obtained during the development of the projects are presented in three different 
chapters. Moreover, each chapter is designed to have its own concise and appropriate introduction 
as well as conclusions and its own experimental section.  
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CHAPTER II 
BSA-dispersed single-walled carbon nanotubes for an 
enhanced biocompatibility 
 
II.1 Introduction 
Thanks to their unique size-related properties, having a diameter included between 0.7 and 3 nm, 
single-walled carbon nanotubes are a promising type of CNTs to be exploited in the field of 
nanomedicine (Liang and Chen 2010).  However, development of SWCNT-based cellular 
technologies necessitates several advances over multiple aspects. First, as already described, the 
generation of biocompatible SWCNTs that are not toxic and/or elicit immune responses is 
demanded. In addition, it is important to remember that one severe problem arises when CNTs are 
used in biology and is related to their poor dispersibility in aqueous media. In fact, strong van der 
Waals attractions among the tubes lead to their aggregation in large bundles (Haddon 2002). At the 
beginning, bundled, non-purified and long SWCNTs have been associated with toxicity and 
negative cellular effects (Kolosnjaj et al. 2007; Holt et al. 2010). However, CNT dispersibility in 
aqueous media can be improved using several dispersant molecules such as DNA (Zheng et al. 
2003; Tardani and Sennato 2014), proteins (Matsuura et al. 2006; Nepal and Geckeler 2006), 
polymers (Rice et al. 2006) and others. Among them, protein dispersions are of particular interest in 
the context of SWCNT bioapplications. In fact, it has been shown that the interaction of some 
proteins with CNTs can enhance their biocompatibility with respect to pristine CNTs (Shim et al. 
2002; Ge et al. 2011). On the other hand, as extensively described in the first chapter, the surface of 
CNTs can also be externally functionalized improving the CNT solubility in aqueous media and 
also biocompatibility (Bianco et al. 2011). Despite this, there are a few studies in literature aiming 
at improving SWCNT biocompatibility, in terms of both solubility and toxicity, after 
functionalization with proteins. 
For a better understanding of the behavior of protein-stabilized SWCNTs in biological 
environments, in this proof-of-concept study, pure and pristine SWCNTs were dispersed with BSA 
protein. BSA-stabilized SWCNTs were then tested for their cytotoxicity and induction of a 
proinflammatory response toward murine fibroblast 3T6, human embryonic kidney cells HEK 293 
and murine RAW 264.7 macrophages. The poorly investigated long-term effects of SWCNTs were 
also analyzed, in terms of cellular proliferation, after cells were let recover from the materials. The 
internalization/interaction mechanisms of protein-stabilized CNTs with cells and their membranes 
are poorly investigated as well (Holt et al. 2012). For this reason, the cellular uptake of BSA-
Chapter II: BSA-dispersed SWCNT biocompatibility  47 
 
SWCNTs was explored by Transmission Electron Microscopy. Furthermore, the CNT effect on 
specific dielectric parameters of the plasma membrane was investigated by a biophysical technique 
named electrorotation.  
 
II.2 Experimental section  
 
Materials 
Pure high-pressure carbon monoxide (HiPco) single-wall carbon nanotubes were purchased from 
Unidym. Main characteristics are shown in Figure 1. SWCNTs were dispersed in 0.5 % BSA in 
deionized water. Stock solutions of 1 mg/ml were prepared sonicating the samples for 2 h in an 
ice/water bath. CNTs were diluted to the appropriate concentrations in complete medium prior to 
cellular exposure.  
 
 
Figure 1. Commercial Unidym pure HiPco SWCNT characteristics and preparation. 
 
The dispersions thus obtained were characterized by Atomic Force Microscopy (AFM) and 
Dynamic Light Scattering (DLS) techniques in collaboration with the Chemistry and Physics 
Department at Sapienza University in Rome. Briefly, for AFM observations, a representative CNT 
sample was deposited on freshly cleaved mica, incubated for 10 min, then rinsed with Milli-Q 
water, gently dried and observed with a Dimension Icon (Bruker AXS)  AFM instrument. DLS 
measurements were performed with a Malvern Zetasizer ZS unit equipped with a He−Ne laser 
operating at a wavelength of 633 nm. The stability of one representative BSA-SWCNT dispersion 
was analyzed following the absorbance changes at 600 nm over time, using a Varian Cary 50 UV-
Vis Spectrophotometer. Prior to the analysis, the 1 mg/ml SWCNT solution was diluted 1:10 either 
2h sonication, 
0,1% NTs in 
0,5 % BSA
Individual SWNT 
Diameter
~0.8 – 1.2 nm
Individual SWNT 
Length
~100 – 1000 nm
TGA Residue as
Fe
< 15 wt %
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in water or in complete cell culture medium (the latter being useful to avoid an effect of the medium 
components on the complex stability).  
 
Cell cultures 
Human embryonic kidney cells HEK 293, murine fibroblast 3T6 and murine macrophages RAW 
264.7 were used in this study. All the cell lines were purchased from ATCC (VA, USA). HEK 293 
and 3T6 cells where maintained in DMEM medium supplemented with 10 % FBS and 
penicillin/streptomicyn (100 U/ml and 100 μg/ml, respectively). Media and solutions were 
purchased from Euroclone. RAW 264.7 cells were cultured in RPMI 1640 medium supplemented 
with 10 % heat inactivated FBS and 100 U/ml gentamycin with the addition of 50 µM β-
mercaptoethanol and 20 mM HEPES. Media and solutions were purchased from Lonza. All the 
cells were incubated at 37 ºC in humidified air containing 5% CO2. When confluency reached 70-80 
%, HEK 293, 3T6 or RAW 264.7 cells were washed with phosphate buffered saline (PBS), 
detached with trypsin or with SE buffer in the case of RAW 264.7 cells (PBS containing 2 mM 
EDTA and 2 % FBS),  and subcultured every 2-3 days. Prior to CNT exposure, cells were detached, 
counted and reseeded in proper well size and density (see each particular experiment for details) 
and allowed to adhere overnight.  
 
Mosmann colorimetric assay (MTT) 
The cytotoxicity of BSA-SWCNTs towards HEK 293 and 3T6 cell lines was first evaluated by the 
MTT assay. NAD(P)H-dependent cellular oxidoreductase enzymes are capable of reducing the 
tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble 
formazan, which has a purple color. The color intensity can be directly correlated to the number of 
viable cells.  
HEK 293 or 3T6 cells were seeded into 24-well culture plates at a density of 10
5 
or
 
5·10
4
 cells per 
well, respectively, and allowed to adhere overnight. The cells were then exposed to different 
concentrations of the CNT samples (from 10 to 100 µg/ml during 24, 48 or 72 h). Dimethyl 
sulfoxide (DMSO-20 %) was used as cellular death positive control. MTT powder (sigma M5655) 
was dissolved in distilled water according to manufacturer’s instruction. Prior to use, MTT was 
diluted 1:5 in serum/antibiotics free medium. At the end of the CNT exposures, cells were washed 
with PBS and 420 µl of the diluted MTT were added to each well. Cells were then incubated for 
about 4 h at 37 ºC (5% CO2). At the end of the incubation, formazan crystals were dissolved adding 
700 µl of acid isopropanol (0.08 M HCl) and the absorbance at 570 nm was read using a Varian 
Cary 50 ultraviolet–visible (UV-Vis) Spectrophotometer.  
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Cell counts 
Cell counts after exposure to BSA-SWCNTs were performed in order to investigate the long-term 
effect of our CNT samples on cellular proliferation. Briefly, HEK 293 or 3T6 cells were seeded into 
24-well culture plates at a density of 10
5 
or
 
5·10
4
 cells per well, respectively, and allowed to adhere 
overnight. The cells were then exposed to 100 µg/ml of BSA-SWCNTs during 24, 48 or 72 h. At 
the end of the incubation, cells were harvested and subcultured in same number for another 24, 48 
or 72 h. After these times, cells were again detached and counted using a Neubauer chamber.  
 
Flow cytometry analysis 
Cell viability 
Cell viability of HEK 293 and 3T6 cells after exposure to our CNT samples was further investigated 
by flow cytometry. 
Cells were seeded into 96-well plates at a density of 2·10
4
 cells per well concerning HEK 293 and 
3T6 and at a density of 1·10
5
 cells/well in the case of RAW 264.7 and allowed to adhere overnigh. 
The cells were then exposed to the same concentrations used for the MTT assay of pristine 
SWCNTs or BSA-SWCNTs during 24, 48 or 72 h. DMSO (20 %) was used as cellular death 
positive control. After incubation, RAW 264.7 supernatants were collected and kept at -20 ºC for 
further investigations and cells were harvested with trypsin (HEK 293 and 3T6) or SE buffer (RAW 
264.7) and stained with both FITC-Annexin V (AnnV; BD Pharmingen 556419) and propidium 
iodide (PI, 0.2 μg/ml; Sigma-Aldrich) in a calcium containing buffer. Cells that are considered 
viable are negative for both AnnV and PI stainings, while cells that are in early apoptosis are AnnV 
positive but PI negative, and cells that are in late apoptosis or necrotic are positive for both 
stainings. The percentage of live (AnnV-/PI-), early apoptotic (AnnV+/PI-) and late 
apoptotic/necrotic (AnnV+/PI+ and AnnV-/PI+) cells was determined by acquiring at least 30000 
events using a Gallios flow cytometer (Beckman Coulter, Villepinte-France) and analysing the data 
with FlowJo software.  
Cell activation 
RAW 264.7 activation was explored through CD86 expression levels. Briefly, cells were seeded as 
previously described for the cell viability experiments. After incubation with CNTs cells were 
detached with SE buffer and stained with PE-Rat anti-Mouse CD86 antibodies (Clone GL1, BD 
Pharmingen 553692), prior to flow cytometry acquisition. Lipopolysaccharide (LPS, 1 μg/ml) was 
used as cell activation positive control. The CD86 associated fluorescence intensity was determined 
by acquiring at least 30000 events using a Gallios flow cytometer (Beckman Coulter, Villepinte-
France) and analysing the data on live cell gated population (AnnV-/PI-) with FlowJo software.  
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TUNEL assay 
The apoptosis induction by BSA-dispersed SWCNTs towards HEK 293 and 3T6 cell lines was 
specifically evaluated by TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) 
assay (DeadEnd
TM 
Fluorometric TUNEL System, Promega). The TUNEL system measures the 
fragmented DNA of apoptotic cells by catalytically incorporating fluorescein-12dUTP at 3´-OH 
DNA ends using the Terminal Deoxynucleotidyl Transferase, Recombinant, enzyme (rTdT). The 
damaged DNA can then be visualized directly by fluorescence microscopy.  
HEK 293 or 3T6 cells were seeded into 6-well plates on glass coverslips at a density of 3·10
5
 cells 
per well and allowed to adhere overnight prior to exposure to 30 or 100 µg/ml of BSA-SWCNTs 
during 24 h. The assay was then performed according to the manufacturer protocol. Briefly, cells 
were fixed in 4% paraformaldehyde for 25´ at 4 ºC. Cells were then washed with PBS and 
permeabilized with 0.2 % triton X-100 solution for 5´. Cells were extensively washed with PBS. A 
positive control was prepared incubating control cells with DNase I. The samples were then 
equilibrated and incubated with a mixture of equilibration buffer, nucleotide mix and rTdT enzyme 
for 1 h in a humidified chamber. After a subsequent 15´ incubation with saline-sodium citrate (SSC) 
buffer, cells were washed and the nuclei were stained with Hoechst 33342 (2 μg/ml in PBS) for 10´. 
The coverslips were then washed with deionised water, mounted on slides and analysed by 
fluorescence microscopy. For each sample, 300 nuclei were counted, in order to calculate the 
percentage of TUNEL-positive cells. 
 
Cytokine determination 
RAW 264.7 macrophages supernatants were collected after treatment for cell viability experiment 
and the levels of murine pro-inflammatory cytokines tumor necrosis factor alpha (TNF α), and 
interleukin 6 (IL6), were detected by a double sandwich ELISA (enzyme-linked immunosorbent 
assay). Lipopolysaccharide (LPS, 1 μg/ml) was used as pro-inflammatory cytochine production 
positive control. Polyvinyl microtiter plates (Falcon) were coated overnight at 4 °C with 50 μl/well 
of purified Hamster Anti-Mouse/Rat TNF α (BD Pharmingen 557516) or purified Rat Anti-Mouse 
IL6 (BD Pharmingen 554400) diluted in 0.05 M carbonate buffer, pH 9.6. After washings with PBS 
containing 0.05 % Tween (PBS-T), a saturation step was performed by adding 100 µl/well of PBS 
containing 10% FBS for 1 h at 37 °C. After washings with PBS-T, 50 μl/well of culture 
supernatants or Recombinant Mouse TNF (BD Pharmingen 554589) or Recombinant Mouse IL6 
(BD Pharmingen 554582), diluted in PBS-10% FBS, were added for 2 h at 37 °C. Plates were then 
washed with PBS-T and 50 μl/well of secondary Biotin Rabbit Anti-Rat/Mouse TNF (BD 
Pharmingen 557432) or Biotin Rat Anti-Mouse TNF (BD Pharmingen 554402), diluted in PBS-
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10% FBS, were incubated for 1 h at 37 °C. Plates were washed with PBS-T, and 50 μl of 
streptavidin conjugated to horseradish peroxidase diluted in PBS-10% FBS were added per well. 
After 30 min incubation at 37 °C, plates were washed extensively and the enzymatic reaction, 
revealing the presence of cytokines in the tested supernatants, was visualized by adding 75 µl/well 
of 3,3’,5,5’-tetramethylbenzidine diluted in 0.1 M citrate buffer, pH 5, in the presence of H2O2. The 
resulting absorbance was measured at 450 nm after the reaction was stopped with 25 µl/well of HCl 
1 N. 
 
Transmission Electron Microscopy 
For TEM observation, HEK 293 or 3T6 cells were seeded into 24-well plates on glass coverslips at 
a density of 5·10
5
 cells per well and allowed to adhere overnight prior to exposure to 50 µg/ml of 
BSA-SWCNTs during 24 h. Cells where then washed with PBS and fixed overnight with 2.5% 
glutaraldehyde diluted in PB buffer (0.1 M phosphate buffer pH 7.2). The day after, cells were 
washed with distilled water and post-fixed with 0.5 % aqueous osmium tetraoxide for 1h at room 
temperature. Cells were rinsed extensively with distilled water and a series of dehydratation baths 
was performed: twice with 50 % ethanol (10 min), once with 70 % ethanol (20 min), once with 
ethanol 95 % (10 min), twice with absolute ethanol (10 min) and finally twice with propylene oxide 
(for 10 min each). Samples were then embedded in epoxy resin Epon (LX 112 Embedding Kit, 
LADD). Mixtures of propylene oxide and Epon resin in 2:1 (1 h) and 1:2 (1 h) ratio and finally with 
pure resin (1 h) were added to the samples. On the last day, resin was replaced with fresh one and 
further incubated during three hours. Polymerized block with embedded cells were then prepared 
filling gelatine capsules with fresh resin and placing them upon the glass coverslips on which cells 
were grown. The capsules were then polymerized at 60 °C for 48 h, afterwards glass coverslips 
were removed from the polimerized block surface and ultrathin sections (70 nm thick) were 
obtained using an ultramicrotome (Leica) with a diamond knife (DiATOME). The ultrathin sections 
were then collected on butvar-coated single-slot copper grids and examined by TEM (Hitachi H600 
or Hitachi H7500).  
 
Determination of cell membrane parameters by electrorotation 
Electrorotation was introduced by Zimmerman (Arnold and Zimmermann 1988) and allows to 
measure cellular properties like the capacitance and conductance of cellular membranes. The 
technique is based on the fact that cells in a low ionic strength electrolyte solution subjected to a 
rotating electric field start to rotate. The rotation time depends on the conductivity (σ) of the 
solution and the frequency of the applied field.  
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3T6 cells were seeded in 6-well culture plate at a density of 3·10
5
 cells/well and allowed to adhere 
overnight prior to exposure to 100 µg/ml of BSA-SWCNTs during 24 h. Cells were then harvested 
with trypsin, washed two times with PBS and resuspended in 1 ml of different sucrose 0.3 M 
solutions differing in conductivity (0.3 M sucrose or 0.3 M sucrose + 0.5, 1 or 1.5 mM NaCl). The 
samples were kept on ice during all the measuring time. An amount of 10 µl of the cellular 
suspension was added to a cell connected to a generator of a rotating electric field. The signal 
frequency can be varied from 240 Hz to 500 KHz in 12 values while the amplitude of the signal is 
fixed at 12V. The rotating cell images can be recorded. The rotation times of at least 25 cells for 
each frequency were determined manually and the acquisitions were repeated for each 4 sucrose 
solutions. The average time of rotation (Tm) was put in graph as a function of the frequency of the 
applied field:   
 
The frequency corresponding to the dielectric relaxation (fc1) was determined for each sample 
calculating the minimum value of the curve. Finally, the 4 relaxation frequencies obtained were put 
in graph as a function of the conductivity of the specific sucrose solution. A linear relation is 
obtained and can be written by the formula fc1=aσ+b. Calculating the angular coefficient and the 
intercept, these parameters can be replaced in the formulas a=1/ πrC and b = G/2πC where C and G 
represent the capacitance and the conductance of the cell membrane, respectively.  
 
Statistical analysis  
The experiments shown (where it is not otherwise specified) are a summary of the data from at least 
three separate experiments run in triplicate for each cell line. Data are presented ± SEM. Statistical 
analyses were performed using a two-way ANOVA test followed by Bonferroni’s post-test. All p 
values < 0.05 were considered significant. 
 
II.3 Results and discussion 
 
II.3.1 BSA-SWCNT characterization  
Pure commercial SWCNTs (1 mg/ml) were dispersed in solutions of BSA at various concentrations 
(from 0.1 to 1 % w/v). The quality of the dispersions was preliminary evaluated by optical 
microscopy and 0.5 % BSA was finally chosen as the best concentration capable of giving a good 
CNT dispersion without many visible aggregates. The BSA-SWCNT dispersion was also relatively 
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stable, as demonstrated following the 600 nm absorbance over time after a 1:10 dilution in both 
BSA solution and complete culture medium (Table 1). In fact, no changes in absorbance were 
detected after 2 weeks from CNT preparation and only a slight sedimentation was noticed after 3-4 
weeks. Taken together these first observations are in agreement with the possibility to use these 
materials for biomedical applications, since CNT biocompatibility is highly dependent on their 
solubility and dispersion in biological, aqueous-based environments (Bianco et al. 2011). 
 
Table 1. Absorbance measurements of BSA-SWCNT dispersion diluted 10 times in 0.5 % BSA solution or 
complete culture medium over time. 
 
 
Weeks 
 
A600  in 
BSA solution 
(100 µg/ml) 
A600  in  
complete medium  
(100 µg/ml) 
1 2,1992 ± 0,01 2,3488 ± 0,01 
2 2,0818 ± 0,01 2,2972 ± 0,01 
3 1,8473 ± 0,01 2,0973 ± 0,01 
4 1,8473 ± 0,01  2,0973 ± 0,01 
 
BSA-SWCNTs were characterized by AFM. Height distribution analysis showed the presence of 
two CNT populations, having an average diameter of about 5 to 9 nm (Figure 2A). 
  
 
Figure 2. AFM observation of SWCNTs dispersed in 0.5 % BSA. The SWCNT height distribution is shown 
in panel A while two profiles of a single SWCNT can be observed in panel B.  
 
In the first case, the increase in CNT diameter compared to the original size (about 1-2 nm) can be 
ascribed to the protein layer surrounding the nanotube while a 10 nm average diameter can be 
0,5 µM
Heights distribution
Profiles
0,1 µM
1
2
A
B
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attributed to CNT aggregation. In Figure 2B the diameter of two section of a single nanotube are 
reported. In particular, the different size of the two sections (about 3.8 nm and 2.5 nm) can be 
ascribed to the uneven distribution of BSA on the surface of CNTs. Results are consistent with 
BSA-SWCNT characterizations described by the work of Ge et al. were a single protein molecule 
on the SWCNT surface was about 2.5 nm in height (Ge et al. 2011). Moreover, increasing amount 
of BSA molecules was added to the complex, SWCNT surface was saturated by the protein. 
Therefore, additional binding of BSA could only occur onto the earlier layer accumulating on the 
CNT surface. The latter observation is consistent with the increase in SWCNTs profile 1 observed 
in Figure 2B. 
 
II.3.2 investigation of BSA-SWCNT cytotoxicity 
To investigate the biocompatibility of BSA-SWCNTs, cytotoxicity, cellular proliferation and 
apoptosis were examined by different methods after cellular exposure to the nanomaterials in 
question. Different cell lines were chosen to verify the effect of the CNT samples on cells having 
different characteristics and origin. In particular, cells capable of different internalization 
mechanisms were compared. The materials were tested on murine fibroblast 3T6, known to be 
phagocytic cells (Lee et al. 1996) and human embryonic kidney cells HEK 293 (non-phagocytic). 
The complexes were further tested on murine RAW 264.7 macrophages, also to assess the induction 
of a possible proinflammatory effect induced by the BSA-SWCNTs.  
 
II.3.2.1 Analysis of the cell viability, proliferation and apoptosis  
MTT assay 
As a preliminary step in our study, cell viability and proliferation after exposure to BSA-SWCNTs 
were evaluated both on 3T6 and HEK 293 cells by MTT test. For this purpose, cells were exposed 
to different concentration of CNTs, ranging from 10 to100 µg/ml, for 24, 48 and 72 hours. During 
these first experiments, a typical optical microscopy image of 3T6 cells was taken, after exposure to 
100 µg/ml of CNTs for 24 hours (Figure 3). The picture shows how CNTs could highly interact 
with the cells in which they seem internalized or stacked on their surface.  
 
 
Figure 3. Optical microscopy images of 3T6 control cells or incubated with 100 µg/ml of BSA-SWCNTs.  
Ctrl                               BSA-SWCNTs
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A different response to the CNT samples was observed in the two cell lines. In fact, in the case of 
3T6 (Figure 4A), despite a slightly significant difference was noticed also at a CNT concentration 
of 30 µg/ml, an important reduction (about 30 %) in the cell viability as compared to the control 
(***p<0.001) was observed only in the case of the highest CNT concentration (100 µg/ml) after 48 
or 72 hours. On the other hand, HEK 293 cells showed a general higher sensitivity to the samples in 
comparison to 3T6 cells (Figure 4B). In fact, a significant reduction in cell survival (of about 20 %) 
was observed already after exposure to 10-30 µg/ml of CNTs during 48 or 72 hours. The higher 
cytotoxic effect compared to 3T6 cells was more evident at 50-100 µg/ml CNT concentrations 
where a decrease of about 40 % in cell viability was detected after 48 or 72 hours. Neither cell types 
showed a reduction in cell viability after a 24 hour CNT exposure demonstrating that long-term 
experiments can be necessary to probe a CNT biological effect. Surprisingly, the non-phagocytic 
cell line, and thus perhaps able to internalize less materials, resulted more sensible to BSA-
SWCNTs. 
 
 
Figure 4. MTT analysis of cell viability in 3T6 cells (A) and HEK 293 cells (B) exposed to different 
concentrations of BSA-SWCNTs for 24, 48 or 72 h. Two-ways ANOVA followed by Bonferroni’s post-test 
was performed to determine the statistical differences versus control cells (*p<0.05; **p<0.01; ***p<0.001). 
The total cell number after exposure to 100 µg/ml of BSA-SWCNTs during 24, 48 or 72 h is shown in panels 
C (3T6) and D (HEK 293).  
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As the MTT test measures the cellular ability to convert the dye into its reduced form, results 
obtained by the test could derive both from a reduction in the metabolic activity of the cells and 
from a decrease in their proliferation. To try to discriminate between the two events, the cell 
proliferation was determined counting the total cell number after 24, 48 or 72 hours of exposure to 
100 µg/ml of BSA-SWCNTs, concentration able to induce the major cytotoxic effect in both cell 
lines. Concerning both 3T6 and HEK 293, no significant change in the total cell number was 
observed (Figure 4 C and D). This suggests that the reduction in the absorbance obtained by the 
MTT test could be due to a reduction in the cellular metabolic activity rather than cellular 
proliferation 
 
TUNEL assay 
For a better understanding of the mechanisms responsible for the cytotoxicity both on murine and 
human cells in response to BSA-SWCNTs, we checked the apoptotic cell death since this is one of 
the principal pathways for a cell to die. For this purpose, 3T6 and HEK 293 were exposed to 50 or 
100 µg/ml of BSA-SWCNTs during 48 hours. Time and concentrations were chosen according to 
the results obtained by the previous test, as they were able to induce a significant reduction in cell 
viability (Figure 4). Typical fluorescence images obtained in the case of 3T6 or HEK 293 cells are 
shown in Figure 5 where the green fluorescence is associated to the damaged DNA of apoptotic 
cells. Positive nuclei were then counted. A significant induction of apoptosis was not observed in 
any case. In fact, the percentage of apoptotic 3T6 cells was only 2-3 % after exposure to 50 µg/ml 
of the material and about 4 % in the case of 100 µg/ml concentration (Figure 5A, bottom panel). 
Regarding HEK 293 cells, despite slightly increased, the same situation was monitored as the 
percentage of apoptotic cells was about 4 and 5 % after cellular exposure to 50 or 100 µg/ml of 
BSA-SWCNTs, respectively. 
The slight level of apoptosis observed by TUNEL assay could not account for the BSA-SWCNT 
cytotoxicity obtained by MTT test suggesting alternative cell death mechanisms. For example, the 
strong CNT interaction with the cell membrane could directly promote its damage eventually 
leading to necrotic cell death. Moreover, it has been shown that CNTs could interfere with the MTT 
assay (Belyanskaya et al. 2007). Taking together these considerations, the cytotoxicity induced by 
BSA-SWCNTs was further explored. 
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Figure 5. Analysis of apoptosis by fluorescence microscopy using TUNEL assay in 3T6 (A) or HEK 293 
cells (B) exposed to 50 or 100 µg/ml of BSA-SWCNTs during 48 h. In the corresponding bottom graphs, the 
percentages of TUNEL-positive cells are shown.   
 
 
Flow cytometry analysis 
The cell viability of HEK 293 and 3T6 cells after exposure to our CNT samples was then further 
investigated by flow cytometry after AnnV/IP staining. The analysis was also performed on RAW 
264.7 macrophages since these immune cells can be considered the primary sentinels of our body to 
infectious organisms but also to external materials (Wynn et al. 2013). For this purpose, cells were 
incubated in the same conditions used for the MTT assay of BSA-dispersed but also with pristine 
SWCNTs as controls. At the end of the incubation, cells were harvested and analyzed by flow 
cytometry. According to the analysis, no changes in cell viability were observed in the case of both 
3T6 (Figure 6A) and HEK 293 (Figure 6B) cells at all treatment times, both in the case of pristine 
and BSA-dispersed SWCNTs. On the contrary, the viability of both cell lines was affected by 
DMSO, used as positive (toxic) control. Therefore, the discrepancy between MTT test and flow 
cytometry data confirms the fact that MTT is not a good method to investigate carbon nanotube 
cytotoxicity. On the other hand, the results of flow cytometry measurements on 3T6 and HEK 293 
cells are consistent with the poor apoptosis observed by TUNEL assay. Nevertheless, the possible 
reduction in the metabolic activity of AnnV/PI negative cells cannot be excluded and could explain 
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the MTT results.   
 
Figure 6. Flow cytometry analysis of cell viability in 3T6 (A), HEK 293 (B) and RAW 264.7 cells (C) 
exposed to different concentrations of SWCNTs (BSA-dispersed or not) during 24 h, 48 h, 72 h. Two-ways 
ANOVA followed by Bonferroni’s post-test was performed to determine the statistical differences versus 
control cells (*p<0.05; **p<0.01; ***p<0.001). 
 
On the contrary, RAW 264.7 showed a different sensitivity to the materials as compared to 3T6 or 
HEK 293 cells (Figure 6C). In fact, despite any effect was observed after an exposure of 24 hours, 
both pristine and BSA-dispersed SWCNTs were able to induce a significant reduction in cell 
viability after 48 hours or 72 hours. In more details, after an exposure of 48 hours to pristine CNTs, 
RAW 264.7 evidenced a concentration-dependent reduction in the percentage of viable cells, 
ranging from about 10 % to 20 % of control (concerning the smallest and highest CNT 
concentrations, respectively). Even though this decrease was not dramatic, it is interesting to note 
that, in the case of BSA-dispersed CNTs, the same concentration-dependent behavior was not 
observed after 48 hours. In fact, the cell viability was only slightly reduced, compared to the control 
cells (5-7 %), in all concentration ranges. This difference between the effects of pristine or BSA-
coated CNTs was further confirmed after a cellular exposure of 72 hours. In this context, a 
concentration-dependent cytotoxicity was detected with both SWCNT samples (coated or 
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uncoated). Nevertheless, cells displayed a significantly higher mortality after contact with pristine 
SWCNTs as compared to BSA-coated ones. In fact, the residual cell viability ranged from 60 to 39 
% or from 70 to 50 % for pristine or BSA-dispersed SWCNTs, respectively.  
 
BSA-SWCNT long-term impact on cell proliferation 
To our knowledge, the CNT long-term impact on cell viability was in general poorly investigated.   
Since no effect on both 3T6 and HEK 293 cells was observed by flow cytometry even after 72 
hours of cellular contact with the highest concentration of both pristine and BSA-coated CNTs, we 
wondered if an effect could be observed some time after the end of exposure. In order to verify this 
issue, cells were exposed to 100 µg/ml BSA-SWCNTs during 24, 48 or 72 hours; thereafter cells 
were harvested, counted and subcultured, in the same number, in fresh medium (CNT free). 
Proliferation was chosen, in this case, as readout of cellular behavior. Therefore, both 3T6 and HEK 
293 cells were counted after they were allowed to grow for further 24, 48 or 72 hours. Regarding 
3T6 cells, no changes in their ability to proliferate, compared to the control, was observed in any 
case (Figure 7A) demonstrating how fibroblast could highly tolerate BSA-SWCNTs. On the other 
hand, in the case of the human cellular model (Figure 7B), a slight reduction in cell number, 
compared to control cells, was noticed 72 hours after the cells were treated with CNTs for 24 hours 
(upper panel). This decrease was more evident in the case of a 48 hours exposure to the materials 
(middle panel). Indeed, in this context, HEK 293 cells showed a reduction in cell number of about 
20 %, with respect to controls, after cells were allowed to grow for further 48 and 72 hours. Despite 
same behavior was not observed 48 hours after an exposure to CNTs of 72 hours (bottom panel), 72 
hours later, HEK 293 cell number was reduced of about 30 % in comparison to control cells.  
The latter result on HEK 293 cells demonstrates that CNT-induced cytotoxic effect can arise even 
some times after the end of the exposure.  
Taken together, all our results on cytotoxicity shed more light on the SWCNT impact on living 
cells. In fact, conflicting results exist in literature about the toxicity of this specific type of CNTs 
and must be better investigated also in view of their possible future applications in biomedicine. 
The discrepancy between the various literature results can be explained by the fact that several 
factors act synergistically in determining single-walled nanotube impact on cells: these factors 
include CNT size, metal catalyst contaminants, dispersant types and surface modifications (Lanone 
et al. 2013; Ong et al. 2014). Furthermore, SWCNT-induced cytotoxic effect can also vary 
depending on the particular cell type analyzed.  
 
60  Chapter II: BSA-dispersed SWCNT biocompatibility 
 
 
 
Figure 7. Determination of the total cell number in 3T6 cells (A) or HEK 293 cells (B) exposed to 100 
µg/ml of BSA-SWCNTs for 24 h (upper panel), 48 h (middle panel) or 72 h (bottom panel) and subcultured 
for further 24, 48 or 72 h after the treatment.  
 
 
In our study, the nanomaterials were dispersed with BSA in order to assess if a “protection effect” 
could be noticed after coating the CNT surface with this biocompatible molecule. In a work by Ge 
et al. different SWCNTs were dispersed with several blood proteins. They demonstrated how the 
diverse protein-nanomaterial conjugates displayed different outcome towards acute monocytic 
leukemia cells (THP-1) or human umbilical vein endothelial cells (HUVEC). First, both cell types 
presented a high sensitivity to pristine SWCNTs (Ge et al. 2011), situation that was not found in our 
study concerning both 3T6 and HEK 293 cells, thus confirming the variability between different 
cellular types. This behavior was reversed when the materials were coated with different types of 
blood proteins among which BSA, observation consistent with our results on murine macrophages. 
SWCNT cellular impact was described also by Holt et al. in different studies. In an earlier work, 
they found that dispersed and purified SWCNTs are relatively benign with regard to cytotoxicity as 
it was investigated in a human cervix cancer cell line. However, despite an acute cytotoxicity was 
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not observed, cell proliferation was greatly reduced with an increase in actin-related division defects 
(Holt et al. 2010). This behavior was not found in all our cell models but only in the case of HEK 
293 cells which were allowed to recover from the materials during 48 or 72 hours (Figure 7). This 
confirms the variability between different cell models and the idea that several factors interplay in 
SWCNT-induced cytotoxicity. Other two works from the same group showed how BSA-stabilized 
SWCNTs could be promptly uptaken by human mesenchymal stem cells, HeLa or murine fibroblast 
(3T3) without apparent acute deleterious cellular effects, encouraging the efficacy of BSA as a 
biocompatible dispersant and a mediator of bioactivity (Holt et al. 2011; Holt et al. 2012). On the 
other hand, the literature on SWCNT cytotoxicity toward macrophages is consistent with our 
results. These immune cells can be considered the first barrier of our body since they are able to 
engulf infectious organisms but also external materials (Wynn et al. 2013). Due to their ability to 
internalize a high quantity of exogenous molecules, an increased sensitivity to CNTs can be easily 
hypothesized.  In a previous study, the cytotoxic effects of either single or multi-walled CNTs 
toward RAW 264.7 macrophages were compared to carbon black (a material produced by the 
incomplete combustion of heavy petroleum products and known to be carcinogenic). The murine 
cell line displayed both a cyto and genotoxicity in response to all the tested materials which were 
able to induce necrosis, chromosomal aberrations, ultrastructural damage and apoptosis (Di Giorgio 
et al. 2011). In another recent study, pristine SWCNTs were able to induce a dose-dependent 
reduction of cell viability in the same cell line. The observed toxicity was related to the induction of 
autophagy accompanied by apoptosis and endoplasmic reticulum stress (Park et al. 2014). In our 
context, BSA protein grafted on SWCNT surface could rather protect RAW 264.7 from their 
cytotoxicity (Figure  5C), making BSA a good dispersant agent for the development of SWCNT-
based biotechnologies. 
 
II.3.2.2 Evaluation of a possible proinflammatory effect 
The induction of a proinflammatory response by CNTs was reported previously, as described in the 
first chapter; therefore, we wanted to explore the cell activation and cytokine production in RAW 
264.7 macrophages after exposure to our CNT samples. On the other hand, it was interesting to see 
if BSA protein grafted around the nanotubes could modify the macrophage immunological response 
to the materials as it was observed during flow cytometry analysis (Figure 5C).  
For the first purpose, CD86 was chosen as readout since this molecule is expressed by macrophages 
upon activation (Nolan et al. 2008). At the end of the incubation with CNTs for 24, 48 or 72 hours, 
CD86 levels were evaluated by flow cytometry. Results are shown in Figure 7. In our case, no 
increase in CD86 expression in comparison to control cells was observed at all concentrations and 
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treatment times, in the case of both pristine and BSA-coated CNTs, instead they responded well to 
LPS, used as positive control. Surprisingly, a similar situation was found when the levels of two 
proinflammatory cytokines were examined by ELISA immunoassay in RAW 264.7 cellular 
supernatants. In particular, neither IL6 (Figure 8A), nor TNFα (Figure 8B) were found in the 
supernatants. 
 
 
Figure 7.  Flow cytometry analysis of CD86 expression in RAW 264.7 exposed to different concentrations 
of SWCNTs (BSA-dispersed or not) during 24 h (A), 48 h (B) or 72 h (C). Two-ways ANOVA followed by 
Bonferroni’s post-test was performed to determine the statistical differences versus control cells and to 
compare the two CNT samples to each other (*p<0.05; **p<0.01; ***p<0.001).   
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Figure 8. Cytokine production by RAW 264.7. IL6 (A) and TNF α (B) levels were determined after 
incubation with different concentrations of SWCNTs (BSA-dispersed or not) during 24 h (upper panel), 48 h 
(middle panel) or 72 h (bottom panel). Two-ways ANOVA followed by Bonferroni’s post-test was 
performed to determine the statistical differences versus control cells and to compare the two CNT samples 
to each other (*p<0.05; **p<0.01; ***p<0.001).  
 
 
In the work performed by Di Giorgio et al., despite SWCNTs were able to reduce RAW 264.7 cell 
viability, no inflammatory response was observed, result consistent with our observations (Di 
Giorgio et al. 2006). On the other hand, several in vivo studies showed that SWCNTs caused an 
acute inflammatory response in the lungs of mice as a result of the high levels of IL6 released in the 
organ, after exposure to pristine SWCNTs (Park et al. 2014). Previously, Murphy et al. revealed the 
mechanisms of pleural inflammation by long carbon nanotubes. Long fiber-like CNTs were able to 
interact with macrophages stimulating them to amplify proinflammatory response in mesothelial 
cells (Murphy et al. 2012). In fact it has been shown that in vivo toxicity is highly dependent upon 
various factors (Dumortier 2013) such as CNT size since shorter nanotubes could be engulfed by 
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macrophages and consequently cleared trough the lymphatic system unlike long CNTs (Kostarelos 
2008). Since no effect on both RAW 264.7 activation and cytokine production was noticed in our 
study, it was not possible to elucidate the role of BSA protein in the protection of SWCNTs in terms 
of a proinflammatory response. Despite this, the use of relatively short SWCNTs together with the 
improvement of their solubility and stability in aqueous media are encouraging characteristics to 
stimulate a further exploration of BSA-SWCNT proinflammatory effect in vivo.   
 
II.3.3 BSA-SWCNT cellular interaction 
 
II.3.3.1 Observation by transmission electron microscopy 
It has been demonstrated that carbon nanotubes are able to enter any cell type (Kam et al. 2006; 
Kostarelos et al. 2007). Furthermore, it has been described that functionalization of their external 
surface can enhance carbon nanotube water-solubility leading to an augmented cellular uptake 
(Kostarelos et al. 2007; Bianco et al. 2011). This is obvious, since a reduced rate of CNT 
aggregation leads to an easier penetration of isolated nanotubes trough the plasma membrane, 
mainly by passive diffusion. Despite these considerations, we showed that BSA is able to improve 
to a large extent the solubility of pristine SWCNTs in aqueous media. The observation suggested 
that our BSA-SWCNT complexes could be efficiently internalized even by non-phagocytic cells.  
In order to verify the latter hypothesis and to investigate BSA-dispersed SWCNT internalization 
mechanisms, 3T6 and HEK 293 cells were exposed to 30 µg/ml CNTs for 24 hours. Samples were 
then processed for TEM observations. In Figure 9, it is possible to observe that BSA-coated 
SWCNTs were found inside both cell types. In particular, the materials were mostly packaged 
inside vesicles, suggesting that energy-dependent pathways were involved in the internalization 
(Lacerda et al. 2012). In addition, it appeared that the tubes could be better internalized by murine 
fibroblasts (A) with respect to human epithelial cells (B). The result was not surprising as 
fibroblasts are known to be phagocytic cells, as it was also evidenced by the presence of large 
vesicles in the cytoplasm. Furthermore, small bundles of CNTs were found also free in the 
cytoplasm (black arrow in Figure 9B). This latter observation could be the result of a passive 
translocation of CNTs through the plasma membrane, or escape from endosome via disruption of 
the organelles. Moreover, it was possible to identify some nanotubes (red arrows in Figure 9) which 
seem to pierce the cellular membrane perpendicularly suggesting a nanoneedle penetration 
mechanism (Pantarotto et al. 2004).   
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Figure 9. TEM images of 3T6 (A) and HEK 293 cells (B) incubated with BSA-SWCNTs (30 µg/ml) during 
24 h. The doted areas in the left images are enlarged in the respective right pictures.  
 
The two latter observations are in contrast with what was reported by Yaron et al. In fact they have 
clearly shown how pluronic-stabilized SWCNTs could penetrate HeLa cells by energy-dependent 
pathways but not trough passive diffusion. Furthermore, according to their model, SWCNTs were 
associated with vesicles but not able to disrupt them (Yaron et al. 2011). On the contrary, TEM 
analysis allowed us to observe free CNTs in the cytoplasm. Therefore the possibility of a SWCNT 
energy-independent internalization or endosome disruption cannot be ruled out.  Further 
investigations involving the use of specific internalization inhibitors should be performed to better 
identify BSA-SWCNT specific cell internalization pathways. Finally, no CNTs were found inside 
the nuclei of both 3T6 and HEK 293 cells. Furthermore, the cytoplasmic and nuclear structures of 
both cell types were well preserved suggesting that BSA-SWCNTs did not induce cell damages. 
This result is consistent with what obtained by the cell viability experiments. The ability of our 
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BSA-stabilized materials to efficiently penetrate different cell types, without inducing cytotoxicity, 
makes the complexes suitable for drug delivery purposes.  
 
II.3.3.2 Effect on the plasma membrane: electrorotational study   
Although neither necrosis nor apoptosis were observed in our cellular models after exposure to the 
nanomaterials, we decided to investigate BSA-SWCNT impact on the cellular membrane by an 
unexplored technique called electrorotation. This technique was already adopted by our team, to 
investigate cellular toxicity mechanisms and the derived membrane damage in a number of 
biological models, induced by different bioactive molecules (for recent works see Milardi et al. 
2014; Stefanutti et al. 2014). In our case, the technique was exploited for a different purpose. In 
fact, the ability of CNTs to interact with cell membrane and to be internalized by our cellular 
models, both by endocytosis or passive diffusion was observed. Therefore, CNTs bound on the cell 
surface or penetrating the cell, could disturb the lipid bilayer creating deformations which lead to 
changes in the dielectric properties of the plasma membrane.  
The 3T6 cell line was chosen for this purpose, as this cellular type could interact with CNTs to a 
larger extent in comparison to HEK 293 cells, as observed by TEM. Thereafter, murine fibroblast 
were incubated or not with 100 µg/ml BSA-SWCNTs. After 24 h of exposure, cells were processed 
for electrorotational studies (Arnold and Zimmermann 1988). The technique allowed us to measure 
two characteristic cellular membrane parameters known as capacitance and conductance. Despite a 
little reduction in the cell membrane capacitance was obtained in comparison to the control (Table 
2), this decrease was not significant and it was consistent in both cases with previous studies 
(Milardi et al. 2014). Furthermore conductance values were again comparable to control cells. 
Capacitance (C) is correlated to the plasma membrane ability to behave like a condenser, since the 
lipid bilayer, impermeable to ions, isolates the negatively charged internal compartment from the 
positively charged external layer. On the other hand, conductance (G) is associated with the plasma 
membrane permeability to ions. Given our results, we can conclude that BSA-SWCNT cellular 
interaction has little, if any, effect on plasma membrane characteristics. This is an innovative result 
since the impact of nanotubes on the plasma membrane dielectric characteristics and ion flux has 
been very poorly investigated up to date.   
 
Table 2. Cellular membrane parameters capacitance (C) and conductance (G) determined in control 3T6 
cells or in 3T6 exposed to 100 µg/ml of BSA-SWCNTs during 24 h.  
 
 C (µF/cm2) SD G (S/m2) SD 
Ctrl           2567       
BSA-SWCNTs            2550       
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II.4 Conclusions  
In this Chapter, pure commercial SWCNTs were dispersed with BSA protein to improve their 
biocompatibility. The best w/w ratio able to give a good SWCNT dispersion, without relevant 
aggregates, was 1:5 for SWCNT and BSA. Moreover, the dispersion was stable in time as 
demonstrated by UV-VIS spectroscopy. The materials were tested on different cell lines, murine 
fibroblasts, human embryonic kidney cells or murine macophages. Cytotoxicity results obtained by 
several methods, showed a different responsiveness to our materials based on the specific cellular 
type. In particular, no changes in the cell viability profiles were monitored in the case of both 3T6 
and HEK 293 cells after exposure to different concentrations of pristine or BSA-SWCNTs. On the 
other hand a cytotoxic effect was observed in the case of murine macrophages treated with both 
pristine and BSA-stabilized CNTs. Interestingly, this effect was minor when CNTs were coated 
with the BSA suggesting an increased biocompatibility. A possible long-term effect on 3T6 or HEK 
293 cells was explored after treatment with BSA-SWCNTs and subsequent subculturing. Cellular 
proliferation was then determined counting the total cell number. In the case of fibroblasts, no 
changes in cellular proliferation compared to the control were observed, while HEK 293 cell 
number was reduced of about 20 % or 30 % of the control after 48 or 72 hours of subculturing in a 
CNT-free medium, respectively. The latter result on HEK 293 cells suggests the possibility that a 
cytotoxic effect could arise, in some cases, even times after the end of the exposure to the 
nanomaterials. Both pristine and BSA-stabilized CNTs were not able to induce an in vitro 
proinflammatory response in macrophages as investigated by cell activation and cytokine 
production. For this reason it was not possible to evidence a role of BSA protein in this context, 
suggesting that further in vivo studies are needed. Thanks to the good dispersion quality, BSA-
SWCNTs were well internalized by both phagocytic and non-phagocytic cell types. Moreover, 
TEM observations suggest that the materials could penetrate the cells by a passive and energy-
dependent mechanism such as endocytosis. Finally, no changes in the dielectric parameters typical 
of 3T6 cell membrane were detected after exposure to BSA-SWCNTs, despite their strict 
interaction with the plasma membrane.  
Taken together, these findings suggest how the surface modification of SWCNTs with bio-
compatible molecules could be advantageous and should be considered during the design and 
preparation of CNTs for safe biomedical application purposes.  
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CHAPTER III 
(Adapted from the article Muzi et al., Nanoscale submitted) 
 
Carbon nanotube diameter-dependent release of a cisplatin 
pro-drug encapsulated in their inner cavity  
 
III.1 Introduction 
Chemotherapy, either alone or in combination with surgery and radiation therapy, is widely used to 
treat different types of cancer. However, limited drug solubility, rapid elimination and lack of 
appropriate selectivity for tumor tissues causing severe side effects, are some of the drawbacks 
faced by current chemotherapeutics. Moreover, various cancers display both an intrinsic and 
acquired multidrug-resistance. As mentioned above, this phenomenon can be ascribed to the P-
glycoprotein, an efflux pump able to recognize and transport the drug out from the cell once 
internalized, thus attenuating the drug-induced cytotoxic effect (Thiebaut et al. 1987).  
Among all, Pt(II) cisplatin analogues, together with carboplatin or oxaliplatin, have a central role in 
cancer chemotherapy, including pathological targets such as testis, cervix, head and neck, ovarian 
and non-small-cell lung cancer (Wang and Lippard 2005). Pt(IV) complexes have been also 
synthesized as inactive cisplatin prodrugs, which can be converted to their active Pt(II) form upon 
cleavage of the axial ligands (Shi et al. 2012). On the other hand, the poor specificity of these drugs 
induces numerous side effects, such as nephrotoxicity, emetogenesis, ototoxicity and neurotoxicity, 
which limit their applications (Rabik and Dolan 2007).
 
Cisplatin mechanism of action involves the 
formation of DNA interstrand cross-links. A so severe cellular DNA damage disrupts the normal 
replication and transcription processes activating cell cycle checkpoints leading to apoptosis To 
make this possible, once internalized, cisplatin undergoes a series of aquation reactions. The active 
mono-aquated form of cisplatin is a highly reactive species which can be recognized by several 
endogenous nucleophiles, thus making the drug potentially vulnerable and leading to a premature 
cytoplasmic inactivation (Siddik 2003). Moreover, in some cancer cells, reduction of drug 
accumulation is the main mechanism of cisplatin resistance. In addition to an increased expression 
of efflux pumps, the mechanism is also associated with the down-regulation of the plasma 
membrane copper transporter Ctr1 involved in cisplatin uptake. An increased DNA damage 
tolerance and the loss of its propagation signals to the apoptotic machinery are other downstream 
cellular resistance mechanisms to cisplatin (Siddik 2003; Ishida et al. 2002; Rebucci and Michiels 
2013). 
 
As described in the first chapter, nanomaterials can help to overcome the limitations described 
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above, offering great advantages to the delivery of therapeutic molecules to the tumors. They can 
help the delivery of drugs with poor solubility and stability, reduce their non-specific accumulation 
and toxicity, improve the pharmacokinetics and bioavailability and increase local drug 
concentrations. As a whole effect, they can enhance both drug permeability and retention at the 
target tissue. Several nano-carriers have been used for the delivery of platinum-based anticancer 
drugs including liposomes, micelles, dendrimers, polymeric nanoparticles and carbon nanotubes 
(Patel et al. 2013; Oberoi et al. 2013; Wang and Guo 2013). Among them, as already described in 
the first chapter, f-CNTs have shown to be very promising tools for biomedical applications.  
In this study, a hydrophobic Pt(IV) prodrug of cisplatin was entrapped within the inner cavity of 
two different diameters fluorescently-labeled multi-walled CNTs and the complexes were tested for 
their activity on two different cellular models. A number of studies on the efficacy of cisplatin-filled 
carbon-based nanomaterials, in particular single-walled CNTs have been published (Ajima et al. 
2005; Feazell et al. 2007; Dhar et al. 2008; Ajima et al. 2008; Bhirde et al. 2009; Guven et al. 
2012). However, the small diameter of SWCNTs allows encapsulating lower amount of drug 
molecules compared to MWCNTs. Furthermore, another advantage of our complexes derives from 
the use of a prodrug, designed to achieve an intracellular controlled release of the cytotoxic Pt(II) 
species. In fact, upon chemical reduction by endogenous reducing agents such as glutathione, the 
prodrug can be released from the CNT cavity being converted into its active hydrophilic Pt(II) form 
which is able to react with DNA (Figure 1). This avoids a fast and premature drug release (unlike 
what happens with cisplatin),
 
preventing also its possible inactivation (Li et al. 2012).
  
 
 
Figure 1. The design concept based on hydrophobic entrapment of a platinum(IV) prodrug within 
MWCNTs. (Adapted from Li et al. 2012). 
 
 
The group of Alberto Bianco and collaborators, previously demonstrated that Pt(IV)@CNTs can 
significantly enhance the drug accumulation in some tissues after being intravenously injected in 
mice without inducing any abnormal inflammation. Moreover, both kidney and liver accumulation 
Reduction by intracellular reducing agents
Pt(IV)-MWCNTs
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were reduced thus decreasing eventual nephrotoxicity, a typical side effect of cisplatin (Li et al. 
2014). For a better understanding of Pt(IV)@CNT complexes activity, in the current study, the 
cytotoxicity, the possible induction of a pro-inflammatory response and the cellular uptake were 
investigated on human cancer cells HeLa and murine macrophages RAW 264.7.  The intracellular 
platinum accumulation after exposures to the different complexes was also explored. In addition, 
the effect of MWCNT diameter on the release and activity of the Pt(IV) prodrug was examined. 
 
III.2 Experimental section 
 
Materials 
Two types of multi-walled carbon nanotubes with different diameter and length distributions were 
used in this study. Small diameter MWCNTs (named hereafter S-CNTs) were provided by Nanocyl 
(Thin MWCNT 95+ % C purity, Nanocyl 3100, batch no. 071119) and they had an average external 
diameter and length of 10 nm and 1.5 µm, respectively. Large diameter MWCNTs (L-CNTs) were 
synthesized by Prof. Ramaprabhu (Indian Institute of Technology, Chennai, India) with a purity > 
95%. L-CNTs had a bigger external diameter (38 nm in average) and length ranging from 200 nm to 
several microns. The average inner diameter of S- and L-CNTs was 4 nm and 10 nm, respectively. 
To reduce their length, both types of CNTs were treated in acid conditions. After oxidation the 
average length of shortened S- and L-CNTs was 274 nm and 855 nm, respectively. Therefore, both 
types of CNTs have similar aspect ratio in the range of 19-21. To monitor the trafficking of CNTs 
upon interaction with cells, the nanotubes were labeled with Cy5 after an amidation step (Figure 2). 
Cy5 loading on the nanotube surfaces was characterized by Kaiser test and it was 235 µmol per 
gram of S-CNTs and 565 µmol per gram of L-CNTs. Both derivatives were filled with 
platinum(IV) prodrug (Figure 1) by nano-extraction procedure and the platinum content was 
determined by inductively coupled plasma optical emission spectrometry (ICP-OES). High Pt(IV) 
levels were measured inside both types of CNTs: 37.3 % and 35.6 % w/w of Pt(IV) for S-CNTs and 
L-CNTs, respectively. Finally Pt(IV) localization within both CNT types was evaluated by high 
resolution TEM (HR-TEM). S- or L-CNTs were dispersed in sterile de-ionized water (200 µg/ml) 
by sonicating the samples for 30´. Fresh solutions were prepared prior to cellular treatment at 
appropriate dilutions in complete cell culture medium.   
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Figure 2. S- and L- CNTs derivatives after the various functionalization steps.   
 
 
Cell cultures  
Non-phagocytic human cervix cancer cells HeLa, were selected as a common neoplastic model to 
study the anticancer efficacy of the Pt(IV)@CNT samples. Phagocytitc murine macrophages RAW 
264.7 were chosen to compare the behavior in two different cell systems of the conjugates and to 
evaluate their proinflammatory effect.  
Both cell lines were purchased from ATCC (VA, USA) and were maintained in RPMI 1640 
medium supplemented with 10 % heat inactivated FBS and 100 U/ml gentamycin with the addition 
of 50 µM β-mercaptoethanol and 20 mM HEPES for RAW 264.7 macrophages and incubated at 37 
ºC in humid 5% CO2 atmosphere. Media and solutions were purchased from Lonza. When 
confluency reached 70-80 %, HeLa or RAW 264.7 cells were washed with PBS, detached with 
trypsin or with SE buffer (PBS containing 2 mM EDTA and 2 % FBS), respectively, and 
subcultured every 2-3 days. Prior to CNT exposure, cells were detached, counted and reseeded in a 
proper well size and density (see each particular experiment for details) and allowed to adhere 
overnight.  
 
Flow cytometry analysis 
Cell viability 
The cytotoxicity of the Pt(IV)@CNTs towards human and murine cell lines was evaluated by flow 
cytometry. For the first series of experiments, cells were seeded into 96-well culture plates at a 
density of 10
5 
cells per well and allowed to adhere overnight. The cells were then exposed to our 
different CNT samples at drug concentrations ranging from 0.5 µM to 10 µM during 24 h. For the 
second series of experiments, cells were seeded into 96-well plates at a density of 2·10
4
 cells per 
well and allowed to adhere overnigh. The cells were then exposed to the conjugates at Pt(IV) 
concentration ranging from 0.1 µM to 2 µM  during 6 h before the medium was renewed with fresh 
Cyanin 5
(Cy5)
Platinum(IV)
72                                                             Chapter III: CNT diameter-dependent release of a cisplatin pro-drug 
 
medium and cells were allowed to grow during further 72 h. In both experiments, the free drug and 
the empty CNTs were used as control and the corresponding CNT concentrations were back-
calculated from Pt(IV) loading inside CNTs while DMSO (20 %) was used as cellular death 
positive control. After incubation, RAW 264.7 supernatants were collected and kept at -20 ºC for 
further investigations and cells were harvested with SE buffer (RAW 264.7) or tripsinized (HeLa) 
and stained with both FITC-Annexin V and propidium iodide as previously described in chapter II. 
The percentage of live, early apoptotic and late apoptotic/necrotic cells was determined by 
acquiring at least 15.000 events using a Gallios flow cytometer (Beckman Coulter, Villepinte-
France) and analysing the data with FlowJo software.  
Cell activation 
RAW 264.7 cell activation was explored through CD86 expression level. Briefly, cells were seeded 
as previously described for both cell viability experiments. After incubation with CNTs cells were 
detached with SE buffer and stained with PE-Rat anti-Mouse CD86 antibodies (Clone GL1, BD 
Pharmingen 553692), prior to flow cytometry acquisition. Lipopolysaccharide (LPS, 1 μg/ml) in 
combination with interferon γ (IFN γ, 1 ng/ml) was used as cell activation positive control. The 
CD86 associated fluorescence intensity was determined by acquiring at least 15.000 events using a 
Gallios flow cytometer (Beckman Coulter, Villepinte-France) and analysing the data on live cell 
gated population (AnnV-/PI-) with FlowJo software.  
Cellular uptake 
HeLa and RAW 264.7 cells were seeded into 24-well plates at a density of 2·10
5 
cells/well and 
allowed to adhere overnight prior to exposure to Pt(IV)@CNTs at drug concentration ranging from 
1 µM to 7.5 µM  during 6 or 24h. After incubation, cells were washed twice with PBS, detached 
with trypsin (HeLa) or with SE buffer (RAW 264.7) and analyzed by flow cytometry. The mean 
fluorescence intensity of at least 25.000 events was measured using a Gallios flow cytometer 
(Beckman Coulter-Villepinte, France) and the data on live cell gated population were analyzed with 
FlowJo software.  
 
Cytokines determination 
RAW 264.7 macrophages supernatants were collected after treatment for flow cytometric analysis 
of cell viability and the levels of murine pro-inflammatory cytokines tumor necrosis factor alpha 
(TNF α), and interleukine-6 (IL6), were detected by a double sandwich ELISA. Lipopolysaccharide 
(LPS, 1 μg/ml) in combination with interferon γ (IFN γ, 1 ng/ml) was used as pro-inflammatory 
cytochine production positive control. The detailed procedure was described previously in chapter 
II. 
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Transmission electron microscopy 
For TEM observation, cells were seeded into 24-well plates on glass coverslips at a density of 5·10
5
 
cells per well and allowed to adhere overnight prior to exposure to 10 µg/ml of empty or 
Pt(IV)@CNTs during 6 or 24 h. (See chapter II for the detailed preparation protocol).  
 
Inductively coupled plasma atomic emission spectroscopy (ICP/AES) 
For the analysis of the intracellular platinum content, HeLa or RAW 264.7 were seeded in 
quadruplicate into 6-well plates at a density of 6·10
5 
cells per well and allowed to adhere overnight 
prior to exposure to the free drug or to Pt(IV)@CNTs at a platinum concentration of 1 µM during 6 
h. Cells were then detached as previously described and the cells in the 4 wells were collected 
together in a glass vial. Samples were then subjected to ICP/AES analysis on an Agilent 7500ce 
apparatus.  
 
Statistical analysis  
The experiments shown are a summary of the data from at least three separate experiments run in 
triplicate for each cell line (HeLa, RAW 264.7). Data are presented ± SEM. Statistical analyses 
were performed using a two-way ANOVA test followed by Bonferroni’s post-test. All p values < 
0.05 were considered significant.  
 
III.3 Results and discussion 
 
III.3.1 Cell viability after exposure to P(IV)@CNTs  
As a first step in our investigation, the cytotoxicity of the two different Pt(IV)@CNTs compared to 
the free drug was evaluated in cells with different characteristic and origin. For this purpose, human 
cervix cancer cells HeLa (non-phagocytic) and murine macrophages RAW 264.7 (phagocytic) were 
chosen. As previously described, nanotubes, defined as S- and L-CNTs, differ only in their diameter 
and length, whereas they have similar aspect ratio and drug loading. In an initial experiment, cells 
were incubated with the free drug or with Pt(IV)@CNT complexes at Pt(IV) concentrations ranging 
from 1 to 15 µM (HeLa) or from 0.5 to 10 µM (RAW 264.7) during 24 h. The corresponding 
amount of CNTs used was back-calculated from the loading of the prodrug inside the tubes (Table 
1). As Pt(IV) loading inside S- and L-CNTs was rather similar (37.3% and 35.6%, respectively), 
almost equal concentrations of the two CNT types were used. At the end of the incubation, cell 
viability was determined by flow cytometry.  
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Table 1. Concentrations of Pt(IV), Small Pt(IV)-CNTs and Large Pt(IV)-CNTs used for the cell treatment. 
The corresponding MWCNTs concentrations were back-calculated from Pt(IV) loading inside MWCNTs. 
 
 
 
 
 
 
 
 
 
Results are shown in Figure 3. In the case of HeLa cells (Figure 3A), a concentration-dependent 
cytotoxicity was observed with both CNT samples and also the free drug. Furthermore, there was 
no significant difference comparing the free drug to Pt(IV)@L-CNTs in the whole concentration 
range. On the contrary, both the free drug and the larger CNTs were more cytotoxic compared to 
the smaller ones.  
This first experiment allowed us to demonstrate the role of MWCNT diameter in the release of the 
embedded drug. As previously described, hydrophobic Pt(IV) prodrug is selectively released by 
chemical reduction and hydrophobicity reversal from the inner cavity of CNTs by reducing agents, 
being converted in its active Pt(II) species (Li et al. 2012). In view of this, a plausible hypothesis to 
explain the different efficacy of the two CNT samples could be represented by a limited 
accessibility to the intracellular reducing agents, such as glutathione, in the case of MWCNTs with 
smaller diameter compared to the larger tubes. Consequently, the active form of the drug could be 
released more slowly by S-CNTs compared to L-CNTs, thus explaining their lower cytotoxicity 
after 24 hours.  
On the other hand, RAW 264.7 cells displayed a general higher sensitivity to the samples compared 
to HeLa cells. In fact, same dose-dependent cytotoxicity but at lower concentrations was observed 
in RAW 264.7 cells (Figure 3B). Moreover, the free drug was significantly more effective 
compared to both Pt(IV)@L-CNTs and Pt(IV)@S-CNTs. This is consistent with the results 
obtained after exposure to 20% DMSO used as positive control. In fact, the residual cell viability 
was about 50 % in the case of HeLa and 0 % in RAW 264.7, suggesting an overall higher 
sensitivity of the murine macrophages with respect to the other cell line. Despite this, as observed in 
HeLa cells, Pt(IV)@S-CNTs were again less cytotoxic compared to Pt(IV)@L-CNTs, result 
consistent with the previous hypothesis.   
Pt(IV) molar 
concentration 
(µM) 
Pt(IV) 
(µg/ml) 
 
Small 
Pt(IV)-MWCNTs 
(µg/ml) 
Large 
Pt(IV)-MWCNTs 
(µg/ml) 
 
0.1 0.05 0.15 0.15 
0.2 0.11 0.29 0.30 
0.5 0.27 0.72 0.76 
1 0.54 1.45 1.52 
2 1.08 2.90 3.00 
3.5 1.89 5.07 5.31 
5 2.70 7.24 7.58 
7.5 4.05 10.86 11.38 
10 5.40 14.48 15.17 
15 8.10 21.75 22.80 
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Figure 3. Flow cytometry analysis of cell viability in HeLa cells (A) and RAW 264.7 cells (B) exposed to 
different concentrations of Pt(IV)@CNTs for 24 h. AnnV-/PI- live cells are shown in this graph. Two-ways 
ANOVA followed by Bonferroni’s post-test was performed to determine the statistical differences versus 
control cells and to compare the two CNT samples to each other and to Pt(IV) (*p<0.05; **p<0.01; 
***p<0.001).  
 
As a slower release of the encapsulated drug was hypothesized in the case of S-CNTs compared to 
L-CNTs, long-term cell viability experiments were performed. For this purpose, both HeLa and 
RAW 264.7 cells were incubated with the free drug or CNTs at concentrations ranging from 0.1 to 
2 µM Pt(IV) for 6 hours before the medium was renewed with fresh medium and cells were allowed 
to grow during further 72 h. In this experiment, HeLa cells began to show a significant mortality 
compared to the control already at 0.2 µM Pt(IV) concentration for both CNT samples (Figure 4A). 
In this case, Pt(IV)@S-CNT cytotoxicity was comparable to the free drug although they were 
poorly effective after 24 hours even at higher concentrations. The gain of function of Pt(IV)@S-
CNTs after a relatively long period of time is fully consistent with our hypothesis. In fact, the 
intracellular reducing agents had more time to induce the release of the drug from the small 
diameter CNTs, resulting in a higher cytotoxicity. On the other hand, the larger CNTs induced 
higher cellular mortality in comparison to both the free drug (from 0.5 to 1 µM) and the smaller 
ones (from 0.5 to 2 µM) even though they showed same cytotoxicity as the free drug in the previous 
experiment. This again supports our explanation. In contrast to the first experiment, the two CNT 
samples but also the free drug displayed a negligible cytotoxicity on RAW 264.7 cells (Figure 4B) 
in comparison to HeLa response. In fact, the residual viability after the treatment with all the 
conjugates was not less than 75% up to a drug concentration of 1 µM for both the free drug and the 
CNTs. In the examined concentration ranges, the free drug was more cytotoxic compared to the 
Pt(IV)@CNTs and there was no difference on the effect between the two CNT types. This result 
can be rationalized by a “recovering” of the murine macrophages after a relatively short exposure to 
A B
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low concentrations of the conjugates, contrarily to HeLa cells, while a continuous exposure to high 
doses of the complexes during 24 h induced a severe cytotoxicity.  
 
 
Figure 4. Flow cytometry analysis of cell viability in HeLa cells (A) and RAW 264.7 cells (B) exposed to 
different concentrations of Pt(IV)@CNTs for 6 h and allowed to grow for further 72 h. AnnV-/PI- live cells 
are shown in this graph. Two-ways ANOVA followed by Bonferroni’s post-test was performed to determine 
the statistical differences versus control cells and to compare the two CNT samples to each other and to 
Pt(IV) (*p<0.05; **p<0.01; ***p<0.001).  
 
 
It has to be noticed that the observed toxicity on the two cell types was only due to Pt(IV)@CNT 
hybrids. In fact, no reduction in cell viability was detected after exposure to same concentrations of 
the empty nanotubes during 24 hours (Figure 5A and B for HeLa and RAW 264.7, respectively) or 
during 6 hours, followed by a cellular growth of another 72 hours (Figure 5C and D for HeLa and 
RAW 264.7, respectively).  
The results obtained on the cell viability experiments demonstrate the efficacy of both 
Pt(IV)@CNT complexes and suggest their possible use as nanovectors for anticancer drugs. 
Moreover, as already mentioned, one of the advantages of our complexes is the use of a 
platinum(IV) prodrug that can be reduced to release the cytotoxic compound cisplatin upon entry 
into the cells. The advantages of Pt(IV)@CNT complexes compared to Pt(II)@CNT, leveraging on 
the greater aqueous stability of Pt(IV) prodrugs, has already been demonstrated by the Lippard and 
collaborators (Feazell et al. 2007; Dhar et al. 2008). In their previous reports, the Pt(IV) prodrug 
was non-covalently linked on the external surface of CNT, while in our work, the drug was 
entrapped within the inner cavity of CNTs. This strategy of hydrophobic entrapment shields the 
prodrug from premature inactivation
 
(Siddik 2003) and enables controlled drug release by reduction, 
contrary to Pt(II) complexes, that are rapidly extruded from the cavity (Li et al. 2012). In this report, 
we demonstrated that the diameter of CNT plays an important role in determining the rate of drug 
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release and directly affects the efficacy of the Pt(IV)@CNT construct. Therefore, CNT diameter 
should be taken into account when in the design and fine-tuning of these delivery vectors.  
 
 
Figure 5. Flow cytometry analysis of cell viability in HeLa or RAW 264.7 cells exposed to different 
concentrations of empty-CNTs during 24 h (panels A and B for HeLa and RAW 264.7, respectively) or 6 h 
followed by a cellular growth of another 72 h (panels C and D for HeLa and RAW 264.7, respectively). 
AnnV-/PI- live cells are shown in this graph. Two-ways ANOVA followed by Bonferroni’s post-test was 
performed to determine the statistical differences versus control cells and to compare the two CNT samples 
to each other (*p<0.05; **p<0.01; ***p<0.001).  
 
III.3.2 PT(IV)@CNT effect on macrophage activation  
Avoiding inflammation is of primary importance, especially in cancer therapy, where its insurgency 
can also play decisive roles at different stages of tumor and affects responses to the therapy 
(Coussens and Werb 2002; Grivennikov et al. 2010). As mentioned previously, the induction of a 
pro-inflammatory response is an important issue of investigation in the case of CNTs (Qu et al. 
2012; Wang et al. 2013). Therefore, cell activation and cytokine production by RAW 264.7 
macrophages were explored after exposure to all CNT samples. Once again, macrophages were 
chosen since they can be considered the primary sentinels of our body to infectious organisms but 
also to exogenous materials (Wynn et al. 2013). For the first purpose, CD86 expression was again 
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chosen as appropriate readout of macrophage activation. Thereforee, RAW 264.7 cells were treated 
with different concentrations of CNTs as previously described in the case of the cell viability 
experiments (from 0.5 to 10 µM for 24 h or from 0.1 to 2 µM for 6 h followed by a further 72 h cell 
growth). CD86 expression on live cell gated population was then measured by flow cytometry. 
After 24 hours (Figure 6A), a significant increase in CD86 expression compared to the control and 
the free drug was observed for the two types of CNTs, starting from a Pt(IV) concentration of 3.5 
µM. Moreover, at this concentration, a major activation in the case of Pt(IV)@L-CNTs was 
observed in comparison to Pt(IV)@S-CNTs. This behavior was not measured at higher 
concentrations. In fact, while in the case of S-CNTs CD86 expression followed a concentration-
dependent trend, its levels decreased as the concentration of the L-CNTs increased. This can be 
explained by the fact that L-CNTs promoted a higher cell mortality at a drug concentration higher 
than 3.5 µM compared to the smaller tubes (Figure 3B). Therefore, the observed reduction of CD86 
expression could be due to the death of highly activated cells that were consequently not detected. 
On the other hand, while the cytotoxicity experiments showed an increased responsiveness of HeLa 
cells to low Pt(IV)@CNTs concentrations 72 h after a 6 h exposure (Figure 4A), only a slight RAW 
264.7 activation (
*
p<0.05) at the highest Pt(IV)@CNT doses was observed (Figure 6B). 
Furthermore, there was no difference between the two CNT types.  
 
 
Figure 6. Flow cytometry analysis of CD86 expression in RAW 264.7 exposed to different concentrations of 
Pt(IV)@CNTs for 24 h (A) or 6 h and allowed to grow for further 72 h (B). Two-ways ANOVA followed by 
Bonferroni’s post-test was performed to determine the statistical differences versus control cells and to 
compare the two Pt(IV)@CNT samples to each other and to Pt(IV) (*p<0.05; **p<0.01; ***p<0.001).  
 
 
To investigate further the macrophage activation profile in response to the conjugates, the cell 
culture supernatants were collected from the previous experiments on RAW 264.7 macrophages and 
the levels of two pro-inflammatory cytokines (IL6 and TNF α) were determined by ELISA. After a 
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24 hour treatment, no IL6 production was detected in the supernatants (Figure 7A).  
 
 
Figure 7.  Cytokine production by RAW 264.7. IL6 (A) and TNF α (B) levels were determined after 
incubation with different concentrations Pt(IV)@CNTs for 24 h or after the cells were grown for further 72 h 
after a 6 h treatment (C and D for IL6 and TNF α, respectively). Two-ways ANOVA followed by 
Bonferroni’s post-test was performed to determine the statistical differences versus control cells and to 
compare the two Pt(IV)@CNT samples to each other and to Pt(IV) (*p<0.05; **p<0.01; ***p<0.001). 
 
 
On the contrary, the TNF α secretion started to rise significantly, as compared to the control, from a 
3.5 µM Pt(IV) concentration in the case of L-CNTs (Figure 7B). A minor effect on TNF α 
production was detected after treatment with Pt(IV)@S-CNTs. In fact a significant difference 
between the two types of nanotubes, starting from 5 µM Pt(IV), could be observed. This is 
consistent with the previous result obtained for RAW 264.7 cell activation. Before the cells started 
to display a high mortality rate, we could observe a more important increase in CD86 levels 
concerning the largest CNTs in comparison to the smaller tubes (Figure 6A). On the other hand, 
neither IL6 nor TNF α production were detected 72 hours after the 6 hour cellular exposure to the 
different complexes at concentrations ranging from 0.1 to 2 µM Pt(IV) (Figure 7C and D, 
respectively). This experimental observation is again consistent with the data obtained previously 
(Figure 6B), where only a slight macrophage activation was observed. We can also exclude an 
intrinsic MWCNT pro-inflammatory action (Pescatori at al. 2013) because no effect on cell 
Control LPS+IFN 0.5 µM 1 µM 3.5 µM 5 µM 7.5 µM 10 µM
0.0
0.1
0.2
0.3
0.4
0.5
30
35
40
45
50
***
IL
 6
 (
n
g
/m
l)
Control LPS+IFN 0.5 µM 1 µM 3.5 µM 5 µM 7.5 µM 10 µM
0
2
4
6
8
10
***
*
*
*
***
***
***
*
**
***
*
**
***
***
T
N
F

 (
n
g
/m
l)
Control LPS+IFN 0.1 µM 0.2 µM 0.5 µM 1 µM 2 µM
0.0
0.1
0.2
0.3
0.4
0.5
30
40
50
60
70
80
***
IL
6
 (
n
g
/m
l)
Control LPS+IFN 0.1 µM 0.2 µM 0.5 µM 1 µM 2 µM
0.0
0.1
0.2
0.3
0.4
0.5
1
2
3
4
5
***
T
N
F

 (
n
g
/m
l)
A B
C D
Control DMSO 1 µM 3.5 µM 5 µM 7.5 µM 10 µM 15 µM
0
20
40
60
80
100
Pt(IV) Pt(IV)@S-CNTs Pt(IV)@L-CNTs
***
***
***
**
*
***
***
***
***
***
*
***
*
**
***
***
***
%
 V
ia
b
le
 C
e
ll
s
80                                                             Chapter III: CNT diameter-dependent release of a cisplatin pro-drug 
 
activation or cytokine production was observed after exposure to the two empty CNT species 
(Figure 8).  
Taken together the results on cell activation and cytokines production encourage further in vivo 
investigations in view of their possible use as nanovectors for cancer therapy. Obviously, as is the 
case of most drugs, safety is dependent on Pt(IV)@CNTs concentrations.    
 
 
Figure 8. Flow cytometry analysis of CD86 expression in RAW 264.7 exposed to different concentrations of 
empty MWCNTs for 24 h (A) or 6 h and allowed to grow for further 72 h (B). IL6 and TNF α production by 
RAW 264.7 cells after exposure to empty MWCNTs for 24 h (C and E) or after cells were allowed to grow 
for 72 h after a 6 h exposure to CNTs (D and F). Two-ways ANOVA followed by Bonferroni’s post-test was 
performed to determine the statistical differences versus control cells and to compare the two Pt(IV)@CNT 
samples to each other and to Pt(IV) (*p<0.05; **p<0.01; ***p<0.001).  
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III.3.3 PT(IV)@CNT cellular uptake 
The results obtained with the cell viability experiments evidenced that the Pt(IV)@CNTs can 
preserve the cytotoxic activity of the encapsulated Pt(IV) prodrug. In fact, upon cellular exposure to 
the complexes, a reduction in cancer cell viability was observed and it was comparable to the free 
drug, or even increased in the case of Pt(IV)@L-CNTs (Fig. 6A). These results suggested an 
efficient drug transport inside the cells and thus the cellular internalization of both CNT complexes. 
To confirm and visualize the CNT cellular uptake and possibly identify its mechanisms, HeLa or 
RAW 264.7 cells were exposed to 10 µg/ml of S- or L-CNTs during 6 h and the samples were 
processed for TEM observations. Both CNT types were found inside the human and murine cells, 
thus confirming their cellular uptake (Figure 9). In more details, aggregation of CNTs inside 
vesicles can be observed in all cases. This suggests an endocytic (HeLa) or phagocytic (RAW 
264.7) internalization pathway (Kostarelos et al. 2007; Lacerda et al. 2012). It was also possible to 
identify some CNTs free into the cytoplasm. The latter observation is consistent with the previously 
reported ability of CNTs to penetrate the cells by passive diffusion as nanoneedles (Kostarelos et al. 
2007). In fact, upon inhibition of energy-dependent internalization pathways, CNTs can be still 
internalized by different types of cells, as it has been reported in a previous work performed in our 
laboratories (Lacerda et al. 2012). On the other hand, the free CNTs could be the result of 
endosome rupture. In Figure 9, a single CNT outside the endosome is evidenced by a red arrow. 
Such behavior is particularly relevant, as nanomaterial ability to escape from the endolysosomal 
network could facilitate the drug access to its target (Chou et al. 2011). No CNTs were found into 
the nucleus of the two cell types. Despite this, the drug was able to reach the nucleus and exert its 
function blocking DNA replication
 
(Cepeda et al. 2007) as evidenced by the cellular viability 
experiments. Besides the nuclear DNA, the free drug could have triggered apoptosis also by 
affecting the mitochondrial DNA or by other mechanisms, such as damage of cytoplasmic proteins 
or of the cytoskeleton (Gonzalez et al. 2001). A model for Pt(IV)@CNT activity mechanism could 
first consist on their internalization by both passive diffusion or endocytosis/phagocytosis. The 
internalized CNTs could be then transported throughout the endolysosomal pathway, subsequently 
escaping from these compartments and slowly release the Pt(II) active form of the drug within the 
cytoplasm (Li et al. 2012). Finally, the free drug translocates into the nucleus or to the 
mitochondrion exerting its cytotoxic function. Finally, the same TEM observations were carried out 
after an incubation of 24 hours with Pt(IV)@CNTs. In this case, a strong impairment of the general 
cellular structure due to the transported drug effect could be observed. Some examples are reported 
in Figure 9C (HeLa) and D (RAW 264.7), in which the cytoplasm of both cell lines shows a wide 
presence of vacuoles and lysis residues.  
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Figure 9. TEM images of HeLa (A) and RAW 264.7 (B) incubated with MWCNTs (10 μg/ml) during 6 h or 
with the same concentration of Pt(IV)@CNTs during 24 h (panels C and D for HeLa and RAW 264.7, 
respectively). When identified, the doted area in the top image is enlarged in the respective bottom picture. 
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The cellular uptake of Pt(IV)@CNTs was also followed by flow cytometry thanks to the 
functionalization with the Cy5 fluorophore (Figure 10). A fluorescence shift of HeLa (Figure 10A) 
or RAW 264.7 (Figure 10B) cell populations (corresponding to the Cy5 on the CNT surface) in 
comparison to the control was observed, thus confirming their intracellular uptake. We can assert 
that only a negligible amount of fluorescence could be derived from the CNTs interacting with the 
cellular surface as the samples were extensively washed before the analysis.  
 
 
Figure 10. Flow cytometry analysis of Pt(IV)@CNTs (10 µg/ml) HeLa (A) or RAW 264.7 (B) cellular 
uptake. The histogram is relative to one of three representative experiments.   
 
III.3.4 Analysis of the cellular platinum content 
Flow cytometry analysis did not allow for a precise quantification of Pt(IV)@CNTs inside the cells 
as the occurrence of fluorescent quenching phenomena by CNTs could not be excluded (Chiu et al. 
2011). 
 
For this reason we used ICP/AES to quantitatively analyze the cellular content of platinum into 
HeLa and RAW 264.7 macrophages after a 6 h exposure to 1 µM of both free Pt(IV) and 
Pt(IV)@CNT samples. It is important to remark that almost equal concentrations of the two CNT 
types were utilized, as Pt(IV) loading inside S- and L-CNTs was rather similar (Table 1). As shown 
in Figure 11A and B, an increase in the cellular platinum content (both entrapped or released) 
compared to the free drug could be observed for both CNT conjugates in the two cell lines. In 
particular, the amount of platinum inside both HeLa and the macrophages was about two times 
higher compared to the free drug when the cells were exposed to Pt(IV)@S-CNTs. Concerning 
Pt(IV)@L-CNTs, the increase in the intracellular drug accumulation compared to free Pt(IV) was 
again more evident. In fact the platinum amount found inside HeLa and RAW 264.7 cells was about 
three and four times higher, respectively, compared to the free drug. Such results allow also 
quantifying the CNT cell internalization. Interestingly, not a great difference in the ability to 
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internalize the complexes between HeLa and RAW 264.7 cells was observed. In fact, as 
macrophages are phagocytic cells, a major CNT uptake compared to HeLa cells was expected. This 
was not the case, demonstrating the ability of non-phagocytic cells to internalize a considerable 
amount of Pt(IV)@CNTs by endocytosis or by passive diffusion (Lacerda et al. 2012). On the other 
hand, L-CNTs were able to enter both cell types more efficiently as compared to S-CNTs; this 
result is consistent with their higher cytotoxicity after 24 hours (Figure 3). However, although less 
internalized, Pt(IV)@S-CNTs showed a cytotoxicity comparable to Pt(IV)@L-CNTs in HeLa cells 
during the long–term cell viability experiment (Figure 4A). The latter observation evidences how 
the slower Pt(IV) release by CNTs having smaller diameter could be advantageous to achieve an 
enhanced long-lasting cytotoxicity against tumor cells, compared to CNTs with larger diameter.  
 
 
Figure 11. ICP/AES analysis of cellular platinum content in HeLa (A) and RAW 264.7 cells (B) exposed to 
Pt(IV) or to Pt(IV)@CNTs (1 µM) for 6 h. One-way ANOVA followed by Bonferroni’s post-test was 
performed to determine the statistical differences versus control cells and to compare the two Pt(IV)@CNT 
samples to each other and to Pt(IV) (*p<0.05; **p<0.01; ***p<0.001).   
 
The results obtained by the cell uptake experiments are encouraging, given the well-documented 
problems in cisplatin cancer therapy. In fact, despite being one of the most potent antitumor agents 
known, cisplatin’s decreased intracellular accumulation is one of the main mechanisms of resistance 
to the drug (Wang and Lippard 2005; Siddik 2003). The results show that our Pt(IV)@CNTs 
complexes could  promote the drug accumulation inside the cells. This, together with the slow drug 
release achieved by using S-CNTs as Pt(IV) carriers, could result in an enhanced drug cytotoxicity 
and retention  into cancer cells compared to the free drug.   
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III.4 Conclusions 
In this study, an hydrophobic Pt(IV) prodrug of cisplatin was entrapped within the cavity of two 
functionalized MWCNTs having different inner diameters. The complexes were tested for their 
activity on two different cellular models. The activity of the entrapped drug was preserved in both 
conjugates and the role of the CNT diameter in the release time of the encapsulated drug was 
demonstrated. Both Pt(IV)@CNT complexes induced negligible cell activation and no pro-
inflammatory cytokine production on RAW 264.7 macrophages 72 h after the end of the treatment. 
Both samples were efficiently internalized by the two types of cells and higher platinum levels were 
found in the cells after Pt(IV)@CNT exposure, compared to the cells treated with the free drug. Our 
study shows that f-MWCNTs are promising nano-carriers to improve the accumulation of a 
chemotherapeutic drug inside the cells and demonstrates that the CNT diameter is an important 
parameter to consider in the preparation of the complexes. In particular, a smaller CNT diameter 
could be advantageous, allowing a slower drug release inside tumor cells compared to CNTs with 
larger diameter. This behavior could allow the drug to be retained in tumor cells and exert its 
function over a longer period of time.  Future studies will include evaluation of the Pt(IV)@CNT 
constructs in both sensitive and Pt-resistant cell lines, to assess whether these nanocarriers are not 
only efficient transporters and delivery systems for chemotherapeutics, but they are also able to  
overcome the cisplatin-associated resistance due to P-glycoprotein efflux pump mechanisms.  
Pt(IV)@CNTs conjugates could be also tested in vivo in tumor-bearing mice cancer model after 
intra-tumoral injection. In addition, the CNT external surface could be further conjugated with a 
specific targeting moiety; this will allow targeting the tumor upon systemic administration in mice, 
exploiting also the enhanced permeability and retention effect. In vivo biodistribution experiments 
of Pt(IV)@CNTs are also currently under investigation.   
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CHAPTER IV 
Graphene biological impact and possible use for cell targeting  
 
IV.1 Introduction 
As extensively described in the first chapter, graphene is considered the most promising new 
material to be exploited for various applications. In particular, some interesting works has been 
performed in the last few years; the main scope was to explore the use of graphene, especially in its 
oxidized form (GO), for widespread biomedical application, ranging from drug/gene delivery, bio-
sensing and imaging, antibacterial activity and tissue engineering (Shen et al. 2012; Liu et al. 2013; 
Goenka et al. 2014; Shi et al. 2014).  
In view of its possible use in biomedicine, studying the toxicity level of graphene is of fundamental 
importance. Being a quite new type of nanomaterial, limited data are present in literature on the 
impact of graphene on health and environment.  Moreover, similarly to carbon nanotubes, graphene 
toxicity can be strongly dependent on the graphene form, size and grade of purity; the effects are 
also dependent on the particular cellular type tested or on the concentration used (Bianco 2013). 
Understanding the impact of this material on the immune cells is also a major goal. In fact, it has 
been proposed that nanomaterials could be used to directly modulate the immune system enhancing 
the efficacy of immune-based therapies against a variety of pathologies including also cancer 
proliferation. This applies to both graphene alone, or conjugated with specific molecule (Orecchioni 
et al. 2014). To investigate further the impact of graphene in a biological environment, we started 
with the comparison of the bioactivity of different graphene types towards two different cellular 
models. For this purpose, different experiments were performed exploiting the diverse techniques 
already described in the previous chapters. In particular, cell viability and activation were 
investigated in HeLa and RAW 264.7, for the reasons illustrated above, after exposure to non-
purified or purified few layer graphene (FLG1 and FLG2, respectively) and to two commercial 
types of graphene oxide (GO-A and GO-N, respectively). Furthermore, the most promising GO 
material was also tested in murine intraperitoneal primary macrophages (mIPM).  
On the other hand, graphene-based nanomaterials have been also used for targeted drug delivery 
purposes. In fact, one of the main goals in biomedicine is the design of therapies able to act 
specifically towards the diseased cell population without affecting the normal cells. This would 
avoid unwanted side effects. A good strategy to achieve efficient specificity is to conjugate drug 
carriers with specific ligands that can recognize molecular signatures: an over-expressed outer-
membrane receptor is, for instance, a good candidate for drug targeting. This strategy may apply to 
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anticancer therapy and autoimmune diseases where specific therapies, depleting specific cell types, 
are unavailable. The ability of GO to target selectively tumor cells has been reported. One example 
is the work by Zhang et al. (Zhang et al. 2010) where GO was covalently conjugated with folic acid 
(FA) to target in a specific manner human breast cancer cells over-expressing FA receptors. The 
study showed an increased efficacy of FA-GO conjugates, carrying also two anticancer drugs, as 
compared to GO loaded with the drugs only. In the last part of my PhD work, the ability of the two 
types of commercial GO to target specifically a B cell model was investigated. For this purpose, the 
GO samples were non-covalently conjugated with Hen Egg Lysozyme (HEL). The ability to target 
A20 cells, genetically modified to over-express B cell receptor (BCR) recognizing the same 
enzyme, was examined.  
 
IV.2 Experimental section 
 
Materials 
Few layer graphene samples were provided by I. Janowska (ICPEES, Strasbourg). The FLGs were 
generated through a simple, fast and low cost production protocol with high yield (Janowska et al. 
2012). The procedure is a chemical-free method consisting of mechanical ablation of pencil lead on 
a harsh glass surface with simultaneous ultrasonication. The high purity sample (FLG1) was 
thermally treated to eliminate potentially adsorbed toluene between the graphene layers (FLG2). 
The average size of the FLG sheets was about 2 µm. FLG obtained by this method, consists mainly 
of 1 to 20 sheets that, occasionally, can go up to fifty sheets. The two samples of oxidized graphene 
(GO) were purchased as monolayer powder from Antolin Grupo (GO-A) or NanoInnova (GO-N). 
According to the manufacter’s information, GO flake thickness was between 0.7-1.2 nm 
(corresponding to 1 to 2 flakes of GO), while they had an average size of few micrometers. GO 
samples were further characterized by dynamic light scattering, measurement of the zeta-potential 
and TEM observations. FLG samples were briefly sonicated in complete cell culture medium at a 
concentration of 100 µg/ml and diluted to the proper concentration prior to use (Figure 1A). Fresh 
FLG dispersions were prepared prior to each cellular exposure while GO solutions were prepared as 
1 mg/ml stocks in deionized water (Figure 1B) and were properly diluted in complete culture 
medium before each cellular treatment. 
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Figure 1. Scheme of preparation of the different graphene samples. FLG1 and FLG2 sample preparation is 
described in panel A while the two commercial GO samples (NanoInnova or Antolin) are shown in panel B.  
 
Conjugation of graphene oxide with Hen Egg Lysozyme 
Lysozyme has a strong and selective adsorption on graphene oxide (Li S et al. 2014). Aqueous 
dispersions of GO-A or GO-N (1 mg/ml) were obtained by adding 10 ml of deionized water to 10 
mg of GO, followed by a 10 min sonication in a cold water bath. HEL (L6876, SIGMA) was added 
step-by-step following the adsorption on the GO surface by UV-Vis spectroscopy. In particular, 
after each addition of HEL to the GO solution, the complexes were left interact for at least 2 hours 
and then an aliquot was taken and centrifuged in order to precipitate GO. The supernatants were 
then analyzed in order to assess the presence of unbound HEL. HEL spectra were obtained 
analyzing the absorption in the wavelength range of 200-400 nm with a Varian Cary 5000 UV-VIS-
NIR absorption spectrophotometer. Twelve mg of HEL were added in total obtaining a GO-HEL 
ratio of 1:1.2. The reaction was performed for 24 h, under stirring at 4 ºC. The samples were then 
filtered through a 0.1 µm pores membrane. The filtration process was repeated 3 times, washing the 
GO samples with deionized water between each step. The GO samples were then subjected to 
exhaustive dialysis through a 300 kDa MWCO. At the end of the dialysis GO-A and GO-N were 
lyophilized for 3 days. The filtration and dialysis membranes were purchased from Millipore and 
Spectrum Laboratories, Inc., respectively. To verify the HEL amount on the GO surface, the 
complexes were characterized by thermogravimetric analysis (TGA) on a TGA1 (Mettler Toledo). 
Briefly, by this technique the weight of a substance is monitored as a function of temperature or 
time as the sample specimen is subjected to a temperature program in a controlled inert atmosphere. 
Organic molecules have a specific degradation profile (weight loss) that is proportional to the 
amount of the given molecule.  
 
A B
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Figure 2. TGA profiles of GO-HEL conjugates (Antolin, panel A or NanoInnova, panel B). In each graph 
the weight loss of GO (green curve), GO-HEL (black curve) and free HEL (red curve) are shown.  
 
Comparing GO-HEL profiles to the free GO profiles it was possible to determine the quantity of 
HEL adsorbed on GO surface. In particular, the estimated HEL loading was about 18.9 % w/w in 
GO-A (Figure 2A) and about 4.8 % w/w in GO-N (Figure 2B), measured at 600 °C. The difference 
in loading between the two samples could be easily explained by the fact that GO-A was better 
dispersed in water compared to GO-N, thus exposing a larger surface area for HEL binding. 
Dispersions were freshly prepared prior to cellular treatments by brief sonication of GO-HEL 
conjugates in complete medium, at a concentration of 500 µg/ml.  
 
Cell cultures  
Human cervix cancer cells and murine macrophages were chosen to compare the behavior of our 
various graphene samples (non-purified or purified FLG and commercial GO from Antolin or 
Nanoinnova) in non-phagocytic (HeLa) and in phagocytic (RAW 264.7) cells and to evaluate their 
proinflammatory effect. Cells were cultured as previously described (see chapter II for detailed 
protocol). Prior to graphene exposure, cells were detached, counted and reseeded in proper well size 
and density (see each particular experiment for details) and allowed to adhere overnight. The two 
commercial GO samples were further tested on a model of primary macrophages. In particular, 
mature and quiescent murine intraperitoneal macrophages (mIPM) were isolated from healthy 
untreated C57BL/6 mice (Charles River) by successive washes of the peritoneal cavity (Cohn A. 
1978) with complete RPMI 1640 medium (medium supplemented with 10 % heat inactivated FBS 
and 100 U/ml gentamycin with the addition of 50 µM β-mercaptoethanol and 20 mM HEPES). 
Cells when then seeded in proper well size and density (see each particular experiment for details) 
and incubated overnight at 37 ºC in humidified air containing 5% CO2 prior to graphene exposure.  
For cellular targeting purpose, mouse B lymphoma cells A20, wild type or over-expressing B cells 
A B
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receptor (BCR) able to specifically recognize HEL, named A20 D1.3, were  kindly provided by 
Helene Dumortier’s group (IBMC, Strasbourg). Both cell lines were maintained in RPMI 1640 
medium supplemented with 10 % heat inactivated FBS and 100 U/ml gentamycin with the addition 
of 50 µM β-mercaptoethanol and 20 mM HEPES incubated at 37 ºC in humidified air containing 
5% CO2. Cells were subcultured each 2-3 days and maintained between 1·10
5
 and 1·10
6
 cells/ml. 
Media and solutions were purchased from Lonza.  
 
Flow cytometry analysis 
Cell viability 
The cytotoxicity of the various graphene samples towards human and murine cell lines was 
evaluated by flow cytometry. Hela and RAW 264.7 cells were seeded into 96-well culture plates at 
a density of 1·10
5 
cells per well and allowed to adhere overnight. The total cells obtained from 
peritoneal washings were seeded into same culture plates at a density of about 1.5·10
5
 and allowed 
to adhere overnight. Cells were then exposed for 24 h to different concentrations of the graphene 
samples ranging from 1 to 100 µg/ml. After incubation, HeLa and RAW 264.7 cells were stained 
with both FITC-Annexin V and propidium iodide as previously described (see chapter II for details) 
while the culture supernatants were collected and kept at -20 ºC for further investigations. The 
percentage of live, early apoptotic and late apoptotic/necrotic cells was determined by acquiring at 
least 30.000 events using a Gallios flow cytometer (Beckman Coulter, Villepinte-France) and 
analyzing the data with FlowJo software. Peritoneal cells were stained with FITC-AnnexinV/PI as 
previously described, and with APC-anti Mouse F4/80 antibodies (Clone BM8, eBioscience 
17480182), cellular surface macrophages marker (Zhang X et al. 2008). At least 50.000 events were 
acquired using the same instrument and the percentage of live, early apoptotic and late 
apoptotic/necrotic cells were determined on both F4/80 positive and F4/80 negative gated 
populations by FlowJo software.  
Cell activation 
RAW 264.7 and mIPM cell activation was explored through CD86 expression as previously 
described. Briefly, after incubation with graphene, the cells were harvested and stained with PE-Rat 
anti-Mouse CD86 antibodies (Clone GL1, BD Pharmingen 553692), prior to flow cytometry 
acquisition. Lipopolysaccharide (LPS, 1 μg/ml) in combination with interferon γ (IFN γ, 1 ng/ml) 
was used as cell activation positive control. The CD86 associated fluorescence intensity in RAW 
264.7 macrophages was determined by acquiring at least 30.000 events using a Gallios flow 
cytometer (Beckman Coulter, Villepinte-France) and analyzing the data on live cell gated 
population (AnnV-/PI-) with FlowJo software. CD86 levels in mIPM were determined acquiring 
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50.000 events using the same instrument and analyzing the CD86 fluorescence intensity on F4/80 
positive and AnnV-/PI- cell population.  
Targeting of A20 D1.3 cells with GO-HEL conjugates 
For cellular targeting purpose, 50 µl of different concentrations of GO-HEL, free HEL or free GO 
(diluted in PBS 2 % FBS) were mixed with 20 µl of A20 wild-type or A20D1.3 diluted in the same 
buffer in a 96-well V-bottom plates (0.5·10
6
 cells/well) and incubated at 4 ºC during 30 min in 
order to avoid any protein internalization. Cells were then washed with PBS 2% FBS and stained 
with Biotin-Rabbit Anti-Mouse HEL antibodies diluted in the same buffer, at 4 ºC during 15 min. 
The antibody was provided by Helene Dumortier’s group and it was produced in rabbit by the 
following protocol: upon injection of HEL soluble, the antibody was isolated by affinity 
chromatography Anti-IgG (DEAE Affi-Gel Blue Gel Biorad Ref 153-7307) and labelled with 
biotin-X-NHS (Calbiochem ref 203188). After washing the samples with PBS 2 % FBS, cells were 
further incubated with PE-Streptavidine (BD Pharmingen 554061), diluted in the same buffer, at 4 
ºC during 15 min. Cells were then again washed and analyzed using a Gallios flow cytometer 
(Beckman Coulter, Villepinte-France) acquiring at least 30.000 events. Data were analyzed with 
FlowJo software.  
 
Cytokine determination 
RAW 264.7 or mIPM supernatants were collected after treatment for cell viability experiment and 
the levels of murine proinflammatory cytokines tumor necrosis factor alpha (TNF α), interleukine 6 
(IL6) and interleukine-1β (IL1β) were detected by a double sandwich ELISA.  LPS (1 μg/ml) in 
combination with IFN γ (1 ng/ml) was used as proinflammatory cytokine production positive 
control. Polyvinyl microtiter plates (Falcon) were coated overnight at 4 °C with 50 μl/well of 
purified Hamster Anti-Mouse/Rat TNF α (BD Pharmingen 557516) or purified Rat Anti-Mouse IL6 
(BD Pharmingen 554400) or Purified Anti-Mouse IL1β (BD Biosciences 51-26661E from ELISA 
Set 559603) diluted in 0.05 M carbonate buffer, pH 9.6. After washings with PBS containing 0.05 
% Tween (PBS-T), a saturation step was performed by adding 100 µl/well of PBS containing 10% 
FBS for 1 h at 37 °C. After washings with PBS-T, 50 μl/well of culture supernatants or 
Recombinant Mouse TNF (BD Pharmingen 554589) or Recombinant Mouse IL6 (BD Pharmingen 
554582) or Recombinant Mouse IL1β (BD Biosciences 51-26666E from ELISA Set 559603), 
diluted in PBS-10% FBS, were added for 2 h at 37 °C. Plates were then washed with PBS-T and 50 
μl/well of secondary Biotin Rabbit Anti-Rat/Mouse TNF (BD Pharmingen 557432) or Biotin Rat 
Anti-Mouse TNF (BD Pharmingen 554402) or Biotinylated Anti-Mouse IL1β (BD Biosciences 51-
26662E from ELISA Set 559603), diluted in PBS-10% FBS, were incubated for 1 h at 37 °C. Plates 
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were washed with PBS-T, and 50 μl of streptavidin conjugated to horseradish peroxidase diluted in 
PBS 10% FBS were added per well. After 30 min incubation at 37 °C, plates were washed 
extensively and the enzymatic reaction, revealing the presence of cytokines in the tested 
supernatants, was visualized by adding 75 µl/well of 3,3’,5,5’-tetramethylbenzidine diluted in 0.1 M 
citrate buffer, pH 5, in the presence of H2O2. The resulting absorbance was measured at 450 nm 
after the reaction was stopped with 25 µl/well of HCl 1 N. 
Targeting of A20 D1.3 cells with GO-HEL conjugates 
To follow HEL-BCR recognition, IL2 secretion was chosen as readout of B cells activation. For this 
purpose, 200 µl of A20 wild-type or A20D1.3 cells were seeded into 96-well cell culture plates at a 
density of 2·10
6
 cells/ml in different concentrations of GO-HEL, free HEL or free GO. After 24 
hours, the plates were centrifuged and supernatants were collected and kept at -20 °C until the 
ELISA test.  
ELISA was performed with a mouse IL2 ELISA set (BD OptEIA™ 555148) according to the 
manufacturer protocol. Plates were washed extensively and the enzymatic reaction, revealing the 
presence of IL2 in the tested supernatants, was visualized by adding 75 µl/well of 3,3’,5,5’-
tetramethylbenzidine diluted in 0.1 M citrate buffer, pH 5, in the presence of H2O2. The resulting 
absorbance was measured at 450 nm after the reaction was stopped with 25 µl/well of HCl 1 N. 
 
Transmission electron microscopy observations 
For TEM observation, mIPM were seeded into 24-well plates on glass coverslips at a density of 
3·10
6
 cells per well and allowed to adhere overnight prior to exposure to 100 µg/ml of GO from 
Antolin or Nanoinnova (See chapter II for the detailed preparation protocol).  
 
Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
GO-A or GO-N, conjugated with HEL, were dispersed in water or in RPMI complete cell culture 
medium at concentration of 1.3 mg/ml or 5 mg/ml, respectively. The concentrations were chosen to 
have the same quantity of lysozyme in both samples, according to the loading of the enzyme on the 
GO surface (determined by TGA). Samples in RPMI were incubated for 2 h or 24 h at 37 °C. The 
same samples were then subjected to ultracentrifugation for 5 min to precipitate all GO and the 
supernatants were collected. Twenty µl amount of the obtained supernatants were then loaded in a 
4–20% polyacrylamide gel (Mini-PROTEAN® TGX™, BIO-RAD), together with free HEL 
solution, complete RPMI alone and GO-A/GO-N-HEL in water (20 µl, corresponding to 25.4 µg or 
100 µg of GO-A and GO-N, respectively). The HEL amount was the same in all samples (4.8 µg). 
Protein migration was performed at 180 V in a tris/glycine/SDS buffer (BIO-RAD) using an 
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electrophoresis apparatus (BIO-RAD).  The gel was then stained over-night with Coomassie 
Brilliant Blue G-250 (BIO-RAD), prepared according to manufacturer’s instructions.   
 
Statistical analysis  
The experiments shown (where it is not otherwise specified) are a summary of the data from at least 
three separate experiments run in triplicate for each cell line. Data are presented ± SEM. Statistical 
analyses were performed using a two-way ANOVA test followed by Bonferroni’s post-test. All p 
values < 0.05 were considered significant.  
 
IV.3 Results and discussion 
 
IV.3.1 Assessment of the cell viability in response to different types of graphene 
As a first step in our study, HeLa (non-phagocytic) or RAW 264.7 (phagocytic) cells were 
incubated for 24 hours with concentrations ranging from 1 to 100 µg/ml of the different graphene 
samples. At the end of the incubation, the cell viability was determined by flow cytometry. Results 
are shown in Figure 3. In the case of HeLa cells, no reduction of cell viability was observed for 
FLG1 and FLG2 (panel A); the sale result was also found for GO-A and GO-N samples (panel C). 
In the case of RAW 264.7 cells exposed to FLG1 or FLG2 (panel B), only a slight non significant 
decrease of cell viability (of about 5 %) was monitored. On the other hand, any cytotoxic effect was 
observed in the case of the two GO types (panel D). Furthermore, no difference between the effects 
of the two FLG samples or between the two commercial GO complexes was evidenced.  
Since primary cells can show a different sensitivity to nanomaterials with respect to tumor cell lines 
and are a more representative model in view of a future bioapplication, the cytotoxicity of GO, 
subsequently used for the cellular targeting strategy, was further investigated using intraperitoneal 
murine primary macrophages (mIPM). Indeed, understanding the GO effect toward this immune 
cell population is of great interest as the material could be exploited in different biomedical contexts 
where macrophages are involved. In fact, macrophages are found in all tissues where they can exert 
a large number of different functions. They have roles in development, homeostasis, tissue repair 
and immunity. Despite their great role in maintaining the normal physiological condition, they can 
also be associated to several pathologies. For this reasons, macrophages have also emerged as 
important therapeutic targets in many human diseases such as neurodegenerative or autoimmune 
diseases, cancer and fibrosis (Wynn et al. 2013).  
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Figure 3. Flow cytometry analysis of cell viability in HeLa cells exposed to different concentrations of 
FLG1 and FLG2 (A) or GO-A and GO-N (C) during 24 h. Same analysis was performed  in RAW 264.7 
cells exposed to FLG1 and FLG2 (B) or GO-A and GO-N (D) during the same time. Two-ways ANOVA 
followed by Bonferroni’s post-test was performed to determine the statistical differences versus control cells 
and to compare the different graphene samples to each other (*p<0.05; **p<0.01; ***p<0.001).  
 
To investigate the behavior of GO toward mIPM, immune cells were collected from the peritoneal 
cavity of non-stimulated mice. Despite these fluids harbor a number of different immune cells 
including B cells and T cells, the presence of a high number of naive macrophages (about 30 %) 
makes the peritoneal cavity a preferred site for the collection of resident macrophages (Zhang et al. 
2008). The cells were therefore incubated for 24 hours with concentrations ranging from 1 to 100 
µg/ml of GO-A or GO-N and analyzed by flow cytometry. Cell viability was determined on both 
F4/80 positive gated population (about 25-30 % of total) corresponding to macrophages (Zhang et 
al. 2008), and F4/80 negative gated population. It was clearly observed a selective cytotoxic effect 
towards the macrophage population concerning the two GO types (Figure 4). In fact, F4/80 negative 
cells (panel B) were absolutely not affected after exposure to these materials, while macrophages 
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displayed a decrease in cell viability after contact with both GO-A and GO-N (panel A). Going 
more in details, a concentration-dependent cytotoxicity was observed in the case of GO-N. In 
particular, mIPM showed a significant reduction of about 20 and 25 % in cell viability, after 
treatment with 50 or 100 µg/ml GO-N, respectively. This concentration-dependent trend was not 
observed in the case of GO-A. In fact, a reduction of about 15-20 % in cell viability was measured, 
to the same extent, from 10 to 100 µg/ml concentration. The selectivity of GO towards 
macrophages can be better appreciated in the corresponding dot plots of cell morphology (Figure 
4C). In fact, despite the clear but not dramatic cytotoxic effect, the population corresponding to 
macrophages (evidenced by a circle in Figure 4C) seems to disappear selectively as GO-A or GO-N 
concentration increases.  
Despite carbon nanomaterials can be internalized by both phagocytic and non-phagocytic cell types, 
the observed specific cytotoxicity toward mIPM could be interpreted as a preferential 
internalization of GO within phagocytic macrophages. This behavior could be adopted at different 
levels in therapeutic applications where an inhibition of macrophage functions would be used to 
modify the disease outcome. For example, it has been demonstrated that tumors are abundantly 
populated by macrophages (Sica and Mantovani 2012) where they can promote tumor initiation, 
progression and metastasis (Qian and Pollard 2010). It has also been shown that the targeted 
depletion of tumor-associated macrophages provides benefits in patients with diffuse-type giant cell 
tumor (Ries et al. 2014). The observed specific cytotoxicity toward this cell population makes GO a 
good candidate for the aimed depletion of tumor-associated macrophages (TAMs). On the other 
hand, it has been demonstrated that TAMs are able to capture nanoparticles and translocate them 
selectively from the periphery to the central hypoxic zone of the tumors (Amoozgar and Goldberg 
2014). This behavior, together with the fact the GO can be functionalized to carry an anti-cancer 
drug, makes the material a good candidate for anticancer therapy. Finally, GO could be also 
employed in diseases such as fibrosis, which can arise after an exacerbated immune response and 
tissue injury driven by macrophages (Duffield et al. 2005).  
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Figure 4. Flow cytometry analysis of cell viability in mIPM (F4/80 positive, panel A) or F4/80 negative cells 
(panel B) exposed to different concentrations of GO-A and GO-N during 24 h. Two-ways ANOVA followed 
by Bonferroni’s post-test was performed to determine the statistical differences versus control cells and to 
compare the different graphene samples to each other (*p<0.05; **p<0.01; ***p<0.001). In panel C the 
corresponding FSC-SSC graphs are reported.  
 
IV.3.2 Evaluation of a possible proinflammatory response  
The literature about the impact of graphene on immune cells is rather limited (Bianco 2013; 
Orecchioni et al. 2014). Therefore, the effect on cell activation and cytokine production of the 
different graphene samples were compared on RAW 264.7 macrophages. As in the case of the 
viability experiments, GO putative induction of a proinflammatory response, was further 
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investigated in mIPM. Results obtained with FLG samples on RAW 264.7 cell line will be first 
described, while comparative results on GO effect on both RAW 264.7 and mIPM will be presented 
in a second moment. 
RAW 264.7 cells were exposed for 24 hours to concentrations ranging from 1 to 100 µg/ml of 
FLG1 or FLG2, in the conditions described above (cell viability assessment). At the end of the 
incubation, the expression of the macrophage activation marker CD86 was analyzed by flow 
cytometry while the culture supernatants were collected to evaluate the levels of two 
proinflammatory cytokines, IL6 and TNF α, by ELISA. As shown in Figure 5, both FLG1 and 
FLG2 were not able to trigger RAW 264.7 activation (panel A) or pro-inflammatory cytokine 
production (panels B and C), contrarily to LPS/IFNγ used as positive activation controls. Similar 
investigation was carried out after exposing, for 24 hours, RAW 264.7 or mIPM to the same 
concentrations of GO-A or GO-N. The levels of IL6, TNF α and also of IL1β, another important 
proinflammatory cytokine, were also examined. Consistent with the results of FLG samples, no 
effect on RAW 264.7 cell activation (Figure 6A) or cytokine production (Figure 6C, E, G) was 
observed after exposure to both GO samples. Concerning mIPM, a concentration dependent 
increase in CD86 expression was evidenced after exposure to GO-A, but not to GO-N (Figure 6B). 
Despite this, the increase was significant only at 100 µg/ml GO-A concentration. This could be 
correlated to a lower purity grade of GO-A compared to GO-N (Ali-Boucetta et al. 2013). 
Analogous to RAW 264.7 macrophages, no proinflammatory cytokine production was found in 
mIPM supernatants after exposure to GO samples (Figure 6D, F, H).  
In general, our results on cell activation and cytokine production revealed no induction of a 
proinflammatory effect by the two commercial GO types on RAW 264.7 cells on mIPM. In fact a 
slight increase in cell activation was observed only in the case of GO-A. Few studies are present in 
literature on the impact of GO on macrophage activation or cytokine production. A previous study 
was focused on the cellular impact of GO sheets having different sizes. The authors showed that 
only GO sheets with a lateral size of about 2 µm triggered strong mIPM activation, contrarily to 
sheets of about 300 nm (Yue et al. 2012). Another study showed cytokine secretion by RAW 264.7 
cells in response to nano-sized or micro-sized GO (Chen et al. 2012). These apparently conflicting 
results with our study could be explained, for instance, by a different grade of purity of the 
materials that, in turn, could influence the immune cell response (Ali-Boucetta et al. 2013).  
On view of these considerations, the results described in this chapter are consistent with a recent 
work of Bianco and collaborators which was focused on the effect of the lateral dimension of GO 
sheets on human and murine primary macrophages. In fact, the lateral size of our GO-A and GO-N 
flakes was about 1-2 µm. The GO of this size was not able to trigger macrophage activation as 
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evidenced in the mentioned study (Russier et al. 2013).  
 
 
Figure 5. Flow cytometry analysis of CD86 expression (A) and cytokines production (IL6 panel B, TNF α 
panel C) in RAW 264.7 cells exposed to different concentrations of FLG1 and FLG2 during 24 h. Two-ways 
ANOVA followed by Bonferroni’s post-test was performed to determine the statistical differences versus 
control cells and to compare the two graphene samples to each other (*p<0.05; **p<0.01; ***p<0.001).  
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Figure 6. Analysis of RAW 264.7 (left panels) or mIPM (right panels) cell activation after exposure to 
different concentrations of GO-A or GO-N during 24 h. Flow cytometry analysis of CD86 expression is 
reported in panel A and B. In the bottom panels, IL6 levels (C and D), TNF α levels (E and D) and IL1β 
levels (G and H) are reported. Two-ways ANOVA followed by Bonferroni’s post-test was performed to 
determine the statistical differences versus control cells and to compare the two graphene samples to each 
other (*p<0.05; **p<0.01; ***p<0.001).  
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IV.3.3 Interaction of graphene oxide with macrophages 
In order to identify possible interactions and internalization mechanisms of GO-A and GO-N with 
cells, mIPMs were exposed for 24 hours to 100 µg/ml of both GO types. At the end of the 
incubation, cells were processed for TEM observations.  
Even though the uptake mechanisms of GO are still not completely elucidated, some studies can be 
found in the literature suggesting both an active and a passive internalization pathway (Yue et al. 
2012; Mu et al. 2012; Peng et al. 2010). 
Concerning our study, it has worth noting that a high degree of GO internalization by mIPMs was 
observed concerning both GO types (Figure 7). In fact GO-A (panel A) and GO-N (panel B) were 
found inside almost all the cells under observation: expected behavior as macrophages are 
phagocytic cells. In the context of the identification of a possible internalization mechanism, GO 
was present inside large vesicles, suggesting a phagocytic internalization pathway; however, free 
GO flakes were also present in the cytoplasm. This could result from a passive translocation of GO 
sheets through the plasma membrane as it has been previously described for CNTs (Pantarotto et 
al. 2004 A) or suggested with dynamic membrane models (Ly et al. 2013).  The free graphene flakes 
could be also the result of endosome disruption and/or evasion. None of the two GO types was 
found inside the nuclei despite their structure, in some cases, the nuclei seemed impaired as 
evidenced by a certain degree of nuclear condensation, typical feature of cells that are dying 
(Ziegler et al. 2004). Such observation can be correlated with the cytotoxicity evidenced after 
mIPM exposure to 100 µg/ml of GO. Moreover, cytoplasmic structures seemed to be impaired to a 
larger extent after cells were treated with GO-A compared to GO-N, as evidenced by the presence 
of big vacuoles, even though they gave similar results in the cell viability experiments. The 
phenomenon could be correlated to a higher dispersibility of GO-A (compared to GO-N) in aqueous 
media, which in turn could be more internalized by mIPM. On the other hand it was possible to 
evidence, very frequently, isolated GO sheets bound parallel to the plasma membrane, (black 
arrows in Figure 7). This is again consistent with the previous study by Russier et al. where a “mask 
effect” by GO, which could isolate cells from their environment, was observed; this could be 
responsible for GO impact on cellular parameters. It was also speculated that the mask effect could 
be used to modulate or deplete cells particularly sensitive to paracrine signals or cell-cell 
interactions (e.g. lymphocytes) (Russier et al. 2013). Moreover, some of the GO sheets enter the 
cell membrane sliding under it (red arrows in Figure 5).  This was also simulated by a computer 
modelling (Guo et al. 2013).  The possible internalization mechanism is illustrated in Figure 8.  
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Figure 7. TEM images of mIPM incubated with 100 µg/ml of GO-A (A) or GO-N (B) during 24 h. The 
framed areas in the left images are enlarged in the respective right pictures.  
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Figure 8. Hypothesized mechanism for GO passive internalization. First, the 
GO sheets dispose themselves parallel to the cellular membrane (A). Then, 
due to the tight interaction, the edge of the GO flake pierces the phospholipid 
bilayer (B), begins to passively enter the cellular membrane (C and D) and 
finally reaches the intracellular compartment (E). (Russier et al. 2013). 
102                                                 Chapter IV: Graphene biological impact and possible use for cell targeting 
 
IV.3.4 B cell targeting with functionalized graphene oxide   
As it was described previously in this thesis, one of the main goals of the researches in the 
biomedical field is the design drugs and vectors with specific activity toward a particular diseased 
cellular type without affecting the healthy components of the cell populations. We also described 
how both nanotube and graphene surfaces can be functionalized with specific moieties, which can 
recognize molecular signatures on the surface of the cells of interest, carrying in the same time a 
bioactive molecule (e.g. a drug).  
After evaluating the impact of GO on different cell types in terms of cytotoxicity and 
proinflammatory response, my interests moved towards a possible application of the material in cell 
targeting. For this purpose, I used a model of B cells (A20 D1.3) genetically modified to over-
express a BCR which specifically recognize HEL. The two commercial GO samples (GO-A or GO-
N) were non-covalently conjugated with HEL. Non-covalent binding between GO and the lysozyme 
were previously described by Li et al. These authors have demonstrated the strong electrostatic 
interaction between the two molecules. Furthermore, GO-HEL association seemed selective when 
the reaction was performed in a mixture of proteins (Li et al. 2014).  
As first step, it was important to determine whether the interaction between GO and the lysozyme 
was stable in complete (see experimental section) cell culture medium. In fact, its components as 
salts, amino acids and the abundant proteins present in the FBS, could disturb GO-HEL interaction, 
thus inducing the detachment of the enzyme. For this purpose, the two GO-HEL conjugates were 
dispersed in the medium in test tubes. The samples were then incubated for 2 or 24 hours. To mimic 
the conditions used for the cell treatment, the incubation was performed at 37 °C. After 
centrifugation (to precipitate GO), the supernatants were subjected to gel electrophoresis (SDS-
PAGE). The free enzyme and the complete medium alone were used as controls. The two GO-HEL 
samples, dispersed in water, were also loaded into the gel, to confirm the presence of the enzyme on 
their surface. GO concentrations (in water or in cell culture medium) were calculated, according to 
the thermogravimetric analysis (see experimental section), to have in all the samples a HEL amount 
of about 5 µg. The low dimensions of lysozyme (compared to FBS proteins) allowed to visualize 
the enzyme by staining the gel with Coomassie blue. The results obtained confirmed the presence of 
lysozyme on the GO surface, as the denaturing conditions of SDS-PAGE make the enzyme 
detaching from the graphene (Figure 9, second and third lane). On the contrary, the enzyme was not 
detected in GO-A and GO-N supernatants after incubation in the cell culture medium, either after 2 
hours or 24 hours (Figure 9, lanes 5-8). The results demonstrated that the complexes are stable also 
in complete RPMI, despite HEL and GO binding was performed via non-covalent interactions.  
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Figure 9. SDS-PAGE representative result. GO-A or GO-N conjugated with HEL and dispersed in water 
(second and third lane): the enzyme detaches from the GO surface, due to the denaturing conditions of the 
electrophoresis, and migrates. GO-A-HEL or GO-N-HEL supernatants after incubation in complete cell 
culture medium for 2 h or 24 h (lanes 5-8): the binding between the two molecules is stable as the enzyme is 
not detected in the supernatants.  
 
Once proved their stability, HEL-GO conjugates were used to target the model B cells (A20 D1.3). 
Upon BCR-HEL binding, B cells produce IL2 (Justement et al. 1989), which could be revealed by 
ELISA. GO-HEL interaction with the BCR could be revealed also by flow cytometry using a 
specific biotinylated anti-HEL antibody (Figure 10).  
  
 
Figure 10. Targeting model: GO-HEL conjugates target B cells over-expressing a BCR specific for HEL 
protein. Upon GO-HEL-BCR binding, IL2 production by B cells is induced and can be detected by ELISA. 
The binding can be also revealed by flow cytometry using a specific biotinylated anti-HEL antibody. 
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Hence, A20 D.13 cells were exposed for 24 hours to concentrations ranging from 10 nM to 600 nM 
HEL of GO-A-HEL and GO-N-HEL. The free enzyme, as well as free GO, was used as control. 
The corresponding GO concentrations were back-calculated from lysozyme loading on GO surface 
(Table 1), accordingly to the termogravimetric analysis (see experimental section for details). At the 
end of the incubation, IL2 levels in the cellular supernatants were determined by ELISA. 
 
Table 1. Concentrations of HEL, GO-A-HEL and GO-N-HEL used for the cell treatment. The corresponding 
GO concentrations were back-calculated from HEL loading onto GO surface. 
 
 
 
 
 
 
 
Figure 11A shows the results obtained with both GO-HEL complexes and free HEL, which were 
able to induce IL2 production by A20 D1.3 cells. This demonstrates that the binding with BCR has 
occurred. The levels of IL2 were constant in all the concentration range in the case of HEL; on the 
contrary, these were higher as GO-HEL concentration increased. The phenomenon was observed 
with both GO samples up to a 100 nM HEL concentration suggesting an increased targeting ability 
by HEL when linked onto the GO-surface. This behavior was reversed in the concentration range 
between 100 nM and 600 nM HEL, even if IL2 levels were still higher as compared to the free 
protein. The latter observation could be explained by a saturation of the receptors and/or by a 
reduction in cell viability at these concentrations. The first hypothesis is the most reasonable as 
F4/80 negative cell population was not affected by GO (see Figure 4B). Finally, no IL2 production 
was monitored after the exposure of A20 D1.3 to free GO-A and GO-N (Figure 11B): therefore, the 
possibility of IL2 production induced by the free material was excluded. The specificity of GO-
HEL conjugates towards A20 D1.3 cells was further confirmed performing the same experiments in 
A20 wild type cells (not expressing BCR against HEL). As expected, no IL2 production was 
detected in the supernatants of free HEL and GO-HEL samples. To further confirm the binding of 
the complexes to the BCR and thus the ability of the material to target specifically our cell model, 
flow cytometry analyses were performed. For this purpose both transgenic and wild type B cells 
were exposed to 30 nM or 100 nM of either free HEL or GO-A/ GO-N conjugated with the enzyme. 
Concentrations were chosen accordingly to the highest IL2 induction obtained in the previous 
experiment. The cells were left to interact with the molecules for 30 min. The treatment was 
HEL molar 
concentration 
(nM) 
HEL 
(µg/ml) 
 
GO-A-HEL 
(µg/ml) 
GO-N-HEL 
(µg/ml) 
 
10 0.22 0.77 3.00 
30 0.43 2.30 9.00 
100 1.43 7.60 29.90 
300 4.30 22.75 89.60 
600 8.60 45.50 179.2 
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performed at 4 °C to avoid the internalization of the complexes by the cells. At the end of the 
exposure, cells were extensively washed and stained with a biotinylated antibody specific for HEL. 
GO-HEL binding to the BCR was revealed by flow cytometry after a second staining with 
streptavidin conjugated with phycoerythrin (PE) fluorophore. 
 
  
 
Figure 11. IL2 production by A20 D1.3 cells exposed to 30 nM or 100 nM concentrations of free HEL, GO-
A-HEL and GO-N-HEL (A) during 24 h or incubated with the corresponding concentrations of free GO-A 
and GO-N as controls (B). Two-ways ANOVA followed by Bonferroni’s post-test was performed to 
determine the statistical differences versus control cells. (*p<0.05; **p<0.01; ***p<0.001). 
 
 
As expected from the ELISA results, both GO-HEL samples could efficiently target A20 D1.3 cells. 
In fact, a clear shift of the entire cell population, corresponding to PE-positive cells, was evidenced 
upon cellular exposure to the two GO-HEL samples confirming their ability to recognize the BCR, 
at the same extent of free HEL. The result is reported in Figure 12A (representative experiment with 
30 nM HEL). Moreover, no difference compared to control cells was noticed in the case of the GO 
samples not conjugated with the enzyme, thus excluding the contribution of GO intrinsic 
fluorescence (Shang et al. 2012). The specificity of this binding towards our cellular model over-
expressing a BCR anti-HEL was further confirmed by the results obtained with A20 wild-type cells. 
In this case, no positive cell population was detected after exposure to all graphene samples (Figure 
12B). The result can be also visualized in Figure 12C and D where the mean fluorescence 
intensities (MFI) of A20 D1.3 and A20 wild-type exposed to 30 nM or 100 nM concentrations of 
free HEL, HEL-GO or free GO are reported. On the other hand, the slight increase in fluorescence 
in the case of A20 D1.3 control cells compared to A20 wild-type control cells could be due to a 
slight interaction of the biotinylated anti-HEL antibody with the BCR in the absence of HEL. 
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Figure 12. Flow cytometry analysis of B cell targeting with GO. PE fluorescence histograms (derived from 
HEL staining) of control cells versus cells exposed to 30 nM HEL, 30 nM GO-A-HEL and 30 nM GO-N-
HEL or to the corresponding concentrations of free GO-A and GO-N (panel A for A20 D1.3, panel B for 
A20 wild type) during 30 min at 4 °C. PE mean fluorescence intensity in A20 D1.3 (C) or A20 wild-type 
cells (D) exposed to 30 nM or 100 nM HEL, GO-A-HEL, GO-N-HEL or to the corresponding concentrations 
of GO-A and GO-N as controls during 30 min at 4 °C. Two-ways ANOVA followed by Bonferroni’s post-
test was performed to determine the statistical differences versus control cells. (*p<0.05; **p<0.01; 
***p<0.001). 
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The results obtained in the experiments illustrated above, demonstrate that functionalized graphene 
is able to target B cells in a selective fashion, thus suggesting its possible application in therapies 
where the specific elimination of B lymphocytes is required. In fact, GO can be further 
functionalized with a cytotoxic molecule. This can concern autoimmune diseases such as Systemic 
Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) in which autoreactive B lymphocytes, 
the direct precursors of autoantibody-secreting cells are involved in the exacerbation of the disease 
(Yanaba  et al. 2008). Recently an important progress has been made with the use of the chimeric 
antibody Rituximab, which specifically targets the CD20 molecule (Gürcan et al. 2009). CD20 is 
mainly expressed at the surface of B lymphocytes, which are then depleted upon recognition by 
anti-CD20 antibodies (Anolik et al. 2004). Despite Rituximab therapy has been reported to be 
successful for systemic autoimmune diseases such as RA (Keystone et al. 2008), trials with the 
same antibody gave variable results in other autoimmune diseases such as SLE (Albert et al. 2008). 
Furthermore, secondary side effects upon Rituximab administration were observed (Carson et al. 
2009). These observations further confirm the fact that other strategies are necessary to achieve the 
specific depletion of autoreactive B cells involved in the pathogenesis. As we have demonstrated, 
graphene could be a promising candidate to reach this ambitious goal. In fact, new specific B-cell 
surface targets and appropriate cytotoxic molecules are currently under investigation and could be 
conjugated at the same time on GO surface; the conjugates could be then tested on murine models 
of SLE.  
 
IV.4 Conclusions 
In the third project in which I was involved during my PhD, the impact of different graphene 
samples toward different cellular types was investigated. Furthermore, the ability of graphene oxide 
to specifically target B cells was studied. This project started with the examination of the cytotoxicy 
of both few layer graphene and two types of commercial graphene oxide toward human cervix 
cancer cells and murine macrophages RAW 264.7 cell lines. In fact, being a promising material to 
be exploited in the biomedical field, a careful characterization of a possible negative impact on 
health is demanded and currently under investigation.  
Reduction in cell viability was not observed after a 24 hour exposure to all materials even at high 
concentrations in both human and murine cellular lines. Moreover, the materials did not trigger 
RAW 264.7 activation or cytokine production. Since tumor cell lines showed an increased tolerance 
to death stimuli, graphene oxide was further tested on murine intraperitoneal primary macrophages. 
In this case, both commercial graphene types were able to reduce mIPM cell viability. Furthermore, 
it should be pointed out that this effect seemed to be macrophage-specific, since F4/80 negative 
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peritoneal cells were not affected by the exposure to GO-A or GO-N. These results suggest a 
possible utilization of GO in therapies in which the suppression of dangerous macrophages could be 
advantageous. This could be the case of cancer immunotherapy since it has been demonstrated that 
macrophages play an important role in cancer development and progression.  
Despite the observed cytotoxicity, both commercial graphene samples did not elicit no 
proinflammatory response toward mIPM, a positive result in view of their possible application in 
biomedicine.  
As expected, both GO samples were efficiently internalized by mIPM either by energy-dependent 
mechanisms and passive diffusion. In fact the nanomaterials were found inside vesicles but also free 
in the cytoplasm. Moreover GO sheets were observed also stacked parallel onto the plasma 
membrane surface, confirming the so called "mask effect" previously reported (Russier et al. 2013).  
In the last part of the project, GO-A and GO-N were non-covalently conjugated with the lyzozyme. 
Both samples were able to target a B cell model genetically modified to over-express a BCR 
specific for HEL. The latter result suggests that GO could be a promising drug support to be 
exploited in specific targeted therapies in which the suppression of armful B-lymphocytes is 
demanded (e.g. SLE). This will be possible with the discovery of new specific surface targets and 
appropriate cytotoxic molecules that could be grafted onto GO surface. The conjugates could be 
then tested in vitro and in vivo in mouse models of SLE. Moreover, this approach can be applied to 
other diseases in which a specific cell population must be depleted such as lymphomas and cancer 
in general.  
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CHAPTER V 
General conclusions and perspectives 
 
Carbon nanotubes and graphene (the latter especially in its oxidized form) are among the most 
promising carbon-based nanomaterials used for widespread biomedical applications. In fact, the 
development of different chemical strategies to functionalize their surface or to fill the CNT inner 
cavity opened the doors for the conjugations of both materials with almost all the molecules of 
biological interest (e. g. DNA, proteins or small drugs). The functionalized materials have shown 
great promises in several context of the biomedical field, especially as nanocarriers for drugs.  
However, a special issue concerns their toxicity as secondary side effects of the therapies must be 
avoided. Besides numerous efforts have been made to make both materials biocompatible and 
biodegradable, conflicting results are present in the literature and several factors interplay in 
determining CNT and graphene toxicity. Thus, further investigations in this context are demanded 
and better strategies to achieve a complete biocompatibility of the materials are still needed.   
The first project carried out during my PhD internship was aimed at improving the solubility and 
the biocompatibility of pristine SWCNTs by non covalent functionalization. Bovine serum albumin 
was able to form a stable dispersion over the time. The materials were then tested on different cell 
lines, murine or human, phagocytic or non-phagocytic, to better elucidate the impact and the 
interactions of such materials with living systems. Interestingly, CNTs were less cytotoxic on 
murine macrophages when coated with BSA, as compared to the uncoated controls. On the other 
hand, both pristine and BSA-stabilized CNTs were not able to induce a proinflammatory response 
in macrophages. Thanks to the good dispersion quality, BSA-SWCNTs were able to penetrate non-
phagocytic and phagocytic cell types by both passive diffusion and ATP-consuming mechanisms. 
Despite being able to interact and to be internalized by the cells, no changes in the dielectric 
parameters of fibroblast membrane were detected after exposure to BSA-CNTs. This is an 
innovative result as the effect of nanotubes on the plasma membrane dielectric characteristics and 
ion flux was very poorly investigated up to date. 
Taken together, the results obtained by the first proof of concept study shed more light on the 
SWCNT impact and interaction with cells. First, we could create highly soluble and stable carbon 
nanotubes without the need of covalent functionalization, simply covering their surface with a 
biocompatible protein which interacts with their surface by hydrophobic interactions. SWCNTs 
showed to be less toxic in macrophages when coated with BSA thus suggesting also an increased 
biocompatibility. Further studies could be performed in mice to investigate the possible induction of 
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tissue damage and inflammation in vivo. Interesting could be also to examine the biodistribution of 
BSA-stabilized CNTs. In fact, it is generally assumed that non-covalently functionalized CNTs 
accumulate in the RES organs and in the lungs promoting in vivo toxicity; same materials showed a 
difficult excretion with urine and feces. However, the non-covalent coating of CNTs with some 
molecules as polymers (PEG) showed a reduced accumulation in the liver/spleen and an enhanced 
blood circulation (which is useful for the carriers to reach their target organs). Despite non-
covalently functionalized CNTs seems to be not degradable, PEG-CNTs could be excreted via the 
bile and renal pathways (Liu et al. 2008 A). It would be of interest to investigate if our BSA-
SWCNT complexes show the same behavior in vivo. Finally, the inner cavity of CNTs could be 
filled with a chemotherapeutic drug. Drug-filled and BSA-stabilized CNTs could be then used to 
passively target tumors by the EPR effect (Iyer et al. 2006).   
In the second project, the anticancer activity of MWCNTs having different diameter and 
encapsulated with a cisplatin prodrug was investigated in a human cancer cell model. The CNTs 
efficently preserve the activity of the drug without inducing a high pro-inflammatory response on 
macrophages. In addition, cell viability experiments suggested a CNT diameter-dependent drug 
release. Moreover, cell internalization experiments and the intracellular platinum levels after 
Pt(IV)@CNT exposure demonstrate that they can promote the drug accumulation inside cells in 
comparison to treatment with the free complex.  
Our study shows how, by tuning CNT diameter it is possible to control the release of a 
chemotherapeutic drug encapsulated inside their cavity. In particular, CNTs having a small diameter 
showed a slower drug release according to the cell viability tests. Such behavior could allow small 
Pt(IV)@CNTs to have an increased anticancer efficacy in vivo. Further investigations could be 
performed on Pt-resistant cells to assess whether it is possible to elude multi-drug resistance by the 
use of CNTs as carriers. The conjugates could be also tested in vivo in tumor-bearing mice after 
intra-tumoral or systemic injection. It would be of great interest to see how the different complexes 
influence the tumor growth according to their diameter and in comparison with the free drug. In 
addition, the Pt(IV)@CNTs external surface could also further functionalized to allow a specific 
tumor targeting. We are also currently investigating the in vivo biodistribution of our complexes to 
assess wether they could affect normal organs and tissues and their excretion profiles. 
In the third and last project, the biological effect of various graphene types towards different cell 
types was examined. In particular, we focused on the impact of graphene oxide, which shows more 
promises in biomedical applications, on macrophages. We evidenced a selective cytotoxic effect of 
GO towards the primary macrophage population, as the viability of F4/80 negative cells 
(corresponding to the other immune peritoneal cells) was not affected by GO. Such behavior could 
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be exploited in therapies were the suppresion of macrophages could be advantageous. This can be 
the case of cancer, in which macrophages have shown to be responsible of tumor initiation, 
progression and metastasis (Qian and Pollard 2010). The mechanisms of GO 
interaction/internalization by primary macrophages were then better elucidated. The materials were 
internalized by both passive diffusion and phagocytosis. Moreover, GO sheets were observed also 
stacked parallel onto the plasma membrane surface, confirming the so-called "mask effect" 
previously reported. Isolating the cells from their environment, the mask effect could be useful to 
modulate or deplete cells particularly sensitive to paracrine signals or cell-cell interactions (Russier 
et al. 2013). In the last part of the project we were able to successfully target a B cell model 
overexpressing a lysozyme-specific B cell receptor (BCR), by functionalizing GO with this enzyme. 
The latter result suggests that GO could be a promising drug support to be exploited in specific 
targeted therapies in which the suppression of armful B-lymphocytes is demanded [e.g. systemic 
lupus erythematosus (SLE) and other autoimmune diseases]. Next step will be to conjugate GO 
with selective targeting moieties and specific cytotoxic drugs for in vitro and in vivo tests in murine 
models of SLE. This ambitious project is currently running at ICT in Strasbourg and promising 
results have been already obtained with CNTs. The group of Helene Dumortier and Sylviane Muller 
indentified the N-terminal region of histone H2B as preferential target of autoantibodies in SLE 
(Dumortier et al. 2010). This observation will allow the specific target of B lymphocytes expressing 
a BCR which specifically recognize that H2B region. In fact, the corresponding antigenic peptide 
can be grafted onto the surface of graphene oxide, together with a specific drug. Finally, this 
approach can be applied to other diseases in which a specific cell population must be depleted such 
as lymphomas and cancer in general.  
All these examples evidence the potential use of carbon-based nanomaterials fot therapeutic 
purposes.  
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